<body style="font: 10pt Times New Roman, Times, Serif"> <document>  <type>   10-K   <sequence>    1    <filename>     tm211758d1_10k.htm     <description>      FORM 10-K      <text>       <title>       </title>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Rule-Page -->       <div style="margin-top: 0; margin-bottom: 0; width: 100%">        <div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">        </div>       </div>       <!-- Field: /Rule-Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         UNITED STATES        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         SECURITIES AND EXCHANGE COMMISSION        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         Washington, D.C. 20549        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         FORM 10-K        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         (Mark One)        </b>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0">          </td>          <td style="width: 0.25in; text-align: left">           <font style="font-family: Wingdings">            x           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             ANNUAL                                            REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">        <b>         For the fiscal year ended December 31,2020        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         or        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0">          </td>          <td style="width: 0.25in; text-align: left">           <font style="font-family: Wingdings">            ¨           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             TRANSITION                                            REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">        <b>         For the transition period from                     to                     .        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         Commission file number 001-13341        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         TITAN PHARMACEUTICALS, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         (Exact name of registrant as specified in itscharter)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td style="width: 50%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Delaware            </b>           </font>          </td>          <td style="width: 50%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             94-3171940            </b>           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             (State or other jurisdiction of             <br/>             incorporation or organization)            </b>           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             (I.R.S. Employer             <br/>             Identification Number)            </b>           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: center">          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             400 Oyster Point Blvd., Suite 505,             <br/>             South San Francisco, California            </b>           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             94080            </b>           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             (Address of principal executive offices)            </b>           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             (Zip code)            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         Registrant’s telephone number, includingarea code: (650) 244-4990        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         Securities registered pursuant to Section 12(b) ofthe Act:        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 32%; border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Title    of each class            </b>           </font>          </td>          <td style="width: 2%; text-align: center">          </td>          <td style="width: 32%; border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Trading    Symbol(s)            </b>           </font>          </td>          <td style="width: 2%; text-align: center">          </td>          <td style="width: 32%; border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Name    of each exchange on which registered            </b>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Common Stock, par value    $0.001           </font>          </td>          <td style="text-align: center">          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            TTNP           </font>          </td>          <td style="text-align: center">          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Nasdaq Capital Market           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         Securities registered pursuant to Section 12(g) ofthe Act: None        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Indicateby check mark if the registrant is a well-known seasoned issuer as defined in Rule 405 of the Securities Act.   Yes        </font>        <font style="font-family: Wingdings">         ¨        </font>        No        <font style="font-family: Wingdings">         x        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Indicateby check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the ExchangeAct.   Yes        </font>        <font style="font-family: Wingdings">         ¨        </font>        No        <font style="font-family: Wingdings">         x        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Indicateby check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the ExchangeAct during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) hasbeen subject to the filing requirements for the past 90 days.   Yes        </font>        <font style="font-family: Wingdings">         x        </font>        No        <font style="font-family: Wingdings">         ¨        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Indicateby check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuantto Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files).        </font>        <font style="font-family: Wingdings; font-size: 10pt">         x        </font>        Yes        <font style="font-family: Wingdings">         ¨        </font>        No       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Indicate by check mark whether the registrantis a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company.See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,”and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td style="width: 30%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Large accelerated filer           </font>          </td>          <td style="width: 20%">           <font style="font-family: Wingdings">            ¨           </font>          </td>          <td style="width: 30%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Accelerated filer           </font>          </td>          <td style="width: 20%">           <font style="font-family: Wingdings">            ¨           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Non-accelerated filer           </font>          </td>          <td>           <font style="font-family: Wingdings; font-size: 10pt">            x           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Smaller Reporting Company           </font>          </td>          <td>           <font style="font-family: Wingdings; font-size: 10pt">            x           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Emerging growth company           </font>          </td>          <td>           <font style="font-family: Wingdings">            ¨           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Ifan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.        </font>        <font style="font-family: Wingdings; font-size: 10pt">         ¨        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Indicate by check mark whether the registranthas filed a report on and attestation to its management’s assessment of        <font style="font-size: 10pt">         the effectiveness of itsinternal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registeredpublic accounting firm that prepared or issued its audit report.         <font style="font-family: Wingdings">          ¨         </font>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Indicateby check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   Yes        </font>        <font style="font-family: Wingdings">         ¨        </font>        No        <font style="font-family: Wingdings">         x        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The aggregate market value of the voting andnon-voting common equity held by non-affiliates of the registrant based on the closing price on June 30, 2020 was approximately$29.7 million.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        As of March 26, 2021, 9,864,068 shares ofcommon stock, $0.001 par value, of the registrant were issued and outstanding.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         DOCUMENTS INCORPORATED BY REFERENCE:        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        NONE       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Rule-Page -->       <div style="margin-top: 0; margin-bottom: 0; width: 100%">        <div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">        </div>       </div>       <!-- Field: /Rule-Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="margin: 0pt">        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">        <b>         Titan Pharmaceuticals, Inc.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">        <b>         Annual Report on Form 10-K        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">        <b>         For the Fiscal YearEnded December 31, 2020        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">        <b>         Table of Contents        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%; text-align: justify">          </td>          <td style="width: 80%">          </td>          <td style="border-bottom: black 1pt solid; width: 10%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Page #           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: justify">           <a href="#a_001">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             PART I            </font>           </a>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: center">           <a href="#a_001">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             3            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: justify">           <a href="#a_002">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item 1.            </font>           </a>          </td>          <td style="text-align: justify">           <a href="#a_002">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Business            </font>           </a>          </td>          <td style="text-align: center">           <a href="#a_002">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             4            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: justify">           <a href="#a_003">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item 1A.            </font>           </a>          </td>          <td style="text-align: justify">           <a href="#a_003">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Risk Factors            </font>           </a>          </td>          <td style="text-align: center">           <a href="#a_003">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             14            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: justify">           <a href="#a_004">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item 1B.            </font>           </a>          </td>          <td style="text-align: justify">           <a href="#a_004">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Unresolved    Staff Comments            </font>           </a>          </td>          <td style="text-align: center">           <a href="#a_004">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             20            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: justify">           <a href="#a_005">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item 2.            </font>           </a>          </td>          <td style="text-align: justify">           <a href="#a_005">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Properties            </font>           </a>          </td>          <td style="text-align: center">           <a href="#a_005">            20           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: justify">           <a href="#a_006">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item 3.            </font>           </a>          </td>          <td style="text-align: justify">           <a href="#a_006">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Legal    Proceedings            </font>           </a>          </td>          <td style="text-align: center">           <a href="#a_006">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             20            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: justify">           <a href="#a_007">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item 4.            </font>           </a>          </td>          <td style="text-align: justify">           <a href="#a_007">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Mine Safety    Disclosures            </font>           </a>          </td>          <td style="text-align: center">           <a href="#a_007">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             21            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: justify">           <a href="#a_008">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             PART II            </font>           </a>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: center">           <a href="#a_008">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             22            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; text-align: justify">           <a href="#a_009">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    5.            </font>           </a>          </td>          <td style="vertical-align: top; text-align: justify">           <a href="#a_009">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Market    for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities            </font>           </a>          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="#a_009">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             22            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: justify">           <a href="#a_010">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item 6.            </font>           </a>          </td>          <td style="text-align: justify">           <a href="#a_010">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Selected    Financial Data            </font>           </a>          </td>          <td style="text-align: center">           <a href="#a_010">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             22            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: justify">           <a href="#a_011">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item 7.            </font>           </a>          </td>          <td style="text-align: justify">           <a href="#a_011">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Management’s    Discussion and Analysis of Financial Condition and Results of Operations            </font>           </a>          </td>          <td style="text-align: center">           <a href="#a_011">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             23            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: justify">           <a href="#a_012">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item 7A.            </font>           </a>          </td>          <td style="text-align: justify">           <a href="#a_012">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Quantitative    and Qualitative Disclosures About Market Risk            </font>           </a>          </td>          <td style="text-align: center">           <a href="#a_012">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             29            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: justify">           <a href="#a_013">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item 8.            </font>           </a>          </td>          <td style="text-align: justify">           <a href="#a_013">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Financial    Statements and Supplementary Data            </font>           </a>          </td>          <td style="text-align: center">           <a href="#a_013">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             29            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: justify">           <a href="#a_014">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item 9.            </font>           </a>          </td>          <td style="text-align: justify">           <a href="#a_014">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Changes    in and Disagreements With Accountants on Accounting and Financial Disclosure            </font>           </a>          </td>          <td style="text-align: center">           <a href="#a_014">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             29            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: justify">           <a href="#a_015">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item 9A.            </font>           </a>          </td>          <td style="text-align: justify">           <a href="#a_015">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Controls    and Procedures            </font>           </a>          </td>          <td style="text-align: center">           <a href="#a_015">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             29            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: justify">           <a href="#a_016">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item 9B.            </font>           </a>          </td>          <td style="text-align: justify">           <a href="#a_016">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Other    Information            </font>           </a>          </td>          <td style="text-align: center">           <a href="#a_016">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             30            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: justify">           <a href="#sp04-01">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             PART III            </font>           </a>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: center">           <a href="#sp04-01">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             31            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: justify">           <a href="#sp04-02">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    10.            </font>           </a>          </td>          <td style="text-align: justify">           <a href="#sp04-02">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Directors,    Executive Officers and Corporate Governance            </font>           </a>          </td>          <td style="text-align: center">           <a href="#sp04-02">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             31            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: justify">           <a href="#sp04-03">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    11.            </font>           </a>          </td>          <td style="text-align: justify">           <a href="#sp04-03">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Executive    Compensation            </font>           </a>          </td>          <td style="text-align: center">           <a href="#sp04-03">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             32            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: justify">           <a href="#sp04-04">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    12.            </font>           </a>          </td>          <td style="text-align: justify">           <a href="#sp04-04">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Security    Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters            </font>           </a>          </td>          <td style="text-align: center">           <a href="#sp04-04">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             36            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: justify">           <a href="#sp04-05">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    13.            </font>           </a>          </td>          <td style="text-align: justify">           <a href="#sp04-05">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Certain    Relationships and Related Transactions, and Director Independence            </font>           </a>          </td>          <td style="text-align: center">           <a href="#sp04-05">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             36            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: justify">           <a href="#sp04-06">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    14.            </font>           </a>          </td>          <td style="text-align: justify">           <a href="#sp04-06">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Principal    Accounting Fees and Services            </font>           </a>          </td>          <td style="text-align: center">           <a href="#sp04-06">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             37            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: justify">           <a href="#sp04-08">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             PART IV            </font>           </a>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: center">           <a href="#sp04-08">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             39            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: justify">           <a href="#sp04-07">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    15.            </font>           </a>          </td>          <td style="text-align: justify">           <a href="#sp04-07">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Exhibits,    Financial Statement Schedules            </font>           </a>          </td>          <td style="text-align: center">           <a href="#sp04-07">            39           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: justify">           <a href="#sp04-09">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    16.            </font>           </a>          </td>          <td style="text-align: justify">           <a href="#sp04-09">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Form 10-K    Summary            </font>           </a>          </td>          <td style="text-align: center">           <a href="#sp04-09">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             39            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td colspan="2" style="text-align: justify">           <a href="#a_017">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             SIGNATURES            </font>           </a>          </td>          <td style="text-align: center">           <a href="#a_017">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             65            </font>           </a>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         2         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         <a name="a_001">         </a>         PART I        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        This Annual Report on Form 10-K or in thedocuments incorporated by reference herein may contain “forward-looking statements” within the meaning of Section 27Aof the Securities Act of 1933 (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934 (the “ExchangeAct”) that involve substantial risks and uncertainties. We have attempted to identify forward-looking statements by terminologyincluding “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “should,” or “will” or the negative of these terms or other comparable terminology. Although we do not make forwardlooking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. Forward-looking statementsincluded or incorporated by reference in this report or our other filings with the Securities and Exchange Commission, or the SEC, include,but are not necessarily limited to, those relating to uncertainties relating to:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        •	     the abilityto raise capital when needed;       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        •	     the wind-downof Probuphine commercialization activities;       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        •	     financingand strategic agreements and relationships;       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        •	     difficultiesor delays in the regulatory approval process;       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        •	     uncertaintiesrelating to manufacturing, sales, marketing and distribution of our drug candidates that may be successfully developed and approved forcommercialization;       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        •	     adverseside effects or inadequate therapeutic efficacy of our drug candidates that could slow or prevent product development or commercialization;       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        •	     dependenceon third party suppliers;       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        •	     the uncertaintyof protection for our patents and other intellectual property or trade secrets; and       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        •	     competition.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Forward-looking statements should not be readas a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by which, thatperformance or those results will be achieved. Forward-looking statements are based on information available at the time they are madeand/or management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties,including the risks outlined under “Risk Factors” or elsewhere in this report, that could cause actual performance or resultsto differ materially from what is expressed in or suggested by the forward-looking statements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Forward-looking statements speak only as of thedate they are made. You should not put undue reliance on any forward-looking statements. We assume no obligation to update forward-lookingstatements to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information, exceptto the extent required by applicable securities laws. If we do update one or more forward-looking statements, no inference should bedrawn that we will make additional updates with respect to those or other forward-looking statements. We caution you not to give undueweight to such projections, assumptions and estimates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        References herein to “we,” “us,” “Titan,” and “our company” refer to Titan Pharmaceuticals, Inc. unless the context otherwise requires.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Probuphine        <sup>         ®        </sup>        and ProNeura™are trademarks of our company. This Annual Report on Form 10-K also includes trade names and trademarks of companies other thanTitan.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 3; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         3         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">        All share and per sharedata in this report gives retroactive effect to a one-for-30 reverse stock split effected in November 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0">          </td>          <td style="width: 0.75in; text-align: left">           <a name="a_002">           </a>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Item                          1.            </b>           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Business            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Overview        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">        We are a pharmaceutical companydeveloping therapeutics utilizing our proprietary long-term drug delivery platform, ProNeura™, for the treatment of select chronicdiseases for which steady state delivery of a drug provides an efficacy and/or safety benefit. ProNeura consists of a small, solid implantmade from a mixture of ethylene-vinyl acetate, or EVA, and a drug substance. The resulting product is a solid matrix that is administeredsubdermally, normally in the inner upper arm, in a brief, outpatient procedure and is removed in a similar manner at the end of the treatmentperiod of several months. These procedures may be performed by trained health care providers, or HCPs, including licensed and surgicallyqualified physicians, nurse practitioners, and physician’s assistants in a HCP’s office or other clinical setting.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Our first product based on our ProNeura technologywas our Probuphine® (buprenorphine) implant, which was approved in the United States, Canada and the European Union, or EU, for themaintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine. Followingreacquisition of the rights to Probuphine from our former licensee in mid-2018, we endeavored to build our infrastructure and grow ourcommercial capabilities with the limited resources at our disposal. While we made important progress in laying the groundwork during2019 to transition into a company with full commercial potential, and also among other things manage the challenges of the restrictiveproduct label, the Risk Evaluation and Mitigation Strategy, or REMS, program        <font style="color: #333333">         and the complexity of the distributionchannel        </font>        , the emergence of the Covid-19 pandemic in early 2020 and the resultant restrictions and lockdown of facilities severelyimpacted our ability to continue to expand our commercial operations. With limited financial resources and insufficient sales revenueduring the first three quarters of 2020, we made the decision to discontinue selling Probuphine in the U.S. and wind down our commercializationactivities, and to pursue a plan that will enable us to focus on our current, early-stage ProNeura-based product development programs.Probuphine continues to be commercialized in Canada and the EU by other companies who have either licensed or acquired the rights fromTitan.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         ProNeura Continuous Drug Delivery Platform        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Our ProNeura continuous drug delivery systemconsists of a small, solid rod-shaped implant made from a mixture of EVA and a drug substance. The resulting product is a solid matrixthat is placed subdermally, normally in the inside part of the upper arm in a short physician office-based procedure and is removed ina similar manner at the end of the treatment period. The drug substance is released continuously through the process of diffusion-controlleddissolution. This results in a continuous, steady rate of release generally similar to intravenous administration. We believe that suchlong-term, almost linear release characteristics are desirable as they avoid the fluctuating peak and trough levels of oral dosing thatoften poses problems in a range of disease settings.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The ProNeura platform was developed to addressthe need for a simple, practical method to achieve continuous long-term drug delivery, and, depending on the characteristics of the compoundto be delivered, can potentially provide treatment on an outpatient basis over extended periods of up to 12 months. We believe that thebenefits of this technology have been demonstrated by the clinical results seen to date with Probuphine, and, in addition, that the developmentand regulatory process have been affirmed by the U.S. Food and Drug Administration, or FDA, the European Medicines Agency, or EMA, andHealth Canada approvals of this product. We have further demonstrated the feasibility of the ProNeura platform with small molecules,hormones, and bio-active peptides. The delivery system works with both hydrophobic and hydrophilic molecules. We have also shown theflexibility of the platform by experimenting with the release characteristics of the EVA implants, layering the implants with varyingconcentrations of drug, and generating implants of different sizes and porosity to achieve a desired delivery profile and have intellectualproperty covering this technology. Formulation development is conducted at a dedicated pilot plant established by Titan at the SouthWest Research Institute, or SWRI, in San Antonio, Texas that includes cGMP manufacturing and testing capabilities. We also receive supportservices from the vast array of SWRI groups with expertise in manufacturing and material sciences. The facilities are compliant withboth FDA and Drug Enforcement Agency, or DEA, requirements enabling us to work with controlled substances, and the manufacturing scaleis ideal for product development during non-clinical and clinical testing stages.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Development Programs        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Kappa Opioid Agonist Peptide Program        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        On October 27, 2020, we entered into an AssetPurchase Agreement with JT Pharmaceuticals, Inc., or JT Pharma, for the acquisition and development of JT Pharma’s kappa opioidagonist peptide, or TP-2021 (formerly JT-09), for use in combination with our ProNeura technology. James McNab, a member of our boardof directors, is a principal of JT Pharma. Several years ago, we began limited laboratory experiments in collaboration with JT Pharmato assess the feasibility of delivering TP-2021 using TP-2021 peptide-infused ProNeura implants, or TP-2021 ProNeura implants, insertedsubdermally in animal models. Our initial work focused on TP-2021’s ability to activate peripheral kappa opioid receptors, potentiallyproviding a non-addictive treatment for certain types of pain. Recently, our experiments have pivoted to explore the feasibility of alsousing TP-2021 ProNeura implants in the treatment of chronic pruritus, a debilitating condition defined as itching of the skin lastinglonger than six weeks. In February 2021, we announced that early non-clinical studies of TP-2021 subdermal injection demonstratedhigh potency and specificity for the human kappa opioid receptor and this enables us to move forward with proof -of- concept studies inappropriate animal models of pruritus to test the implant formulation.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In 2015, an estimated 23 – 44 million Americanssuffered from chronic pruritus in the setting of both cutaneous and systemic conditions. Current treatments include anti-histamines,corticosteroids, and over-the-counter lotions, all of which are relatively ineffective and may have undesirable side-effect profiles.The antipruritic effect of kappa opioid agonists is thought to be related to their binding to kappa opioid receptors on keratinocytes,immune cells and peripheral itch neurons. We believe, based on our early non-clinical data, that subcutaneous implantation of the TP-2021ProNeura implants could potentially deliver therapeutic concentrations of TP-2021 for up to six months or longer following a single in-officeprocedure. We are currently conducting the initial non-clinical studies designed to establish proof-of-concept, and if successful, wewill need to conduct Investigational New Drug, or IND, enabling non-clinical safety and pharmacology studies prior to any clinical studies.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 4; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         4         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Nalmefene Development Program        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In September 2019, the National Institutefor Drug Addiction, or NIDA, awarded us an approximately $8.7 million grant over two years for our nalmefene implant development programfor the prevention of opioid relapse following detoxification of patients suffering opioid use disorder, or OUD. An injectable formulationof nalmefene was approved by the FDA in 1995 for the management and reversal of opioid overdose, including respiratory depression. Oralnalmefene was approved by the EMA in 2013 for treating alcohol dependence. A nasal formulation of nalmefene is currently in clinicaldevelopment by another company for the treatment of opioid overdose.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The NIDA grant provides funds for the completionof implant formulation development, cGMP manufacturing and non-clinical studies required for filing an IND. During the first quarterof 2020 we met with the FDA to review our non-clinical development plans and obtain guidance regarding filing an IND. Since other nalmefeneformulations had already been approved by the FDA, we were pursuing a shorter, more streamlined 505(b)(ii) regulatory pathway inour development program. However, the FDA provided clear guidance on the type of development plan that we should follow, specificallythat this product development should follow the more expansive 505(b)(i) regulatory pathway due to the lack of chronic safety dataon nalmefene employing a long acting formulation, and the specific non-clinical studies that will be required to file an IND. Based onthis input, collecting all the non-clinical chronic toxicology data will require an additional study as well as increasing the durationof an ongoing study that will delay filing of the IND to at least mid-2021. We have discussed the change in development plan with NIDAand they have accepted our plan to reallocate previously approved funds for conduct of the studies. Based on pursuing the 505(b)(i) pathway,the overall product development program cost is expected to increase considerably, and while we will discuss this further with NIDA,it is uncertain whether these additional funds will be available from NIDA or from any other sources.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Other programs        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        We are collaborating with the Walter Reed ArmyInstitute of Research, or WRAIR, and SWRI in the early non-clinical evaluation of the ProNeura platform in malaria prophylaxis. The earlydata from this collaboration are encouraging and have been presented by the WRAIR staff at several conferences, and WRAIR has now receivedadditional funding from the Department of Defense to continue the program with additional non-clinical testing of the atovaquone andproguanil implant formulations in large animal studies. WRAIR is also pursuing additional grant funding for testing other compounds thathave shown promise as a prophylactic treatment for malaria and we will collaborate with WRAIR and SWRI as needed for the preparationof these implant formulations that, if successful, could be available to us for potential development and commercialization.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        We have also conducted feasibility assessmentsand implant formulation activities with drugs used in the areas of chronic pain, type 2 diabetes and hypothyroidism, some of which wasdone in collaboration with third parties. Further research and development efforts on a product pipeline based on our ProNeura platformtechnology will depend on the availability of funding, either through corporate collaborations, grants or other sources.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20">        <b>         Management Restructuring        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">         Effective        </font>        October 18, 2020, Kate Beebe        <font style="color: #231f20">         DeVarney, Ph.D, our Executive Vice President and Chief ScientificOfficer and a member of the board of directors, assumed the roles of President and Chief Operating Officer. Effective October 31,2020, Sunil Bhonsle retired from his roles as President and Chief Executive Officer. Marc Rubin, M.D. our Executive Chairman, assumedthe responsibilities associated with the Chief Executive role, and together with        </font>        Dr. Beebe DeVarney        <font style="color: #231f20">         ,oversee our product development activities.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Agreements        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">        <b>         Knight        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">        Pursuant to an agreement (asamended, the Knight Agreement), we granted Knight Therapeutics Inc., or Knight, an exclusive license to commercialize Probuphine in Canadaas well as a right of first negotiation in the event we intend to license commercialization rights to any other products in Canada. Weare entitled to receive royalty payments from Knight on net sales of Probuphine in Canada ranging in percentage from the low-teens tothe mid-thirties. In addition, we agreed to be the exclusive supplier of Probuphine to Knight subject to a supply agreement between usand Knight. During the term of the Knight Agreement, we may not commercialize any product in Canada containing buprenorphine that isintended for a treatment duration of six months or more.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 5; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         5         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">        Unless earlier terminated, theinitial term of the Knight Agreement will expire on the 15th anniversary of the date of the first commercial sale of Probuphine for opioidaddiction in Canada, which occurred during the fourth quarter of 2018. If Probuphine is approved for another indication in Canada afterthe fifth anniversary of the first commercial sale of Probuphine for opioid addiction in Canada, we must negotiate in good faith whetherto extend the initial term. After the initial term, the Knight Agreement will automatically renew for two-year periods until either partyprovides the other party with written notice of its intent not to renew at least 180 days prior to the expiration of the initial termor then-current term. We or Knight may terminate the Knight Agreement in the event that (i) either party determines in good faiththat it is not advisable for Knight to continue to commercialize Probuphine in Canada as a result of a bona fide safety issue, (ii) theother party has filed for bankruptcy, reorganization, liquidation or receivership proceedings, or (iii) the other party materiallybreached the agreement and has not cured such breach within a specified time period. In addition, subject to certain exceptions and requirements,we may terminate the Knight Agreement (i) if Knight discontinues the commercial sale of Probuphine for a period of at least threemonths and fails to resume sales within the specified cure period, or (ii) in the event that Knight commences any legal proceedingsseeking to challenge the validity or ownership of any of our patents related to Probuphine.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">        In the event of termination,among other things, Knight shall (i) cease commercialization of Probuphine in Canada, (ii) transfer title to all current andpending regulatory submissions and regulatory approvals for Probuphine to us and (iii) pay any royalty payments generated by Knight’ssales of Probuphine in Canada due to us.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">        <b>         Molteni        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In March 2018, we entered into and in August2018 amended an Asset Purchase, Supply and Support Agreement, or the Purchase Agreement, with L. Molteni &amp; C. Dei Frattelli AlittiSocieta Di Esercizio S.P.A., or Molteni, pursuant to which Molteni acquired the European intellectual property related to Probuphineand the exclusive right to commercialize Probuphine (which it renamed Sixmo) in Europe, as well as certain countries of the Commonwealthof Independent States, the Middle East and North Africa, or the Molteni Territory. We received an initial payment of €2.0 million($2,448,000) for the purchased assets and an additional payment of €950,000 ($1,107,000) upon execution of the amendment. Additionally,Titan was entitled to receive earn-out payments for up to 15 years on net sales of Probuphine in the Molteni Territory.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The Purchase Agreement also provided that Titanwould supply Molteni with semi-finished product (i.e., the implant and the applicator) on an exclusive basis at a fixed price throughDecember 31, 2019, with subsequent price increases not to exceed annual cost increases to Titan under its current manufacturingagreement and for the purchase of the active pharmaceutical ingredient.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In March 2018, we entered into a loan agreement,or the Loan Agreement, which amended and restated our prior loan agreement with Horizon Technology Finance Corp., or Horizon. Under theLoan Agreement, Horizon assigned $2,400,000 of the $4,000,000 outstanding principal balance of the loan to Molteni and Molteni was appointedcollateral agent and assumed majority and administrative control of the debt. Molteni was given the right to convert its portion of thedebt into shares of our common stock at a conversion price of $216.00 per share and was required to effect this conversion of debt toequity if we completed an equity financing resulting in gross proceeds of at least $10,000,000 at a price per share of common stock inexcess of $216.00 and repaid the $1,600,000 principal balance of Horizon’s loan amount. In September 2019, we amended the LoanAgreement with the goal of reducing our cash burn rate to enable us to focus on commercialization activities by extending the interest-onlypayment and forbearance periods by one year to December 31, 2020 and the maturity date by one year to June 1, 2022. In connectionwith the amendment to the Loan Agreement, as clarified by a subsequent amendment dated March 12, 2020, the final payments to thelenders were increased by an aggregate of $312,500 (exclusive of a restructuring fee payable to Horizon) and the conversion provisionsrelated to Molteni’s portion of the loan amount were revised to eliminate the mandatory conversion feature, to reduce the conversionprice to $6.75 per share and to cap the number of shares issuable upon conversion to 114,093.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 6; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         6         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In September 2018, Molteni made a convertibleloan to us of €550,000 (approximately $642,000) which was converted in full into 14,943 shares of our common stock at $45.00 pershare upon the receipt of regulatory approval of Sixmo for the EU in June 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In September 2019, we entered into an amendmentto the Purchase Agreement pursuant to which the percentage earn-out payments on net sales were reduced from the original range of low-teensto mid-twenties to low-teens to mid-teens. We also agreed to delay payments of any earn-outs until the later of (i) January 1,2021 or (ii) the one year anniversary of completion of compliance by our manufacturer with EU requirements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In October 2020, in connection with ourdecision to wind down our commercial operations, we entered into a Debt Settlement and Release Agreement, or DSRA, Agreement with Molteniand Horizon, the holders of our approximately $5.2 million of outstanding secured debt ($4.0 million principal amount and approximately$1.2 million in payoff amounts) to settle such obligations for $1.6 million in cash, the transfer of certain Probuphine assets to Molteni,including all of our manufacturing equipment, and the termination of our rights to future payments under the Purchase Agreement withMolteni. The DSRA Agreement provided for the release to us of the remaining collateral to enable us to continue operating as a researchand development company.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         JT Pharmaceuticals        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In October 2020, we entered into an AssetPurchase Agreement, or the JT Agreement, with JT Pharmaceuticals, Inc., or JT Pharma, to acquire JT Pharma’s kappa opioidagonist peptide, TP-2021, for use in combination with our ProNeura long-term, continuous drug delivery technology for the treatment ofchronic pruritus and other potential medical applications. Under the terms of the JT Agreement, JT Pharma received a $15,000 closingpayment and is entitled to receive future milestone payments, payable in cash or in stock, based on the achievement of regulatory milestones,and single-digit percentage earn-out payments on net sales of the product if successfully developed and approved for commercialization.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Intellectual Property        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Our goal is to obtain, maintain and enforce patentprotection for our product candidates, formulations, processes, methods and any other proprietary technologies, preserve our trade secrets,and operate without infringing on the proprietary rights of other parties, both in the United States and in other countries. Our policyis to actively seek to obtain, where appropriate, the broadest intellectual property protection possible for our current product candidatesand any future product candidates, proprietary information and proprietary technology through a combination of contractual arrangementsand patents, both in the United States and abroad. However, patent protection may not afford us with complete protection against competitorswho seek to circumvent our patents.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in">        We also depend upon the skills,knowledge, experience and know-how of our management and research and development personnel, as well as that of our advisors, consultantsand other contractors. To help protect our proprietary know-how, which may not be patentable, and for inventions for which patents maybe difficult to enforce, we currently rely and will in the future rely on trade secret protection and confidentiality agreements to protectour interests. To this end, we require all of our employees, consultants, advisors and other contractors to enter into confidentialityagreements that prohibit the disclosure of confidential information and, where applicable, require disclosure and assignment to us ofthe ideas, developments, discoveries and inventions important to our business.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In June 2010, the United States Patent andTrademark Office (“USPTO”) issued a patent covering methods of using Probuphine for the treatment of opiate addiction. Titanis the owner of this patent which claims a method for treating opiate addiction with a subcutaneously implanted device comprising buprenorphineand EVA, a biocompatible copolymer that releases buprenorphine continuously for extended periods of time. This patent will expire inApril 2024. A U.S. continuation application is currently pending which includes claims related to Probuphine for the treatment ofpain.  Related patents covering use of Probuphine with the continuous delivery technology for the treatment of opiate addictionhave also been issued in Australia, Canada, Europe, India, Japan, Mexico, New Zealand, and Hong Kong. On March 21, 2018, weexecuted the Purchase Agreement with Molteni whereby the European intellectual property covering Probuphine, including the European patent,was acquired by Molteni. In October 2020, as part of the DSRA Agreement, Molteni acquired the issued patents related to Probuphinein Australia, India, Japan, Mexico, New Zealand, and Hong Kong. Patents covering certain dopamine agonist implants, including ropiniroleimplant, have already been issued in the United States, Europe, Japan, China, Australia, Canada, South Korea, Mexico, New Zealand, SouthAfrica, Israel and Hong Kong.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In October 2020, we acquired patent applicationsto a sustained release composition comprising certain kappa-opioid receptor agonists in combination with a biocompatible polymer matrixfrom JT Pharmaceuticals.  Applications are pending in the United States, Europe, Japan, China, and Hong Kong.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 7; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         7         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        We also have pending patent applications in theUS, Australia, Canada, China, Europe, India, Japan and Mexico for implants for release of lipophilic or amphiphilic pharmaceuticalsubstances, and for loadable porous structures for use as implants.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        We have filed additional patent applicationsfor a heterogeneous implant designed with some unique properties that may provide benefits to the structural integrity of the implantsand potentially enhance drug delivery. Corresponding patents have been granted in the US, Australia, Canada, Europe, Hong Kong, India,Japan, South Korea, Mexico, Singapore, and South Africa.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Future court decisions or changes in patent lawmight materially affect the patents or patent applications, including, but not limited to, their expiration dates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Competition        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">        The pharmaceutical and biotechnologyindustries are characterized by rapidly evolving technology and intense competition. Many companies, including major pharmaceutical companiesand smaller specialized biotechnology companies, are engaged in the development and commercialization of therapeutic agents designedfor the treatment of the same diseases and disorders that we target. Many of our competitors have substantially greater financial andother resources, larger research and development staff and more experience in the regulatory approval process. Moreover, potential competitorshave or may have patents or other rights that conflict with patents covering our technologies. Our product development programs are currentlyin non-clinical stages of development and once these commence clinical development we can assess and provide details on specific competitiveenvironment.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Manufacturing        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The manufacturing of Probuphine is primarilyconducted at DPT Laboratories, Inc., or DPT, pursuant to a commercial manufacturing agreement with DPT that governs the terms ofthe production and supply of Probuphine. During 2020, we modified and expanded the manufacturing facility at this contract manufacturerto establish commercial scale capability to support EU regulatory requirements for the manufacture of Probuphine. In October 2020,we entered into the DSRA Agreement which transferred our manufacturing facility at DPT to Molteni. Under the agreement, we will retainaccess to the facility for the manufacture and supply of Probuphine to Knight for Canada.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Ongoing formulation development is conductedat a dedicated facility established by Titan at SWRI in San Antonio, Texas that includes cGMP manufacturing and testing capabilities.We also receive support services from the vast array of SWRI groups with expertise in manufacturing and material sciences. The facilitiesare compliant with both FDA and Drug Enforcement Agency, or DEA, requirements enabling us to work with controlled substances, and themanufacturing scale is ideal for product development during non-clinical and clinical testing stages.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 8; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         8         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Government Regulation        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Government authorities in the United States atthe federal, state and local level and in other countries extensively regulate, among other things, the research, development, testing,manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approvalmonitoring and reporting, marketing and export and import of drug products. Generally, before a new drug can be marketed, considerabledata demonstrating its quality, safety and efficacy must be obtained, organized into a format specific to each regulatory authority,submitted for review and approved by the regulatory authority.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>          U.S. drug development         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In the United States, the FDA regulates drugsand devices under the Food, Drug and Cosmetics Act, or FDCA. Drugs and devices are also subject to other federal, state and local statutesand regulations. Products composed of both a drug product and device product are deemed combination products. If marketed individually,each component would be subject to different regulatory pathways and reviewed by different centers within the FDA. A combination product,however, is assigned to a center that will have primary jurisdiction over its regulation based on a determination of the combinationproduct’s primary mode of action, which is the single mode of action that provides the most important therapeutic action. In thecase of some of our product candidates, we expect the primary mode of action to be attributable to the drug component of the product,which means that the FDA’s Center for Drug Evaluation and Research would have primary jurisdiction over the premarket development,review and approval. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, localand foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with theapplicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicantto administrative or judicial sanctions. These sanctions could include, among other actions, the FDA’s refusal to approve pendingapplications, withdrawal of an approval, a clinical hold, untitled or warning letters, product seizures, total or partial suspensionof production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement, or civil or criminal penalties.Additionally, a manufacturer may need to recall a product from the market. Any agency or judicial enforcement action could have a materialadverse effect on us.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px">           <font style="font-family: Wingdings">            ¨           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Our product candidates must be approved by the FDA    through the NDA process before they may be legally marketed in the United States. The process required by the FDA before a drug may    be marketed in the United States generally involves the following:           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px">           <font style="font-family: Wingdings">            ¨           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Completion of extensive nonclinical laboratory tests,    animal studies and formulation studies in accordance with applicable regulations, including the FDA’s Good Laboratory Practice,    or GLP, regulations;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px">           <font style="font-family: Wingdings">            ¨           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Submission to the FDA of an IND application, which    must become effective before human clinical trials may begin;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px">           <font style="font-family: Wingdings">            ¨           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Approval by an independent institutional review board,    or IRB, or ethics committee at each clinical trial site before each trial may be initiated;           </font>          </td>         </tr>        </tbody>       </table>       <!-- Field: Split-Segment; Name: a2 -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px">           <font style="font-family: Wingdings">            ¨           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Performance of adequate and well-controlled human clinical    trials in accordance with applicable IND and other clinical trial-related regulations, referred to as good clinical practices, or    GCPs, to establish the safety and efficacy of the proposed drug for each proposed indication;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px">           <font style="font-family: Wingdings">            ¨           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Submission to the FDA of an NDA for a new drug;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px">           <font style="font-family: Wingdings">            ¨           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            A determination by the FDA within 60 days of its receipt    of an NDA to file the NDA for review;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px">           <font style="font-family: Wingdings">            ¨           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Satisfactory completion of an FDA pre-approval inspection    of the manufacturing facility or facilities where the drug is produced to assess compliance with cGMP requirements to assure that    the facilities, methods and controls are adequate to preserve the drug’s identity, strength, quality and purity;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px">           <font style="font-family: Wingdings">            ¨           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Potential FDA audit of the nonclinical study and/or    clinical trial sites that generated the data in support of the NDA; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px">           <font style="font-family: Wingdings">            ¨           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            FDA review and approval of the NDA, including consideration    of the views of any FDA advisory committee, prior to any commercial marketing or sale of the drug in the United States.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The nonclinical and clinical testing and approvalprocess requires substantial time, effort and financial resources, and we cannot be certain that any approvals for our product candidateswill be granted on a timely basis, if at all.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 9; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         9         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The data required to support an NDA is generatedin two distinct development stages: nonclinical and clinical. For new chemical entities, the nonclinical development stage generallyinvolves synthesizing the active component, developing the formulation and determining the manufacturing process, as well as carryingout non-human toxicology, pharmacology and drug metabolism studies in the laboratory, which support subsequent clinical testing. Thesenonclinical tests include laboratory evaluation of product chemistry, formulation, stability and toxicity, as well as animal studiesto assess the characteristics and potential safety and efficacy of the product. The conduct of the nonclinical tests must comply withfederal regulations, including GLPs. The sponsor must submit the results of the nonclinical tests, together with manufacturing information,analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. An IND isa request for authorization from the FDA to administer an investigational drug product to humans. Some nonclinical testing may continueeven after the IND is submitted, but an IND must become effective before human clinical trials may begin. The central focus of an INDsubmission is on the general investigational plan and the protocol(s) for human trials. The IND automatically becomes effective30 days after receipt by the FDA, unless the FDA raises concerns or questions regarding the proposed clinical trials, including concernsthat human research subjects will be exposed to unreasonable health risks, and places the IND on clinical hold within that 30-day timeperiod. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDAmay also impose clinical holds on a drug candidate at any time before or during clinical trials due to safety concerns or non-compliance.Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun,issues will not arise that could cause the trial to be suspended or terminated.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The clinical stage of development involves theadministration of the drug candidate to healthy volunteers or patients under the supervision of qualified investigators, generally physiciansnot employed by or under the trial sponsor’s control, in accordance with GCPs, which include the requirement that all researchsubjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocolsdetailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria andthe parameters to be used to monitor subject safety and assess efficacy. Each protocol, and any subsequent amendments to the protocol,must be submitted to the FDA as part of the IND. Further, each clinical trial must be reviewed and approved by an independent institutionalreview board, or IRB, at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protectingthe welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinicaltrials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that mustbe provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completion. Thereare also requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        A sponsor who wishes to conduct a clinical trialoutside the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinicaltrial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of an NDA so long as theclinical trial is conducted in compliance with GCP and FDA is able to validate the data through an onsite inspection if the agency deemsit necessary.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Clinical trials         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Clinical trials are generally conducted in threesequential phases that may overlap, known as Phase 1, Phase 2 and Phase 3 clinical trials.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px">           <font style="font-family: Wingdings">            ¨           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Phase 1 clinical trials generally involve a small number    of healthy volunteers who are initially exposed to a single dose and then multiple doses of the product candidate. The primary purpose    of these clinical trials is to assess the metabolism, pharmacologic action, side effect tolerability and safety of the drug.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px">           <font style="font-family: Wingdings">            ¨           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Phase 2 clinical trials typically involve studies in    disease-affected patients to determine the dose required to produce the desired benefits and provide a preliminary evaluation of    efficacy. At the same time, safety and further pharmacokinetic and pharmacodynamic information is collected, as well as identification    of possible adverse effects and safety risks.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px">           <font style="font-family: Wingdings">            ¨           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Phase 3 clinical trials generally involve large numbers    of patients at multiple sites (from several hundred to several thousand subjects) and are designed to provide the data necessary    to demonstrate the effectiveness of the product for its intended use, its safety in use and to establish the overall benefit/risk    relationship of the product and provide an adequate basis for physician labeling. Phase 3 clinical trials may include comparisons    with placebo and/or comparator treatments.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Post-approval trials, sometimes referred to asPhase 4 clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience fromthe treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the conduct of Phase 4 clinicaltrials as a condition of approval of an NDA.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 10; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         10         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Progress reports detailing the results of theclinical trials must be submitted at least annually to the FDA. Written IND safety reports must be submitted to the FDA and the investigatorswithin 15 calendar days for serious and unexpected suspected adverse events, finding from other studies or animal or in vitro testingthat suggests a significant risk for human subjects, and any clinically important increase in the rate of a serious suspected adversereaction over that listed in the protocol or investigator brochure. Additionally, a sponsor must notify the FDA of any unexpected fatalor life-threatening suspected adverse reaction within 7 calendar days. Phase 1, Phase 2 and Phase 3 clinical trials may not be completedsuccessfully within any specified period, if at all. The FDA or the sponsor may suspend or terminate a clinical trial at any time onvarious grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly,an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordancewith the IRB's requirements or if the drug has been associated with unexpected serious harm to patients. Additionally, some clinicaltrials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoringboard or committee. This group provides authorization for whether or not a trial may move forward at designated check points based onaccess to certain data from the trial.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Pursuant to the Cures Act, the manufacturer ofan investigational drug for a serious disease or condition is required to make available, such as by posting on its website, its policyon evaluating and responding to requests for individual patient access to such investigational drug. This requirement applies on thelater of 60 calendar days after the date of enactment of the Cures Act or the first initiation of a Phase 2 or Phase 3 trial of the investigationaldrug.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Concurrent with clinical trials, companies usuallycomplete additional animal studies and must also develop additional information about the chemistry and physical characteristics of thedrug as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturingprocess must be capable of consistently producing quality batches of the drug candidate and, among other things, the sponsor must developmethods for testing the identity, strength, quality and purity of the final drug product. Additionally, appropriate packaging must beselected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deteriorationover its shelf life.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>          NDA and FDA review process         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The results of the nonclinical studies and clinicaltrials, together with other detailed information, including extensive manufacturing information and information on the composition ofthe drug and proposed labeling, are submitted to the FDA in the form of an NDA requesting approval to market the drug for one or morespecified indications. The FDA reviews an NDA to determine, among other things, whether a drug is safe and effective for its intendeduse and whether the product is being manufactured in accordance with cGMP to assure and preserve the product's identity, strength, qualityand purity. FDA approval of an NDA must be obtained before a drug may be offered for sale in the United States.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In addition, under the Pediatric Research EquityAct, or PREA, an NDA or supplement to an NDA must contain data to assess the safety and efficacy of the drug for the claimed indicationsin all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the productis safe and effective. The FDA may grant deferrals for submission of pediatric data or full or partial waivers.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The FDA reviews all NDAs submitted before itaccepts them for filing and may request additional information rather than accepting an NDA for filing. The FDA must make a decisionon accepting an NDA for filing within 60 days of receipt. Once the submission is accepted for filing, the FDA begins an in-depth reviewof the NDA. Under the goals and policies agreed to by the FDA under Prescription Drug User Fee Act, or PDUFA, for drugs that do not containa new chemical entity the FDA has 10 months from the receipt date in which to complete its initial review of a standard NDA and respondto the applicant, and six months from the receipt date for a priority NDA. For drugs containing a new chemical entity, these 10 and sixmonth review timeframes are from the filing date of an NDA. The FDA does not always meet its PDUFA goal dates for standard and priorityNDAs, and the review process is often significantly extended by FDA requests for additional information or clarification.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        After the NDA submission is accepted for filing,the FDA reviews the NDA to determine, among other things, whether the proposed product is safe and effective for its intended use, andwhether the product is being manufactured in accordance with cGMP to assure and preserve the product's identity, strength, quality andpurity. Before approving an NDA, the FDA will conduct a pre-approval inspection of the manufacturing facilities for the new product todetermine whether they comply with cGMPs. The FDA will not approve the product unless it determines that the manufacturing processesand facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications.In addition, before approving an NDA, the FDA may also audit data from clinical trials to ensure compliance with GCP requirements. Additionally,the FDA may refer applications for novel drug products or drug products which present difficult questions of safety or efficacy to anadvisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whetherthe application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, butit considers such recommendations carefully when making decisions. The review and evaluation of an NDA by the FDA is extensive and timeconsuming and may take longer than originally planned to complete, and we may not receive a timely approval, if at all.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 11; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         11         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        After the FDA evaluates an NDA, it may issuean approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with specific prescribinginformation for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and theapplication is not ready for approval. A Complete Response Letter usually describes all of the specific deficiencies in the NDA identifiedby the FDA. The Complete Response Letter may require additional clinical data and/or an additional pivotal Phase 3 clinical trial(s),and/or other significant and time-consuming requirements related to clinical trials, nonclinical studies or manufacturing. If a CompleteResponse Letter is issued, the applicant may resubmit the NDA addressing all of the deficiencies identified in the letter, withdraw theapplication, or request an opportunity for a hearing. Even if such data and information is submitted, the FDA may ultimately decide thatthe NDA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive and the FDA may interpretdata differently than we interpret the same data.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        There is no assurance that the FDA will ultimatelyapprove a drug product for marketing in the United States and we may encounter significant difficulties or costs during the review process.If a product receives marketing approval, the approval may be significantly limited to specific diseases and dosages or the indicationsfor use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certaincontraindications, warnings or precautions be included in the product labeling or may condition the approval of the NDA on other changesto the proposed labeling, development of adequate controls and specifications, or a commitment to conduct post-marketing testing or clinicaltrials and surveillance to monitor the effects of approved products. For example, the FDA may require Phase 4 testing which involvesclinical trials designed to further assess a drug's safety and efficacy and may require testing and surveillance programs to monitorthe safety of approved products that have been commercialized. The FDA also may place other conditions on approvals including the requirementfor a risk evaluation and mitigation strategy, or REMS, to assure the safe use of the drug. A REMS could include medication guides, physiciancommunication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimizationtools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensingof products. Product approvals may be withdrawn for non-compliance with regulatory requirements or if problems occur following initialmarketing. As a condition to the FDA's approval of Probuphine, Braeburn was required to put the Probuphine REMS in place.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>          505(b)(1) approval process         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Section 505(b)(1) of the FDCA provideswhat is considered traditional drug development pathway to FDA approval of a drug product. This pathway is typically used for novel drugsthat have not been previously studied or approved. This development approach requires the sponsor to conduct all studies necessary todemonstrate the safety and efficacy of the drug product.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>          505(b)(2) approval process         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Section 505(b)(2) of the FDCA providesan alternate regulatory pathway to FDA approval for new or improved formulations or new uses of previously approved drug products. Specifically,Section 505(b)(2) was enacted as part of the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referredto as the Hatch-Waxman Amendments, and permits the filing of an NDA where at least one or more of the investigations relied upon by theapplicant for approval were not conducted by or for the applicant and for which the applicant has not obtained a right of reference oruse from the person by or for whom the investigations were conducted. The applicant may rely upon the FDA's prior findings of safetyand effectiveness for a previously approved product or on published scientific literature, in support of its application. The FDA mayalso require 505(b)(2) applicants to perform additional trials to support the changes from the previously approved drug and to furtherdemonstrate the new drug's safety and effectiveness. The FDA may then approve the new product candidate for all or some of the labeledindications for which the referenced product has been approved, as well as for any new indication sought by the Section 505(b)(2) applicant.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>          Expedited development and review programs         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The FDA has a Fast Track program that is intendedto expedite or facilitate the process for reviewing new drugs that meet certain criteria. Specifically, new drugs are eligible for FastTrack designation if they are intended to treat a serious or life-threatening condition and demonstrate the potential to address unmetmedical needs for the condition. Fast Track designation applies to the combination of the product and the specific indication for whichit is being studied. Any product submitted to the FDA for marketing, including under the Fast Track program, may be eligible for othertypes of FDA programs intended to expedite development and review, such as priority review. A product is eligible for priority reviewif it has the potential to provide safe and effective therapy where no satisfactory alternative therapy exists or offers a significantimprovement in the treatment, diagnosis or prevention of a disease compared to marketed products. Additionally, a drug may be eligiblefor designation as a breakthrough therapy if the drug is intended, alone or in combination with one or more other drugs, to treat a seriousor life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvementover existing therapies on one or more clinical development. Fast Track designation, priority review, and breakthrough designation donot change the standards for approval but may expedite the development or approval process.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 12; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         12         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>          Pediatric trials         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The Food and Drug Administration Safety and InnovationAct, or FDASIA, which was signed into law on July 9, 2012, amended the FDCA to require that a sponsor who is planning to submita marketing application for a drug that includes a new active ingredient, new indication, new dosage form, new dosing regimen or newroute of administration submit an initial Pediatric Study Plan, or PSP, that includes within 60 days of an end-of-Phase 2 meeting oras may be agreed between the sponsor and the FDA. The initial PSP must include an outline of the pediatric study or studies that thesponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach, or a justificationfor not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of therequirement to provide data from pediatric studies along with supporting information.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>          Reimbursement         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Sales of any product candidates we may successfullydevelop will depend, in part, on the extent to which such products are covered by third-party payors, such as government health programs,commercial insurance and managed healthcare organizations. In the United States no uniform policy of coverage and reimbursement for drugproducts exists. Accordingly, decisions regarding the extent of coverage and amount of reimbursement to be provided for any productswill be made on a payor by payor basis. As a result, the coverage determination process is often a time-consuming and costly processthat will require our licensees to provide scientific and clinical support for the use of our product to each payor separately, withno assurance that coverage and adequate reimbursement will be obtained.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>          Affordable Care Act and other reform initiatives         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In the United States and some foreign jurisdictions,there have been, and likely will continue to be, a number of legislative and regulatory changes and proposed changes regarding the healthcaresystem directed at broadening the availability of healthcare, improving the quality of healthcare, and containing or lowering the costof healthcare.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        For example, in March 2010, the ACA wasenacted in the United States. The ACA includes measures that have significantly changed, and are expected to continue to significantlychange, the way healthcare is financed by both governmental and private insurers. There have been judicial and Congressional challengesto the ACA, and we expect such challenges and amendments to continue in the future. Other legislative changes have been proposed andadopted in the United States since the ACA was enacted and there has been increasing legislative and enforcement interest in the UnitedStates with respect to specialty drug pricing practices.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        We cannot predict what healthcare reform initiativesmay be adopted in the future. Further federal, state and foreign legislative and regulatory developments are likely, and we expect ongoinginitiatives to increase pressure on drug pricing. Such reforms could have an adverse effect on anticipated revenues from product candidatesand may affect our overall financial condition and ability to develop product candidates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Employees        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        As of March 26, 2021, we had 12 full-timeemployees.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 13; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         13         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="text-align: left; width: 70px">           <a name="a_003">           </a>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Item    1A.            </b>           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Risk Factors            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Risks Related to Our Business and Industry        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>          Our ProNeura development programs are atvery early stages and will require substantial additional resources that may not be available to us.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <font style="color: #231F20">         To date, other thanour work on Probuphine in OUD, and our work on nalmefene, we have conducted only limited research and development activities assessingour ProNeura delivery system’s applicability in other potential indications. While the nalmefene program is being funded in largepart by NIDA, there is no assurance that NIDA will continue to provide the necessary funding to complete the regulatory approval processfor this product candidate. We will also require substantial additional funds        </font>        to advance TP-2021 beyond the proof-of-concept stageand        <font style="color: #231F20">         to support further research and development activities, including the anticipated costs of nonclinicalstudies and clinical trials, regulatory approvals and eventual commercialization of any therapeutic based on our ProNeura platform technology.If we are unable to obtain substantial government grants or enter into third party collaborations to fund our ProNeura programs, we willneed to seek additional sources of financing, which may not be available on favorable terms, if at all. If we do not succeed in obtainingthe requisite funding for our ProNeura programs, we could be forced to discontinue product development. Furthermore, funding arrangementswith collaborative partners or others may require us to relinquish rights to technologies, product candidates or products that we wouldotherwise seek to develop or commercialize ourselves or license rights to technologies, product candidates or products on terms thatare less favorable to us than might otherwise be available.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231F20">        Our ability to successfully developany future product candidates based on our ProNeura drug delivery technology is subject to the risks of failure and delay inherent inthe development of new pharmaceutical products, including: delays in product development, clinical testing, or manufacturing; unplannedexpenditures in product development, clinical testing, or manufacturing; failure to receive regulatory approvals; emergence of superioror equivalent products; inability to manufacture on our own, or through any others, product candidates on a commercial scale; and failureto achieve market acceptance. Importantly, if the TP-2021 initial proof-of-concept efforts are unsuccessful and we discontinue this program,our future prospects could be materially adversely impacted. Because of these risks, our research and development efforts may not resultin any commercially viable products and our business, financial condition, and results of operations could be materially harmed.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Clinicaltrials required for new product candidates are expensive and time-consuming, and their outcome is uncertain          </i>         </b>        </font>        <i>         .        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Conducting clinical trials is a lengthy, time-consuming,and expensive process. The length of time may vary substantially according to the type, complexity, novelty, and intended use of theproduct candidate, and often can be several years or more per trial. Delays associated with products for which we are directly conductingclinical trials may cause us to incur additional operating expenses. The commencement and rate of completion of clinical trials may bedelayed by many factors, including, for example:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 23px; text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            •           </font>          </td>          <td style="text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            inability to manufacture    sufficient quantities of qualified materials under cGMP for use in clinical trials;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 23px; text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            •           </font>          </td>          <td style="text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            slower than expected rates    of patient recruitment;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 23px; text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            •           </font>          </td>          <td style="text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            failure to recruit a sufficient    number of patients; modification of clinical trial protocols;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 23px; text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            •           </font>          </td>          <td style="text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            changes in regulatory requirements    for clinical trials;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 23px; text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            •           </font>          </td>          <td style="text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the lack of effectiveness    during clinical trials;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 23px; text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            •           </font>          </td>          <td style="text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the emergence of unforeseen    safety issues;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 23px; text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            •           </font>          </td>          <td style="text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            delays, suspension, or    termination of the clinical trials due to the institutional review board responsible for overseeing the study at a particular study    site; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 23px; text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            •           </font>          </td>          <td style="text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            government or regulatory    delays or “clinical holds” requiring suspension or termination of the trials.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The results from early clinical trials are notnecessarily predictive of results obtained in later clinical trials. Accordingly, even if we obtain positive results from early clinicaltrials, we may not achieve the same success in future clinical trials. Clinical trials may not demonstrate statistically significantsafety and effectiveness to obtain the requisite regulatory approvals for product candidates. The failure of clinical trials to demonstratesafety and effectiveness for the desired indications could cause us to abandon a product candidate and could delay development of otherproduct candidates. Any delay in, or termination of, our clinical trials could materially harm our business, financial condition, andresults of operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 14; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         14         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>          The winding down of our commercial operationsmay be more costly and time-consuming than we anticipate.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The cessation of our Probuphine related commercialactivities requires us to comply with FDA and state regulatory requirements, including those related to notifications to various stakeholdersand the continuation of adverse event reporting, as well as to address a number of business considerations, such as termination of third-partyagreements and transfer of manufacturing equipment. The costs and timing associated with the wind down of our commercial operations mayexceed our current estimates, requiring a reallocation of proceeds that may limit what we can accomplish in our product development programsunless additional financing is procured sooner than we currently anticipate.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Weface risks associated with third parties conducting preclinical studies and clinical trials of our products          </i>         </b>        </font>        <i>         .        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        We depend on third-party laboratories and medicalinstitutions to conduct preclinical studies and clinical trials for our products and other third-party organizations to perform datacollection and analysis, all of which must maintain both good laboratory and good clinical practices. We also depend upon third partymanufacturers for the production of any products we may successfully develop to comply with cGMP of the FDA, which are similarly outsideour direct control. If third party laboratories and medical institutions conducting studies of our products fail to maintain both goodlaboratory and clinical practices, the studies could be delayed or have to be repeated.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Weface risks associated with product liability lawsuits that could be brought against us          </i>         </b>        </font>        <i>         .        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The testing, manufacturing, marketing and saleof human therapeutic products entail an inherent risk of product liability claims. We currently have a limited amount of product liabilityinsurance, which may not be sufficient to cover claims that may be made against us in the event that the use or misuse of our productcandidates causes, or merely appears to have caused, personal injury or death. In the event we are forced to expend significant fundson defending product liability actions, and in the event those funds come from operating capital, we will be required to reduce our businessactivities, which could lead to significant losses. Adequate insurance coverage may not be available in the future on acceptable terms,if at all. If available, we may not be able to maintain any such insurance at sufficient levels of coverage and any such insurance maynot provide adequate protection against potential liabilities. Whether or not a product liability insurance policy is obtained or maintainedin the future, any claims against us, regardless of their merit, could severely harm our financial condition, strain our management andother resources or destroy the prospects for commercialization of the product which is the subject of any such claim.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Wemay be unable to protect our patents and proprietary rights          </i>         </b>        </font>        <i>         .        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Our future success will depend to a significantextent on our ability to:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 23px; text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            •           </font>          </td>          <td style="text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            obtain and keep patent    protection for our products, methods and technologies on a domestic and international basis;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 23px; text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            •           </font>          </td>          <td style="text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            enforce our patents to    prevent others from using our inventions;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 23px; text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            •           </font>          </td>          <td style="text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            maintain and prevent others    from using our trade secrets; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 23px; text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            •           </font>          </td>          <td style="text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            operate and commercialize    products without infringing on the patents or proprietary rights of others.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        We cannot assure you that our patent rights willafford any competitive advantages, and these rights may be challenged or circumvented by third parties. Further, patents may not be issuedon any of our pending patent applications in the U.S. or abroad. Because of the extensive time required for development, testing andregulatory review of a potential product, it is possible that before a potential product can be commercialized, any related patent mayexpire or remain in existence for only a short period following commercialization, reducing or eliminating any advantage of the patent.If we sue others for infringing our patents, a court may determine that such patents are invalid or unenforceable. Even if the validityof our patent rights is upheld by a court, a court may not prevent the alleged infringement of our patent rights on the grounds thatsuch activity is not covered by our patent claims.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In addition, third parties may sue us for infringingtheir patents. In the event of a successful claim of infringement against us, we may be required to:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 23px; text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            •           </font>          </td>          <td style="text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            pay substantial damages;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 23px; text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            •           </font>          </td>          <td style="text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            stop using our technologies    and methods;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 23px; text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            •           </font>          </td>          <td style="text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            stop certain research and    development efforts;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <!-- Field: Page; Sequence: 15; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         15         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 23px; text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            •           </font>          </td>          <td style="text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            develop non-infringing    products or methods; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 23px; text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            •           </font>          </td>          <td style="text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            obtain one or more licenses    from third parties.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        If required, we cannot assure you that we willbe able to obtain such licenses on acceptable terms, or at all. If we are sued for infringement, we could encounter substantial delaysin development, manufacture and commercialization of our product candidates. Any litigation, whether to enforce our patent rights orto defend against allegations that we infringe third party rights, will be costly, time consuming, and may distract management from otherimportant tasks.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        We also rely in our business on trade secrets,know-how and other proprietary information. We seek to protect this information, in part, through the use of confidentiality agreementswith employees, consultants, advisors and others. Nonetheless, we cannot assure you that those agreements will provide adequate protectionfor our trade secrets, know-how or other proprietary information and prevent their unauthorized use or disclosure. To the extent thatconsultants, key employees or other third parties apply technological information independently developed by them or by others to ourproposed products, disputes may arise as to the proprietary rights to such information, which may not be resolved in our favor.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Wemust comply with extensive government regulations          </i>         </b>        </font>        <i>         .        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The research, development, manufacture, labeling,storage, record-keeping, advertising, promotion, import, export, marketing and distribution of pharmaceutical products are subject toan extensive regulatory approval process by the FDA in the U.S. and comparable health authorities in foreign markets. The process ofobtaining required regulatory approvals for drugs is lengthy, expensive and uncertain. Approval policies or regulations may change, andthe FDA and foreign authorities have substantial discretion in the pharmaceutical approval process, including the ability to delay, limitor deny approval of a product candidate for many reasons. Despite the time and expense invested in clinical development of product candidates,regulatory approval is never guaranteed. Regulatory approval may entail limitations on the indicated usage of a drug, which may reducethe drug’s market potential. Even if regulatory clearance is obtained, post-market evaluation of the products, if required, couldresult in restrictions on a product’s marketing or withdrawal of the product from the market, as well as possible civil and criminalsanctions. Of the large number of drugs in development, only a small percentage successfully complete the regulatory approval processand are commercialized.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Weface intense competition          </i>         </b>        </font>        <i>         .        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        With respect to our product development programs,we face competition from numerous companies that currently market, or are developing, products for the treatment of the diseases anddisorders we have targeted, many of which have significantly greater research and development capabilities, experience in obtaining regulatoryapprovals and manufacturing, marketing, financial and managerial resources than we have. We also compete with universities and otherresearch institutions in the development of products, technologies and processes, as well as the recruitment of highly qualified personnel.Our competitors may succeed in developing technologies or products that are more effective than the ones we have under development orthat render our proposed products or technologies noncompetitive or obsolete. In addition, our competitors may achieve product commercializationor patent protection earlier than we will.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Wedepend on a small number of employees and consultants          </i>         </b>        </font>        <i>         .        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        We are highly dependent on the services of alimited number of personnel and the loss of one or more of such individuals could substantially impair our ongoing commercializationefforts. We compete in our hiring efforts with other pharmaceutical and biotechnology companies and it may be difficult and could takean extended period of time because of the limited number of individuals in our industry with the range of skills and experience requiredand because of our limited resources.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In addition, we retain scientific and clinicaladvisors and consultants to assist us in all aspects of our business. Competition to hire and retain consultants from a limited poolis intense. Further, because these advisors are not our employees, they may have commitments to, or consulting or advisory contractswith, other entities that may limit their availability to us, and typically they will not enter into non-compete agreements with us.If a conflict of interest arises between their work for us and their work for another entity, we may lose their services. In addition,our advisors may have arrangements with other companies to assist those companies in developing products or technologies that may competewith ours.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 16; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         16         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Weface potential liability related to the privacy of health information we obtain from clinical trials sponsored by us or our collaborators,from research institutions and our collaborators, and directly from individuals          </i>         </b>        </font>        <i>         .        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Numerous federal and state laws, including statesecurity breach notification laws, state health information privacy laws, and federal and state consumer protection laws, govern thecollection, use, and disclosure of personal information. In addition, most health care providers, including research institutions fromwhich we or our collaborators obtain patient health information, are subject to privacy and security regulations promulgated under theHealth Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic andClinical Health Act. Although we are not directly subject to HIPAA, we could potentially be subject to criminal penalties if we, ouraffiliates, or our agents knowingly obtain or disclose individually identifiable health information maintained by a HIPAA-covered entityin a manner that is not authorized or permitted by HIPAA.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Weface risks related to health epidemics, such as the current COVID-19 global pandemic, that could adversely affect our operations or financialresults          </i>         </b>        </font>        <i>         .        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The spread of COVID-19, the novel coronavirus,including restrictions on travel, “shelter in place” orders, and quarantine policies put into place by businesses and stateand local governments to mitigate its transmission, may have a material adverse effect on our business. While the duration of the pandemicand its potential economic impact are difficult to predict, it already has caused significant disruption in the healthcare industry andis likely to have continuing impacts as it continues. The travel restrictions, “shelter in place” orders, quarantine policies,and general concerns about the spread of COVID-19 was a significant factor in our decision to wind down our commercial operations becauseof the resulting disruptions in the delivery of healthcare to patients, our sales and marketing efforts and REMS training activities,as well as the operations of the various parts of our supply and distribution chain. The ultimate impact of the COVID-19 pandemic, orany other health epidemic, is highly uncertain and subject to change. We do not yet know the full extent of potential impacts on ourbusiness, healthcare systems or the global economy as a whole. As the pandemic continues, it may result in a sustained economic downturnthat could affect our ability to access capital on reasonable terms, or at all.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">        <b>         RisksRelated to Our Financial Condition and Need for Additional Capital        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Wehave incurred net losses in almost every year since our inception and we may never achieve profitability          </i>         </b>        </font>        .       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        We have incurred net losses in almost every yearsince our inception. Our financial statements have been prepared assuming that we will continue as a going concern. For the years endedDecember 31, 2020 and 2019, we had net losses of approximately $18.2 million and $16.5 million, respectively, and had net cash usedin operating activities of approximately $17.2 million and $15.4 million, respectively. These net losses and negative cash flows havehad, and will continue to have, an adverse effect on our stockholders’ equity and working capital. We expect to continue to incurnet losses and negative operating cash flow for the foreseeable future as we wind down our commercial activities and focus on developmentof ProNeura based products. The amount of future net losses will depend, in part, on the rate of future growth of our expenses and ourability to obtain government or third party funding for our development programs. We may never achieve profitability.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Wewill require additional proceeds to fund our product development programs          </i>         </b>        </font>        .       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        We currently estimate that our available cashand cash equivalents will be sufficient to fund our working capital needs and product development efforts into the first quarter of 2022.We will require additional funds to advance TP-2021 beyond the proof-of-concept stage, if successful, for which we expect to have theresults of the initial studies during the second or third quarter of 2021, and to fund any of our ProNeura development programs intothe clinic and to complete the regulatory approval process necessary to commercialize any products we might develop. While we are currentlyevaluating the alternatives available to us, including government grants and third-party collaborations for one or more of our ProNeuraprograms, our efforts to address our liquidity requirements may not be successful. There can be no assurance that any source of capitalwill be available to us on acceptable terms.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>          Our net operating losses and research anddevelopment tax credits may not be available to reduce future federal and state income tax payments.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        At December 31, 2020, we had federal netoperating loss and tax credit carryforwards of approximately $268.8 million and approximately $8.0 million, respectively, and state netoperating loss and tax credit carryforwards of approximately $109.7 million and approximately $9.2 million, respectively, available tooffset future taxable income, if any. Current federal and state tax laws include substantial restrictions on the utilization of net operatingloss and tax credits in the event of an ownership change and we cannot assure you that our net operating loss and tax carryforwards willcontinue to be available.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 17; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         17         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Wereceived a loan under the Paycheck Protection Program of the CARES Act, and all or a portion of the loan may not be forgivable          </i>         </b>        </font>        .       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        On April 20, 2020, we received an approximately$0.7 million PPP Loan pursuant to the Paycheck Protection Program of the CARES Act. The PPP Loan matures in April 2022 with an annualinterest rate of 1.0%. The PPP Loan has a sixteen month deferral of payments period and may be prepaid at any time without penalty. Theproceeds of the PPP Loan are to be used to retain workers and maintain payroll and make mortgage interest, lease and utility payments.Under the CARES Act, we will be eligible to apply for forgiveness of all loan proceeds used to pay payroll costs, rent, utilities andother qualifying expenses during the 24-week period following receipt of the loan, provided that we maintain our number of employeesand compensation within certain parameters during such period. Not more than 40% of the forgiven amount may be for non-payroll costs.If the conditions outlined in the PPP loan program are adhered to by us, all or part of such loan could be forgiven. However, we cannotprovide any assurance that we will be eligible for loan forgiveness or that any amount of the PPP loan will ultimately be forgiven bythe SBA. Any forgiven amounts will not be included in our taxable income.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Risks Related to our Common Stock        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         Our failure to meet the continued listingrequirements of Nasdaq could result in a de-listing of our common stock.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        During 2020, we received several notices fromthe Listing Qualifications Department the Nasdaq Stock Market, or Nasdaq, regarding the fact that the market price of our common stockwas below the $1.00 minimum bid price requirement for continued listing. As a result of the reverse stock split we effected on November30, 2020, we were able to regain compliance with the minimum bid requirement and remain listed on Nasdaq. We have also previously receivednotices of noncompliance due to our failure to maintain the $2,500,000 minimum stockholders’ equity requirement for continued listing.We were able to regain compliance with that requirement through capital raises and our discontinuation of the expenses associated withProbuphine commercial operations. There can be no assurance that we will continue to meet all of the criteria necessary for Nasdaq toallow us to remain listed.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        If our common stock is delisted from Nasdaq,our common stock would likely then trade only in the over-the- counter market. If our common stock were to trade on the over-the-countermarket, selling our common stock could be more difficult because smaller quantities of shares would likely be bought and sold, transactionscould be delayed, and we could face significant material adverse consequences, including: a limited availability of market quotationsfor our securities; reduced liquidity with respect to our securities; a determination that our shares are a “penny stock,”which will require brokers trading in our securities to adhere to more stringent rules, possibly resulting in a reduced level of tradingactivity in the secondary trading market for our securities; a reduced amount of news and analyst coverage for our Company; and a decreasedability to issue additional securities or obtain additional financing in the future. These factors could result in lower prices and largerspreads in the bid and ask prices for our common stock and would substantially impair our ability to raise additional funds and couldresult in a loss of institutional investor interest and fewer development opportunities for us.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In addition to the foregoing, if our common stockis delisted from Nasdaq and it trades on the over-the- counter market, the application of the “penny stock” rules couldadversely affect the market price of our common stock and increase the transaction costs to sell those shares. The Securities and ExchangeCommission, or SEC, has adopted regulations which generally define a “penny stock” as an equity security that has a marketprice of less than $5.00 per share, subject to specific exemptions. If our common stock is delisted from Nasdaq and it trades on theover-the- counter market at a price of less than $5.00 per share, our common stock would be considered a penny stock. The SEC’spenny stock rules require a broker-dealer, before a transaction in a penny stock not otherwise exempt from the rules, to delivera standardized risk disclosure document that provides information about penny stocks and the risks in the penny stock market. The broker-dealermust also provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and thesalesperson in the transaction, and monthly account statements showing the market value of each penny stock held in the customer’saccount. In addition, the penny stock rules generally require that before a transaction in a penny stock occurs, the broker-dealermust make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser’sagreement to the transaction. If applicable in the future, these rules may restrict the ability of brokers-dealers to sell our commonstock and may affect the ability of investors to sell their shares, until our common stock no longer is considered a penny stock.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>          Our share price may be volatile, whichcould prevent you from being able to sell your shares at or above your purchase price.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in">        The market price of sharesof our common stock has been and may continue to be subject to wide fluctuations in response to many risk factors listed in this section,and others beyond our control, including:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 24px; text-indent: 0.25in">           •          </td>          <td style="text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            results of our product    development efforts;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 24px; text-indent: 0.25in">           •          </td>          <td style="text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            regulatory actions with    respect to our products under development or our competitors’ products;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 24px; text-indent: 0.25in">           •          </td>          <td style="text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            actual or anticipated fluctuations    in our financial condition and operating results;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 24px; text-indent: 0.25in">           •          </td>          <td style="text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            actual or anticipated fluctuations    in our competitors’ operating results or growth rate;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <!-- Field: Page; Sequence: 18; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         18         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Split-Segment; Name: a3 -->       <p style="font-size: 10pt; margin-top: 0; margin-bottom: 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 24px; text-indent: 0.25in">           •          </td>          <td style="text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            announcements by us, our    potential future collaborators or our competitors of significant acquisitions, strategic collaborations, joint ventures, or capital    commitments;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 24px; text-indent: 0.25in">           •          </td>          <td style="text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            issuance of new or updated    research or reports by securities analysts;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 24px; text-indent: 0.25in">           •          </td>          <td style="text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            fluctuations in the valuation    of companies perceived by investors to be comparable to us;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 24px; text-indent: 0.25in">           •          </td>          <td style="text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            inconsistent trading volume    levels of our shares;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 24px; text-indent: 0.25in">           •          </td>          <td style="text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            additions or departures    of key personnel;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 24px; text-indent: 0.25in">           •          </td>          <td style="text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            disputes or other developments    related to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 24px; text-indent: 0.25in">           •          </td>          <td style="text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            announcement or expectation    of additional financing efforts;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 24px; text-indent: 0.25in">           •          </td>          <td style="text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            sales of our common stock    by us, our insiders or our other stockholders;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 24px; text-indent: 0.25in">           •          </td>          <td style="text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            market conditions for biopharmaceutical    stocks in general; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 24px; text-indent: 0.25in">           •          </td>          <td style="text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            general economic and market    conditions.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The stock markets have experienced extreme priceand volume fluctuations that have affected and continue to affect the market prices of equity securities of many companies. These fluctuationsoften have been unrelated or disproportionate to the operating performance of those companies. These broad market and industry fluctuations,as well as general economic, political and market conditions such as recessions, interest rate changes or international currency fluctuations,may negatively impact the market price of shares of our common stock and could subject us to securities class action litigation.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>          If securities or industry analysts do notpublish research or publish inaccurate or unfavorable research about our business, our share price and trading volume could decline.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The trading market for our common stock willdepend on the research and reports that securities or industry analysts publish about us or our business. We do not have any controlover these analysts. There can be no assurance that analysts will cover us or provide favorable coverage. If one or more of the analystswho cover us downgrade our stock or change their opinion of our stock, our share price would likely decline. If one or more of theseanalysts cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets,which could cause our share price or trading volume to decline.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>          Provisions in our corporate charter documentsand under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and mayprevent attempts by our stockholders to replace or remove our current management.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Provisions in our certificate of incorporationand our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of our company that stockholders mayconsider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions could alsolimit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market priceof our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, theseprovisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficultfor stockholders to replace members of our board of directors. Among other things, these provisions provide that:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 24px; text-indent: 0.25in">           •          </td>          <td style="text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the authorized number of    directors can be changed only by resolution of our board of directors;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 24px; text-indent: 0.25in">           •          </td>          <td style="text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our bylaws may be amended    or repealed by our board of directors or our stockholders;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 24px; text-indent: 0.25in">           •          </td>          <td style="text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            stockholders may not call    special meetings of the stockholders or fill vacancies on the board of directors;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 24px; text-indent: 0.25in">           •          </td>          <td style="text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our board of directors    is authorized to issue, without stockholder approval, preferred stock, the rights of which will be determined at the discretion of    the board of directors and that, if issued, could operate as a “poison pill” to dilute the stock ownership of a potential    hostile acquirer to prevent an acquisition that our board of directors does not approve;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <!-- Field: Page; Sequence: 19; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         19         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 24px; text-indent: 0.25in">           •          </td>          <td style="text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our stockholders do not    have cumulative voting rights, and therefore our stockholders holding a majority of the shares of common stock outstanding will be    able to elect all of our directors; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 24px; text-indent: 0.25in">           •          </td>          <td style="text-indent: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our stockholders must comply    with advance notice provisions to bring business before or nominate directors for election at a stockholder meeting.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Moreover, because we are incorporated in Delaware,we are governed by the provisions of Section 203 of the Delaware General Corporation Law, or the DGCL, which prohibits a personwho owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the dateof the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination isapproved in a prescribed manner.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         Future sales of our common stock, or the perceptionthat future sales may occur, may cause the market price of our common stock to decline, even if our business is doing well.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Sales by our stockholders of a substantial numberof shares of our common stock in the public market could occur in the future. These sales, or the perception in the market that the holdersof a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        We will seek to raise additional funds and mayfinance acquisitions or develop strategic relationships by issuing securities that would dilute your ownership. Depending on the termsavailable to us, if these activities result in significant dilution, it may negatively impact the trading price of our shares of commonstock.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        We have financed our operations, and we expectto continue to finance our operations, acquisitions, if any, and the development of strategic relationships by issuing equity and/orconvertible securities, which could significantly reduce the percentage ownership of our existing stockholders. Further, any additionalfinancing that we secure, including any debt financing, may require the granting of rights, preferences or privileges senior to, or paripassu with, those of our common stock. Any issuances by us of equity securities may be at or below the prevailing market price of ourcommon stock and in any event may have a dilutive impact on your ownership interest, which could cause the market price of our commonstock to decline. We may also raise additional funds through the incurrence of debt or the issuance or sale of other securities or instrumentssenior to our shares of common stock. The holders of any securities or instruments we may issue may have rights superior to the rightsof our common stockholders. If we experience dilution from the issuance of additional securities and we grant superior rights to newsecurities over common stockholders, it may negatively impact the trading price of our shares of common stock and you may lose all orpart of your investment.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         We have never paid any cash dividends andhave no plans to pay any cash dividends in the future.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Holders of shares of our common stock are entitledto receive such dividends as may be declared by our board of directors. To date, we have paid no cash dividends on our shares of ourpreferred or common stock and we do not expect to pay cash dividends in the foreseeable future. In addition, the declaration and paymentof cash dividends is restricted under the terms of our existing Loan Agreement. We intend to retain future earnings, if any, to providefunds for operations of our business. Therefore, any return investors in our preferred or common stock may have will be in the form ofappreciation, if any, in the market value of their shares of common stock.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 70px">           <a name="a_004">           </a>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Item 1B.            </b>           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Unresolved Staff Comments.            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        None.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 70px">           <a name="a_005">           </a>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Item 2.            </b>           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Properties            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in">        Our executive offices are locatedin approximately 9,255 square feet of office space in South San Francisco, California that we occupy under a five-year operating leaseexpiring in June 2021. It is our intention to reduce the office space commensurate with the current number of employees and continueto be based in South San Francisco.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 70px">           <a name="a_006">           </a>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Item 3.            </b>           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Legal Proceedings            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.35pt 0pt 0; text-indent: 0.25in">        A legal proceeding has been initiatedby a former employee alleging wrongful termination, retaliation, infliction of emotional distress, negligent supervision, hiring andretention and slander. An independent investigation into this individual’s allegations, while still an employee, was conductedutilizing an outside expert and concluded that such allegations were without merit. We intend to vigorously defend the lawsuit; however,in light of our cash position, there can be no assurance that the defense and/or settlement of this matter will not have a material adverseimpact on our business.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.35pt 0pt 0; text-indent: 0.25in">       </p>       <!-- Field: Page; Sequence: 20; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         20         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 70px">           <a name="a_007">           </a>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Item 4.            </b>           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Mine Safety Disclosures.            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Not applicable.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 21; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         21         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         <a name="a_008">         </a>         PART II        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 70px">           <a name="a_009">           </a>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Item 5.            </b>           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Market for Registrant’s    Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Our common stock is listed on the Nasdaq CapitalMarket (“Nasdaq”) under the symbol “TTNP”.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Approximate Number of Equity Security Holders        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        At March 26, 2021, there were 9,864,068shares of our common stock outstanding held by 84 holders of record. The number of record holders was determined from the records ofour transfer agent and does not include beneficial owners of common stock whose shares are held in the names of various security brokers,dealers, and registered clearing agencies.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Dividends        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        We have never declared or paid any cash dividendson our common stock and we do not anticipate paying any cash dividends to stockholders in the foreseeable future. Any future determinationto pay cash dividends will be at the discretion of our Board and will be dependent upon our financial condition, results of operations,capital requirements, and such other factors as the Board deems relevant.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Equity Compensation Plan Information        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The following table sets forth aggregate informationregarding our equity compensation plans in effect as of December 31, 2020:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">        <tbody>         <tr style="vertical-align: bottom">          <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">           Plan category          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Number of securities to           <br/>           be issued upon exercise           <br/>           of outstanding options,           <br/>           warrant and rights           <br/>           (a)          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Weighted-average           <br/>           exercise price of           <br/>           outstanding options,           <br/>           warrants and rights           <br/>           (b)          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Number of securities           <br/>           remaining available for           <br/>           future issuance under           <br/>           equity compensation           <br/>           plans           <br/>           (c)          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: left">           Equity compensation plans approved by security    holders(1)          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">           26,196          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">           210.65          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">           30,786          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Equity compensation plans not approved    by security holders(2)(3)          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           1,697          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           737.38          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif">           Total          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           27,893          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           242.70          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           30,786          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0px">          </td>          <td style="width: 22px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (1)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            In January 2021, our stockholders approved an    amendment to the 2015 Omnibus Equity Incentive plan to increase the number of authorized shares to 1,000,000 shares.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (2)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Includes 412 shares underlying options granted to employees    and consultants who are not officers or directors of Titan under our 2001 Employee Non-Qualified Stock Option Plan.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (3)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Includes 1,285 non-qualified stock options and restricted    share awards granted to employees, directors and consultants under our 2014 Incentive Plan. For a description of the 2014 Plan, see    Note 9 to the financial statements.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 70px">           <a name="a_010">           </a>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Item 6.            </b>           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Selected Financial Data            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Not applicable       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 22; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         22         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="margin-top: 0; margin-bottom: 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 70px">           <a name="a_011">           </a>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Item 7.            </b>           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Management’s Discussion    and Analysis of Financial Condition and Results of Operations.            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <i>         You should read the following discussion andanalysis of our financial condition and results of our operations together with its financial statements and the notes thereto appearingelsewhere in this report. This discussion contains forward-looking statements reflecting our current expectations, whose actual outcomesinvolve risks and uncertainties. Actual results and the timing of events may differ materially from those stated in or implied by theseforward-looking statements due to a number of factors, including those discussed in the sections entitled “Risk Factors”, “Cautionary Statement regarding Forward-Looking Statements” and elsewhere in this report.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>          Overview         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        We are a pharmaceutical company developing therapeuticsutilizing our proprietary long-term drug delivery platform, ProNeura™, for the treatment of select chronic diseases for which steadystate delivery of a drug provides an efficacy and/or safety benefit. ProNeura consists of a small, solid implant made from a mixtureof ethylene-vinyl acetate, or EVA, and a drug substance. The resulting product is a solid matrix that is administered subdermally, normallyin the inner upper arm, in a brief, outpatient procedure and is removed in a similar manner at the end of the treatment period of severalmonths. These procedures may be performed by trained health care providers, or HCPs, including licensed and surgically qualified physicians,nurse practitioners, and physician’s assistants in a HCP’s office or other clinical setting.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Our first product based on our ProNeura technologywas our Probuphine® (buprenorphine) implant, which was approved in the United States, Canada and the European Union, or EU, for themaintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine. Followingreacquisition of the rights to Probuphine from our former licensee in mid-2018, we endeavored to build our infrastructure and grow ourcommercial capabilities with the limited resources at our disposal. While we made important progress in laying the groundwork during2019 to transition into a company with full commercial potential, and also among other things manage the challenges of the restrictiveproduct label, the Risk Evaluation and Mitigation Strategy, or REMS, program        <font style="color: #333333">         and the complexity of the distributionchannel        </font>        , the emergence of the Covid-19 pandemic in early 2020 and the resultant restrictions and lockdown of facilities severelyimpacted our ability to continue to expand our commercial operations. With limited financial resources and insufficient sales revenueduring the first three quarters of 2020, we made the decision to discontinue selling Probuphine in the U.S. and wind down our commercializationactivities, and to pursue a plan that will enable us to focus on our current, early-stage ProNeura-based product development programs.Probuphine continues to be commercialized in Canada and the EU by other companies who have either licensed or acquired the rights fromTitan.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        We operate in only one business segment, thedevelopment of pharmaceutical products. We make available free of charge through our website, www.titanpharm.com, our periodic reportsas soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Critical Accounting Policies and the Use of Estimates        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The preparation of our financial statements inconformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions thataffect the amounts reported in our financial statements and accompanying notes. Actual results could differ materially from those estimates.We believe the following accounting policies for the years ended December 31, 2020 and 2019 to be applicable:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <i>         Revenue Recognition        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">        Beginning January 1, 2018,we have followed the provisions of ASC Topic 606,        <i>         Revenue from Contracts with Customers        </i>        . The guidance provides a unified modelto determine how revenue is recognized.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        We generate revenue principally from collaborativeresearch and development arrangements, technology licenses and sales, government grants and, until the discontinuance of our commercialoperations, the sale of Probuphine in the U.S. Consideration received for revenue arrangements with multiple components is allocatedamong the separate performance obligations based upon their relative estimated standalone selling price.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In determining the appropriate amount of revenueto be recognized as we fulfill our obligations under our agreements, we perform the following steps for our revenue recognition: (i) identificationof the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performanceobligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, includingthe constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimatedselling prices; and (v) recognition of revenue when (or as) we satisfy each performance obligation.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Net Product Revenue        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Prior to the discontinuation of our commercializationactivities relating to Probuphine in the U.S., we recognized revenue from product sales when control of the product transfers, generallyupon shipment or delivery, to our customers, which include distributors. As customary in the pharmaceutical industry, our gross productrevenue was subject to a variety of deductions in the forms of variable consideration, such as rebates, chargebacks, returns and discounts,in arriving at reported net product revenue. This variable consideration was estimated using the most-likely amount method, which isthe single most-likely outcome under a contract and was typically at stated contractual rates. The actual outcome of this variable considerationcould materially differ from our estimates. From time to time, we would adjust our estimates of this variable consideration when trendsor significant events indicated that a change in estimate is appropriate to reflect the actual experience. Additionally, we continuedto assess the estimates of our variable consideration as we continued to accumulate additional historical data.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 23; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         23         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">        Returns – Consistentwith the provisions of ASC 606, we estimated returns at the inception of each transaction, based on multiple considerations, includinghistorical sales, historical experience of actual customer returns, levels of inventory in our distribution channel, expiration datesof purchased products and significant market changes which could impact future expected returns to the extent that we would not reverseany receivables, revenues, or contract assets already recognized under the agreement.  During the year ended December 31, 2019,we entered into agreements with large national specialty pharmacies with a distribution channel different from that of our existing customersand, therefore, the related reserves had unique considerations. We continued to evaluate the activities with these specialty pharmaciesand updated the related reserves accordingly.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">        Rebates – Ourprovision for rebates was estimated based on our customers’ contracted rebate programs and our historical experience of rebatespaid.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">        Discounts –Theprovision was estimated based upon invoice billings, utilizing historical customer payment experience.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Performance Obligations        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        A performance obligation is a promise in a contractto transfer a distinct good or service to the customer. Our performance obligations include commercialization license rights, developmentservices and services associated with the regulatory approval process.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        We have optional additional items in contracts,which are accounted for as separate contracts when the customer elects such options. Arrangements that include a promise for future commercialproduct supply and optional research and development services at the customer’s discretion are generally considered as options.We assess if these options provide a material right to the customer and, if so, such material rights are accounted for as separate performanceobligations. If we are entitled to additional payments when the customer exercises these options, any additional payments are recordedin revenue when the customer obtains control of the goods or services.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Transaction Price        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        We have both fixed and variable consideration.Non-refundable upfront payments are considered fixed, while milestone payments are identified as variable consideration when determiningthe transaction price. Funding of research and development activities is considered variable until such costs are reimbursed at whichpoint they are considered fixed. We allocate the total transaction price to each performance obligation based on the relative estimatedstandalone selling prices of the promised goods or services for each performance obligation.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        At the inception of each arrangement that includesmilestone payments, we evaluate whether the milestones are considered probable of being achieved and estimate the amount to be includedin the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur,the value of the associated milestone is included in the transaction price. Milestone payments that are not within our control, suchas approvals from regulators, are not considered probable of being achieved until those approvals are received.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        For arrangements that include sales-based royaltiesor earn-out payments, including milestone payments based on the level of sales, and the license or purchase agreement is deemed to bethe predominant item to which the royalties or earn-out payments relate, we recognizes revenue at the later of (a) when the relatedsales occur, or (b) when the performance obligation to which some or all of the royalty or earn-out payment has been allocated hasbeen satisfied (or partially satisfied).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Allocation of Consideration        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        As part of the accounting for these arrangements,we must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identifiedin the contract. Estimated selling prices for license rights are calculated using the residual approach. For all other performance obligations,we use a cost-plus margin approach.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 24; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         24         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Timing of Recognition        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Significant management judgment is required todetermine the level of effort required under an arrangement and the period over which we expect to complete our performance obligationsunder an arrangement. We estimate the performance period or measure of progress at the inception of the arrangement and re-evaluate iteach reporting period. This re-evaluation may shorten or lengthen the period over which revenue is recognized. Changes to these estimatesare recorded on a cumulative catch up basis. If we cannot reasonably estimate when our performance obligations either are completed orbecome inconsequential, then revenue recognition is deferred until we can reasonably make such estimates. Revenue is then recognizedover the remaining estimated period of performance using the cumulative catch-up method. Revenue is recognized for licenses or salesof functional intellectual property at the point in time the customer can use and benefit from the license. For performance obligationsthat are services, revenue is recognized over time proportionate to the costs that we have incurred to perform the services using thecost-to-cost input method.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         Inventories        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Inventories are recorded at the lower of costor net realizable value. Cost is based on the first in, first out method. We regularly review inventory quantities on hand and writedown to its net realizable value any inventory that we believe to be impaired. The determination of net realizable value requires judgmentincluding consideration of many factors, such as estimates of future product demand, product net selling prices, current and future marketconditions and potential product obsolescence, among others.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         Share-Based Payments        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        We recognize compensation expense for all share-basedawards made to employees, directors and consultants. The fair value of share-based awards is estimated at the grant date based on thefair value of the award and is recognized as expense, net of estimated pre-vesting forfeitures, ratably over the vesting period of theaward.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        We use the Black-Scholes option pricing modelto estimate the fair value method of our awards. Calculating stock-based compensation expense requires the input of highly subjectiveassumptions, including the expected term of the share-based awards, stock price volatility, and pre-vesting forfeitures. We estimatethe expected term of stock options granted for the years ended December 31, 2020 and 2019 based on the historical experience of similarawards, giving consideration to the contractual terms of the share-based awards, vesting schedules and the expectations of future employeebehavior. We estimate the volatility of our common stock at the date of grant based on the historical volatility of our common stock.The assumptions used in calculating the fair value of stock-based awards represent our best estimates, but these estimates involve inherentuncertainties and the application of management judgment. As a result, if factors change and we use different assumptions, our stock-basedcompensation expense could be materially different in the future. In addition, we are required to estimate the expected pre-vesting forfeiturerate and only recognize expense for those shares expected to vest. We estimate the pre-vesting forfeiture rate based on historical experience.If our actual forfeiture rate is materially different from our estimate, our stock-based compensation expense could be significantlydifferent from what we have recorded in the current period.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         Income Taxes        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        We make certain estimates and judgments in determiningincome tax expense for financial statement purposes. These estimates and judgments occur in the calculation of certain tax assets andliabilities, which arise from differences in the timing of recognition of revenue and expense for tax and financial statement purposes.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        As part of the process of preparing our financialstatements, we are required to estimate our income taxes in each of the jurisdictions in which we operate. This process involves us estimatingour current tax exposure under the most recent tax laws and assessing temporary differences resulting from differing treatment of itemsfor tax and accounting purposes.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        We assess the likelihood that we will be ableto recover our deferred tax assets. We consider all available evidence, both positive and negative, expectations and risks associatedwith estimates of future taxable income and ongoing prudent and feasible tax planning strategies in assessing the need for a valuationallowance. If it is not more likely than not that we will recover our deferred tax assets, we will increase our provision for taxes byrecording a valuation allowance against the deferred tax assets that we estimate will not ultimately be recoverable.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         Clinical Trial Accruals        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        We also record accruals for estimated ongoingclinical trial costs. Clinical trial costs represent costs incurred by CROs and clinical sites. These costs are recorded as a componentof research and development expenses. Under our agreements, progress payments are typically made to investigators, clinical sites andCROs. We analyze the progress of the clinical trials, including levels of patient enrollment, invoices received and contracted costswhen evaluating the adequacy of accrued liabilities. Significant judgments and estimates must be made and used in determining the accruedbalance in any accounting period. Actual results could differ from those estimates under different assumptions. Revisions are chargedto expense in the period in which the facts that give rise to the revision become known. The actual clinical trial costs for studiesconducted in the past three years have not differed materially from the estimated projection of expenses.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 25; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         25         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         Warrants Issued in Connection with EquityFinancing        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        We generally account for warrants issued in connectionwith equity financings as a component of equity, unless there is a deemed possibility that we may have to settle warrants in cash. Forwarrants issued with deemed possibility of cash settlement, we record the fair value of the issued warrants as a liability at each reportingperiod and record changes in the estimated fair value as a non-cash gain or loss in the statements of operations and comprehensive loss.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         Leases        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In February 2016, the Financial AccountingStandards Board (the “FASB”) issued Accounting Standard Update, or ASU, No. 2016-02, Leases (Topic 842), to enhancethe transparency and comparability of financial reporting related to leasing arrangements. We adopted the standard effective January 1,2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        We determine whether the arrangement is or containsa lease at inception. Operating lease right-of-use assets and lease liabilities are recognized at the present value of the future leasepayments at commencement date. The interest rate implicit in lease contracts is typically not readily determinable, and therefore, weutilize our incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amountequal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for itemssuch as initial direct costs paid or incentives received.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Lease expense is recognized over the expectedterm on a straight-line basis. Operating leases are recognized on our balance sheet as right-of-use assets, operating lease liabilities,current and operating lease liabilities, non-current. We no longer recognize deferred rent on our balance sheet.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Liquidity and Capital Resources        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        We have funded our operations since inceptionprimarily through the sale of our securities and the issuance of debt, as well as with proceeds from warrant and option exercises, corporatelicensing and collaborative agreements, the sale of royalty rights, sales of Probuphine and government-sponsored research grants. AtDecember 31, 2020, we had working capital of approximately $3.1 million compared to working capital of approximately $4.7 million atDecember 31, 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             2020            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             2019            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td colspan="6">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             <u>              As of December 31:             </u>            </b>           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="width: 74%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Cash and cash equivalents           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="width: 10%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5,413           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="width: 10%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5,223           </font>          </td>          <td style="width: 1%">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Working capital           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3,105           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4,708           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Current ratio           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1.7:1           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2.3:1           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             <u>              Years Ended December 31:             </u>            </b>           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Cash used in operating activities           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (17,203           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (15,445           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Cash used in investing activities           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (540           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (256           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Cash provided by financing activities           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            17,933           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            11,268           </font>          </td>          <td>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Net cash used in operating activities for theyear ended December 31, 2020 consisted primarily of the net loss for the period of approximately $18.2 million and approximately $2.0million related to changes in the fair value of assets transferred as part of the DSRA Agreement. This was partially offset by an approximately$0.9 million non-cash gain due to changes in the fair value of warrants, approximately $0.5 million in non-cash interest expense, $0.3million of depreciation and amortization expense, approximately $0.2 million of finance costs associated with warrant issuances, approximately$0.1 million related to losses on debt extinguishment and approximately $1.0 million related to net changes in other operating assetsand liabilities. Uses of cash in operating activities were primarily to fund commercialization activities, product development programsand administrative expenses.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Net cash used in investing activities for theyear ended December 31, 2020 was related to purchases of equipment.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Net cash provided by financing activities forthe year ended December 31, 2020 consisted primarily of approximately $11.6 million in proceeds from our equity offerings, proceedsof approximately $7.2 million from the exercise of warrants to purchase our common stock and approximately $0.7 million received underour PPP Loan. This was partially offset by approximately $1.6 million in cash payments related to the DSRA Agreement.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in">        During the year ended December 31,2020, we received approximately $7.2 million in cumulative net cash proceeds from the exercise of outstanding warrants to purchase 1,112,313shares of our common stock.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In January 2021, we completed a registered directoffering pursuant to which we issued 2,725,000 shares of our common stock at an offering price of $3.55 per share and private placementwarrants to purchase 2,725,000 shares of our common stock with an exercise price of $3.55 per share. We received net cash proceeds ofapproximately $8.9 million after the deduction of underwriting fees and other offering expenses.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 17.4pt 0pt 0; text-indent: 15.25pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 26; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         26         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 17.4pt 0pt 0; text-indent: 15.25pt">        In October 2020, we completed a publicoffering pursuant to which we sold 2,666,667 shares of our common stock and issued warrants to purchase 2,666,667 shares of our commonstock with an exercise price of $3.00 per share. We received net cash proceeds of approximately $5.7 million, after deduction of underwritingfees, other offering expenses and the $1.6 million payment pursuant to the DSRA Agreement.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 17.4pt 0pt 0; text-indent: 15.25pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In October 2020, we entered into the DSRA Agreementwith Molteni and Horizon to settle our outstanding debt obligations for $1.6 million in cash, the transfer of certain Probuphine assetsto Molteni, including all of our manufacturing equipment, and the termination of our rights to future payments under the Purchase Agreementwith Molteni. The DSRA Agreement, provided for the release to us of the remaining collateral.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In September 2020, we completed a registereddirect offering with several institutional investors pursuant to which we issued 648,000 shares of our common stock at a price of $4.20per share. We received net cash proceeds of approximately $2.4 million, after the deduction of underwriting fees and other offering expenses.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In January 2020, we completed a registered directoffering pursuant to which we issued 290,000 shares of our common stock at an offering price of $7.50 per share and private placementwarrants to purchase 290,000 shares of our common stock with an exercise price of $7.50 per share. We received net cash proceeds of approximately$1.9 million, after the deduction of underwriting fees and other offering expenses.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In October 2019, we completed an underwrittenpublic offering pursuant to which we issued 1,342,534 units at an offering price of $6.75 per unit, consisting of 1,196,200 shares ofour common stock, pre-funded warrants to purchase 146,334 shares of our common stock with an exercise price of $0.30 per share and ClassB warrants to purchase 1,342,534 shares of our common stock at an exercise price of $6.75 per share. We received net cash proceeds totalingapproximately $8.1 million, after the deduction of underwriting fees and other offering expenses.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In August 2019, we completed an offering pursuantto which we issued 49,334 shares of our common stock and pre-funded warrants to purchase 45,744 shares of our common stock with an exerciseprice of $0.30 per share in a registered direct offering and private placement warrants to purchase 95,078 shares of our common stockwith an exercise price of $32.10 per share in a concurrent private placement. We received net cash proceeds totaling approximately $1.8million, after deduction of underwriting fees and other offering expenses.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In June 2019, we issued 14,943 shares ofour common stock upon the conversion of the Molteni Convertible Loan upon the receipt of the EMA approval of Sixmo.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In April 2019, we implemented an at-the-marketoffering, or the ATM, for the sale of up to $8.6 million of our common stock. During the year ended December 31, 2019, we received totalnet proceeds of approximately $0.5 million from the sale of 10,989 shares of our common stock at a weighted-average price of $48.00 pershare under the ATM.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        At December 31, 2020, we had cash and cash equivalentsof approximately $5.4 million, which we believe, together with the approximately $8.9 million of the net proceeds from the January 2021Offering, are sufficient to fund our planned operations into the first quarter of 2022. We will require additional funds to finance ouroperations beyond such period; however, there can be no assurance that our efforts to obtain the funding required to continue our operationswill be successful. There is substantial doubt about our ability to continue as a going concern.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 27; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         27         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Results of Operations        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>          Year Ended December 31, 2020 Comparedto Year Ended December 31, 2019         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>          Revenues         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="10" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Years ended December 31,            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             2020            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             2019            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Change            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td colspan="10" style="text-align: center">           <font style="font-size: 10pt">            <b>             (in thousands)            </b>           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-size: 10pt">            Revenue:           </font>          </td>          <td>          </td>          <td colspan="2" style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="width: 61%; padding-left: 27pt; text-indent: -12pt">           <font style="font-size: 10pt">            License revenue           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="width: 10%; text-align: right">           <font style="font-size: 10pt">            11           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="width: 10%; text-align: right">           <font style="font-size: 10pt">            315           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="width: 10%; text-align: right">           <font style="font-size: 10pt">            (304           </font>          </td>          <td style="width: 1%">           <font style="font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 27pt; text-indent: -12pt">           <font style="font-size: 10pt">            Product revenue           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            528           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            528           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 1pt; padding-left: 27pt; text-indent: -12pt">           <font style="font-size: 10pt">            Grant revenue           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            4,299           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            2,290           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            2,009           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-bottom: 2.5pt; padding-left: 45pt; text-indent: -12pt">           <font style="font-size: 10pt">            Total revenue           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-size: 10pt">            4,838           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-size: 10pt">            2,605           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-size: 10pt">            2,233           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Product revenues from continuing operations forthe year ended December 31, 2020 consisted of sales of our Probuphine product materials to Molteni and Knight for the EU and Canada,respectively. Revenue from sale of Probuphine in the U.S. has been reclassified to discontinued operations for all periods presented(see Note 11 to the financial statements included in this report for more information).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        License revenue for the year ended December 31,2020 reflects royalties received on sales of Probuphine by Knight in Canada. License revenue for the year ended December 31, 2019 reflectsamortization of deferred revenue related to the sale to Molteni of the European intellectual property rights to our Probuphine product.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The increase in grant revenue was due to ourincreased activities related to the NIDA grant for the development of a nalmefene implant.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Split-Segment; Name: a4 -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Operating Expenses         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">         <tbody>          <tr style="vertical-align: bottom">           <td style="font-size: 10pt">           </td>           <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">           </td>           <td colspan="10" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">            Years ended December 31,           </td>           <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">           </td>          </tr>          <tr style="vertical-align: bottom">           <td style="font-size: 10pt">           </td>           <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">           </td>           <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">            2020           </td>           <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">           </td>           <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">           </td>           <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">            2019           </td>           <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">           </td>           <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">           </td>           <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">            Change           </td>           <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">           </td>          </tr>          <tr style="vertical-align: bottom">           <td style="font-size: 10pt">           </td>           <td style="font-size: 10pt; font-weight: bold">           </td>           <td colspan="10" style="font-size: 10pt; font-weight: bold; text-align: center">            (in thousands)           </td>           <td style="font-size: 10pt; font-weight: bold">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="font-size: 10pt; text-align: left; text-indent: -12pt; padding-left: 12pt">            Operating expenses:           </td>           <td style="font-size: 10pt">           </td>           <td style="font-size: 10pt; text-align: left">           </td>           <td style="font-size: 10pt; text-align: right">           </td>           <td style="font-size: 10pt; text-align: left">           </td>           <td style="font-size: 10pt">           </td>           <td style="font-size: 10pt; text-align: left">           </td>           <td style="font-size: 10pt; text-align: right">           </td>           <td style="font-size: 10pt; text-align: left">           </td>           <td style="font-size: 10pt">           </td>           <td style="font-size: 10pt; text-align: left">           </td>           <td style="font-size: 10pt; text-align: right">           </td>           <td style="font-size: 10pt; text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td style="width: 58%; font-size: 10pt; text-align: left; text-indent: -12pt; padding-left: 27pt">            Cost of goods sold           </td>           <td style="width: 2%; font-size: 10pt">           </td>           <td style="width: 1%; font-size: 10pt; text-align: left">            $           </td>           <td style="width: 10%; font-size: 10pt; text-align: right">            472           </td>           <td style="width: 1%; font-size: 10pt; text-align: left">           </td>           <td style="width: 2%; font-size: 10pt">           </td>           <td style="width: 1%; font-size: 10pt; text-align: left">            $           </td>           <td style="width: 10%; font-size: 10pt; text-align: right">            —           </td>           <td style="width: 1%; font-size: 10pt; text-align: left">           </td>           <td style="width: 2%; font-size: 10pt">           </td>           <td style="width: 1%; font-size: 10pt; text-align: left">            $           </td>           <td style="width: 10%; font-size: 10pt; text-align: right">            472           </td>           <td style="width: 1%; font-size: 10pt; text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="font-size: 10pt; text-align: left; text-indent: -12pt; padding-left: 27pt">            Research and development           </td>           <td style="font-size: 10pt">           </td>           <td style="font-size: 10pt; text-align: left">           </td>           <td style="font-size: 10pt; text-align: right">            5,916           </td>           <td style="font-size: 10pt; text-align: left">           </td>           <td style="font-size: 10pt">           </td>           <td style="font-size: 10pt; text-align: left">           </td>           <td style="font-size: 10pt; text-align: right">            5,080           </td>           <td style="font-size: 10pt; text-align: left">           </td>           <td style="font-size: 10pt">           </td>           <td style="font-size: 10pt; text-align: left">           </td>           <td style="font-size: 10pt; text-align: right">            836           </td>           <td style="font-size: 10pt; text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: White">           <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -12pt; padding-left: 27pt">            General and administrative           </td>           <td style="font-size: 10pt; padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">            5,801           </td>           <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           </td>           <td style="font-size: 10pt; padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">            5,401           </td>           <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           </td>           <td style="font-size: 10pt; padding-bottom: 1pt">           </td>           <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           </td>           <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">            400           </td>           <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           </td>          </tr>          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">           <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; text-indent: -12pt; padding-left: 45pt">            Total operating expenses           </td>           <td style="font-size: 10pt; padding-bottom: 2.5pt">           </td>           <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">            $           </td>           <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">            12,189           </td>           <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">           </td>           <td style="font-size: 10pt; padding-bottom: 2.5pt">           </td>           <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">            $           </td>           <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">            10,481           </td>           <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">           </td>           <td style="font-size: 10pt; padding-bottom: 2.5pt">           </td>           <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">            $           </td>           <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">            1,708           </td>           <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">           </td>          </tr>         </tbody>        </table>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Cost                                            of goods sold from continuing operations reflects costs and expenses associated with sales                                            of our Probuphine product to Molteni and Knight for the EU and Canada, respectively. Cost                                            of goods sold related to the sale of Probuphine in the U.S. has been reclassified to discontinued                                            operations for all periods presented (see Note 11 to the financial statements included in                                            this report for more information).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The increase in research and development costsfrom continuing operations was primarily associated with increased activities related to non-clinical studies required for the plannedIND submission as part of our NIDA grant for the development of a nalmefene implant. Other research and development expenses includeinternal operating costs such as research and development personnel-related expenses, non-clinical and clinical product development relatedtravel expenses, and allocation of facility and corporate costs. Research and development expenses related to our U.S. Probuphine activitieshave been reclassified to discontinued operations for all periods presented (see Note 11 to the financial statements included in thisreport for more information). As a result of the risks and uncertainties inherently associated with pharmaceutical research and developmentactivities described elsewhere in this document, we are unable to estimate the specific timing and future costs of our clinical developmentprograms or the timing of material cash inflows, if any, from our product candidates. However, we anticipate that our research and developmentexpenses will increase as we continue our current or any future ProNeura development programs to the extent these costs are not supportedthrough grants or partners.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The increase in general and administrative expenseswas primarily due to increases in consulting and professional fees. This was partially offset by decreases in non-cash stock compensationexpense. Selling and marketing expenses related to the sale of Probuphine in the U.S. have been reclassified to discontinued operationsfor all periods presented (see Note 11 to the financial statements included in this report for more information).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 28; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         28         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>          Other Expenses, Net         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="10" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           Years ended December 31,          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           2020          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           2019          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           Change          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold">          </td>          <td colspan="10" style="font-size: 10pt; font-weight: bold; text-align: center">           (in thousands)          </td>          <td style="font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; text-indent: -12pt; padding-left: 12pt">           Other income (expense):          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="width: 58%; font-size: 10pt; text-align: left; text-indent: -12pt; padding-left: 27pt">           Interest expense, net          </td>          <td style="width: 2%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           (769          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           )          </td>          <td style="width: 2%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           (967          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           )          </td>          <td style="width: 2%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           198          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; text-indent: -12pt; padding-left: 27pt">           Other income (expense), net          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (258          </td>          <td style="font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           17          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (275          </td>          <td style="font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; text-indent: -12pt; padding-left: 27pt">           Non-cash gain (loss) on changes in the fair    value of warrants          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (923          </td>          <td style="font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           1,110          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (2,033          </td>          <td style="font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; text-indent: -12pt; padding-left: 27pt">           Non-cash gain on changes in the fair value    of assets          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           1,975          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           —          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           1,975          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -12pt; padding-left: 27pt">           Gain (loss) on debt extinguishment          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (81          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           226          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (307          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -12pt; padding-left: 45pt">           Other income (expense),    net          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (56          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           386          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (442          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The decrease in other income (expense) for theyear ended December 31, 2020 was primarily due to non-cash losses related to changes in the fair value of warrants, losses related todebt extinguishment and expenses related to the issuance of the January 2020 Warrants. This was partially offset by non-cash gains onchanges in the fair value of assets and decreases in interest expense related to our loans. Net other income for the year ended December31, 2019 was primarily due to non-cash gains on changes in the fair value of warrants and again on debt extinguishment related to ourMolteni loan, partially offset by interest expense on our loans. Higher interest expense for the year ended December 31, 2019 was primarilydue to higher loan balances, partially offset by the settlement of our Molteni convertible loan in June 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>          Discontinued Operations         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Following our October 2020 decision to discontinuethe commercialization of our Probuphine product in the U.S., we recorded a loss on discontinued operations for the years ended December31, 2020 and 2019 of approximately $10.8 million and $9.0 million, respectively (see Note 11 to the financial statements included inthis report for more information).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">        <b>         <i>          Net Loss and Net Loss per Share         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Our net loss from continuing operations applicableto common stockholders for the year ended December 31, 2020 was approximately $7.4 million, or approximately $1.96 per share, comparedto our net loss continuing operations applicable to common stockholders of approximately $7.5 million, or approximately $9.78 per share,for the comparable period in 2019. Our net loss from discontinued operations applicable to common stockholders for the year ended December31, 2020 was approximately $10.8 million, or approximately $2.87 per share, compared to our net loss discontinued operations applicableto common stockholders of approximately $9.0 million, or approximately $11.71 per share, for the comparable period in 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Off-Balance Sheet Arrangements        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        We have never entered into any off-balance sheetfinancing arrangements and we have never established any special purpose entities. We have not guaranteed any debt or commitments ofother entities or entered into any options on non-financial assets.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 70px">           <a name="a_012">           </a>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Item 7A.            </b>           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Quantitative and Qualitative    Disclosures About Market Risk            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Not applicable.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 70px">           <a name="a_013">           </a>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Item 8.            </b>           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Financial Statements    and Supplementary Data.            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The response to this item is included in a separatesection of this Report. See “Index to Financial Statements” on Page F-1.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 70px">           <a name="a_014">           </a>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Item 9.            </b>           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Changes and Disagreements    with Accountants on Accounting and Financial Disclosure.            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        None.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 70px">           <a name="a_015">           </a>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Item 9A.            </b>           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Controls and Procedures.            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        (a)        <i>         Evaluation of Disclosure Controlsand Procedures        </i>        : Our principal executive and financial officers reviewed and evaluated the effectiveness of our disclosure controlsand procedures (as defined in Exchange Act Rule 13a-15(e)) as of the end of the period covered by this Annual Report on Form 10-K.Based on that evaluation, our principal executive and financial officers concluded that our disclosure controls and procedures are effectivein timely providing them with material information relating to Titan, as required to be disclosed in the reports we file under the ExchangeAct.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        (b)        <i>         Management’s Annual Reporton Internal Control Over Financial Reporting        </i>        :       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Internal control over financial reporting refersto the process designed by, or under the supervision of, our principal executive officer and principal financial officer, and effectedby our Board, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and thepreparation of financial statements for external purposes in accordance with generally accepted accounting principles, and includes thosepolicies and procedures that:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in">        (1) Pertain to the maintenanceof records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 29; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         29         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in">        (2) Providereasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generallyaccepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorization of our managementand directors; and       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in">        (3) Provide reasonable assuranceregarding prevention or timely detection of unauthorized acquisitions, use or disposition of our assets that could have a material effecton the financial statements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Internal control over financial reporting cannotprovide absolute assurance of achieving financial reporting objectives because of its inherent limitations. Internal control over financialreporting is a process that involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting fromhuman failures. Internal control over financial reporting also can be circumvented by collusion or improper management overrides. Dueto such limitations, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal controlover financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it ispossible to design into the process safeguards to reduce, though not eliminate, this risk. Management is responsible for establishingand maintaining adequate internal control over financial reporting for Titan.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Management has used the framework set forth inthe report entitled        <i>         Internal Control—Integrated Framework        </i>        published by the Committee of Sponsoring Organizations of theTreadway Commission (2013 framework), known as COSO, to evaluate the effectiveness of Titan’s internal control over financial reporting.Based on this assessment, management has concluded that our internal control over financial reporting was effective as of December 31,2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        (c)        <i>         Changes in Internal Control OverFinancial Reporting        </i>        : There were no changes in our internal control over financial reporting (as defined in Rules 13(a)-15(f) and15(d)-15(f) under the Securities Act) during our most recent fiscal quarter that have materially affected, or are reasonably likelyto materially affect, our internal control over financial reporting.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 70px">           <a name="a_016">           </a>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Item 9B.            </b>           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Other Information.            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        None.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 30; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         30         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <a name="sp04-01">        </a>        <b>         PART III        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0px">          </td>          <td style="width: 72px">           <a name="sp04-02">           </a>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Item 10.            </b>           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Directors; Executive    Officers and Corporate Governance            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Set forth below are the name, age and positionand a brief account of the business experience of each of our executive officers and directors:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">           Name          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Age          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Office          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Director Since          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 27%; font: 10pt Times New Roman, Times, Serif; text-align: left">           Marc Rubin, M.D.          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center">           66          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 35%; font: 10pt Times New Roman, Times, Serif; text-align: left">           Executive Chairman of the Board          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 23%; font: 10pt Times New Roman, Times, Serif">           November 2007          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Katherine Beebe DeVarney, Ph.D.          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">           60          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           President, Chief Operating Officer and Director          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           December 2019          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Joseph A. Akers (1)(2)(3)          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">           75          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           Director          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           November 2014          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           M. David MacFarlane, Ph.D. (1)(2)(3)          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">           80          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           Director          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           May 2002          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           James R. McNab, Jr. (1)(2)(3)          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">           77          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           Director          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           November 2014          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 2%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (1)           </font>          </td>          <td style="width: 98%; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Member of Audit    Committee           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-right: 0.8pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (2)           </font>          </td>          <td style="padding-right: 0.8pt; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Member    of Compensation Committee           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-right: 0.8pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (3)           </font>          </td>          <td style="padding-right: 0.8pt; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Member    of Governance Committee           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           MarcRubin, M.D.          </i>         </b>        </font>        served as our President and Chief Executive from October 2007 until December 2008 and was re-engagedas our Executive Chairman in May 2009. Until February 2007, Dr. Rubin served as Head of Global Research and Developmentfor Bayer Schering Pharma, as well as a member of the Executive Committee of Bayer Healthcare and the Board of Management of Bayer ScheringPharma. Prior to the merger of Bayer Pharmaceuticals and Schering AG in June 2006, Dr. Rubin was a member of the ExecutiveBoard of Schering AG since joining us in October 2003, as well as Chairman of Schering Berlin Inc. and President of Berlex Pharmaceuticals,a division of Schering AG. From 1990 until August 2003, Dr. Rubin was employed by GlaxoSmithKline where he held positions ofincreasing responsibility in global clinical and commercial development overseeing programs in the United States, Europe, Asia and LatinAmerica. From 2001 through 2003, he was Senior Vice President of Global Clinical Pharmacology &amp; Discovery Medicine. Dr. Rubinholds an M.D. from Cornell University Medical College. Dr. Rubin currently serves on the board of directors of Curis Inc. and GalectinTherapeutics. Based on Dr. Rubin’s position as our Executive Chairman, his extensive senior management experience and serviceon boards of directors in the biotechnology and pharmaceutical industries and his medical background, our Board believes that Dr. Rubinhas the appropriate set of skills to serve as a member of the Board.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>          Katherine Beebe DeVarney, Ph.D.         </i>        </b>        joinedTitan in February 2007 and currently serves as our President and Chief Operating Officer. She has been a member of the Board sinceDecember 2019. During her 14 years with us, she has served in various scientific and medical research and development capacities, withprimary responsibility for oversight of our product research and development, Regulatory Affairs, and Medical Affairs.  Dr. BeebeDeVarney has 24 years of experience as a Neuroscientist in the pharmaceutical industry, including positions of increasing responsibilitywith SmithKline Beecham, GlaxoSmithKline, Merck, and Corcept Therapeutics.  Prior to her pharmaceutical career, Dr. Beebe DeVarneywas a hospital-based clinician and worked in academic medicine for 10 years.  She received her Ph.D. in Clinical Neuropsychologyfrom George Mason University, and completed a two-year post-doctoral fellowship at Graduate Hospital and the University of Pennsylvania.Based on Dr. Beebe DeVarney’s extensive knowledge of the medical, research, and regulatory requirements of product developmentprograms, our Board believes that Dr. Beebe DeVarney has the appropriate set of skills to serve as member of the Board.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           JosephA. Akers          </i>         </b>        </font>        was employed in various capacities by Bayer Corporation, Bayer Healthcare and certain related entities, includingas president of the Hematology/Cardiology Business Unit from 2004 to 2007, president and chief executive officer of Bayer Business andCorporate Services from July 2002 through 2003 and executive vice president and chief administrative and financial officer from1999 to July 2002. Mr. Akers received a B.S. in marketing and an M.B.A. in finance from the University of California at Berkeley.Based on Mr. Akers’ extensive management experience in the pharmaceutical industry, particularly in the areas of administrationand finance, our Board believes that Mr. Akers has the appropriate set of skills to serve as a member of the Board.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           M.David MacFarlane, Ph.D.          </i>         </b>        </font>        served as Vice President and Responsible Head of Regulatory Affairs of Genentech, Inc. from1989 until his retirement in August 1999. Prior to joining Genentech, Inc., he served in various positions with Glaxo Inc.,last as Vice President of Regulatory Affairs. Based on Dr. MacFarlane’s management experience in the pharmaceutical industry,particularly in the area of clinical and regulatory affairs, our Board believes that Dr. MacFarlane has the appropriate set of skillsto serve as a member of the Board.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 31; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         31         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           JamesR. McNab, Jr.          </i>         </b>        </font>        has served since June 2014 as chief executive officer of JT Pharmaceuticals, Inc., a privately-helddrug discovery company he founded. Since 2009, Mr. McNab has served as executive chairman of FirstString Research, Inc., aprivately-held biopharmaceutical company. Mr. McNab has co-founded several privately-held companies, including Sontra Medical Corporation,a drug delivery company, and Parker Medical Associates, a manufacturer and worldwide supplier of orthopedic and sports-related products.He received a B.A. in economics from Davidson College and an M.B.A. from the University of North Carolina at Chapel Hill. Based on Mr. McNab’sextensive management experience in the pharmaceutical industry, our Board believes that Mr. McNab has the appropriate set of skillsto serve as a member of the Board.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        As indicated above, each of our directors hasextensive management and operational experience in one or more facets of the pharmaceutical industry, including research, product development,clinical and regulatory affairs, manufacturing and sales and marketing, providing our company with the leadership needed by a biotechnologycompany in all stages of its development.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Directors serve until the next annual meetingor until their successors are elected and qualified. Officers serve at the discretion of the Board, subject to rights, if any, undercontracts of employment. See “Item 11. Executive Compensation—Employment Agreements.”       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Board Leadership Structure        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Currently, our principal executive officer andchairman of the Board positions are held by Marc Rubin, MD.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Code of Ethics        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        We adopted a Code of Business Conduct and Ethics(the “Code”) in February 2013 that applies to all directors, officers and employees. The Code is filed as an exhibitto this Annual Report on Form 10-K and is available on our website at        <i>         www.titanpharm.com.        </i>        A copy of our code of ethics willalso be provided to any person without charge, upon written request sent to us at our offices located at 400 Oyster Point Blvd, Suite 505,South San Francisco, California 94080.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Changes in Director Nomination Process for Stockholders        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        None.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0px">          </td>          <td style="width: 72px">           <a name="sp04-03">           </a>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Item 11.            </b>           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Executive Compensation            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         SUMMARY COMPENSATION TABLE        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The following table provides information regardingthe compensation paid during the years ended December 31, 2020 and 2019 to each of the executive officers named below, who are collectivelyreferred to as “named executive officers” elsewhere in this report.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">          <td style="white-space: nowrap; border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif">           <p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">            <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">             <b>             </b>            </font>           </p>           <p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">            <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">             <b>              Name and Principal              <br/>              Position             </b>            </font>           </p>          </td>          <td style="white-space: nowrap; font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Year           </font>          </td>          <td style="white-space: nowrap; font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="white-space: nowrap; font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Salary ($)           </font>          </td>          <td style="white-space: nowrap; font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="white-space: nowrap; font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Bonus            <br/>            ($)           </font>          </td>          <td style="white-space: nowrap; font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="white-space: nowrap; font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Options            <br/>            Awards            <br/>            ($) (1)           </font>          </td>          <td style="white-space: nowrap; font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="white-space: nowrap; font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Stock            <br/>            Awards            <br/>            ($) (1)           </font>          </td>          <td style="white-space: nowrap; font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="white-space: nowrap; font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            All Other            <br/>            Compensation            <br/>            ($)           </font>          </td>          <td style="white-space: nowrap; font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="white-space: nowrap; font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Total            <br/>            Compensation            <br/>            ($)           </font>          </td>          <td style="white-space: nowrap; font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>         </tr>         <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 8pt Times New Roman, Times, Serif; width: 37%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Marc Rubin, MD(2)           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            2020           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            250,521           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            —           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            —           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            —           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            —           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            250,521           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>         </tr>         <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Executive    Chairman           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            2019           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            318,750           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            —           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            266,629           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            —           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            —           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            583,379           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>         </tr>         <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>         </tr>         <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Sunil    Bhonsle (2)(3)           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            2020           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            239,063           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            —           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            —           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            —           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            65,385           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            (4)           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            304,448           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>         </tr>         <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Chief    Executive Officer, President and Principal Financial Officer           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            2019           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            417,115           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            —           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            266,629           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            —           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            —           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            683,744           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>         </tr>         <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">          <td style="font: 8pt Times New Roman, Times, Serif; padding-left: 9pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>         </tr>         <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Katherine    Beebe DeVarney, Ph.D. (3)           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            2020           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            365,000           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            —           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            —           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            —           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            —           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            365,000           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>         </tr>         <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Executive    Vice President and Chief Scientific Officer           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            2019           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            365,000           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            —           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            18,017           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            —           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            —           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            383,017           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>         </tr>         <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">          <td style="font: 8pt Times New Roman, Times, Serif; padding-left: 9pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>         </tr>         <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Dane    Hallberg (5)           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            2020           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            124,856           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            —           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            —           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            —           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            175,000           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            (6)           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            299,856           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>         </tr>         <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Executive    Vice President and Chief Commercial Officer           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            2019           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            350,000           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            —           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            72,748           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            —           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            —           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            422,748           </font>          </td>          <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 32; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         32         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (1)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Amounts shown represent the grant date fair value computed    in accordance with FASB ASC 718. The assumptions used by us with respect to the valuation of option grants and stock awards are set    forth in Note 9 to the financial statements.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (2)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Beginning in January 2020, our Chief Executive    Officer and our Executive Chairman agreed to a 50% reduction in their base salaries through June 30, 2020.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (3)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            In October 2020, Mr. Bhonsle retired and    Dr. Beebe DeVarney assumed the roles of President and Chief Operating Officer.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (4)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Amounts shown represent the payment of accrued vacation    at time of retirement.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (5)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Mr. Hallberg’s employment terminated in    April 2020.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (6)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Amounts shown represent severance payments.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Employee Benefits Plans        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The principal purpose of our stock incentiveplans is to attract, motivate, reward and retain selected employees, consultants and directors through the granting of stock-based compensationawards. The stock option plans provide for a variety of awards, including non-qualified stock options, incentive stock options (withinthe meaning of Section 422 of the Code), stock appreciation rights, restricted stock awards, performance-based awards and other stock-basedawards.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>          2001 Stock Option Plan         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In August 2001, we adopted the 2001 EmployeeNon-Qualified Stock Option Plan, or the 2001 NQ Plan, pursuant to which 1,768 shares of common stock were authorized for issuance foroption grants to employees and consultants who are not officers or directors of Titan. The 2001 NQ Plan expired by its terms in August 2011.On December 31, 2020, options to purchase an aggregate of 412 shares of our common stock were outstanding under the 2001 NQ Plan.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>          2002 Stock Incentive Plan         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In July 2002, we adopted the 2002 StockIncentive Plan, or the 2002 Plan. Under the 2002 Plan, as amended, a total of approximately 7,234 shares of our common stock were authorizedfor issuance to employees, officers, directors, consultants, and advisers. The 2002 Plan expired by its terms in July 2012. On December 31,2020, options to purchase an aggregate of 1,426 shares of our common stock were outstanding under the 2002 Plan.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>          2014 Incentive Plan         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In February 2014, our Board adopted the2014 Incentive Plan, or the 2014 Plan, pursuant to which 2,526 shares of our common stock were authorized for issuance to employees,directors, officers, consultants and advisors. On December 31, 2020, options to purchase 1,285 shares of our common stock were outstandingunder the 2014 Plan.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>          2015 Omnibus Equity Incentive Plan         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In August 2015, our stockholders approvedthe 2015 Omnibus Equity Incentive Plan, or the 2015 Plan. The 2015 Plan, as amended, authorized a total of 1,000,000 shares of our commonstock for issuance to employees, directors, officers, consultants and advisors. On December 31, 2020, options to purchase 24,770shares of our common stock were outstanding under the 2015 Plan.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Outstanding Equity Awards At Fiscal Year-End        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The following table summarizes the number of securities underlyingoutstanding plan awards for each named executive officer as of December 31, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 33; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         33         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="10" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Option Awards          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">           Name          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Number of           <br/>           Securities Underlying           <br/>           Unexercised Awards (#)           <br/>           Exercisable          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Number of           <br/>           Securities Underlying           <br/>           Unexercised Awards           <br/>           (#) Unexercisable          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Exercise           <br/>           Price ($)          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Expiration           <br/>           Date          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 38%; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt">           Marc Rubin,    M.D.          </td>          <td style="width: 2%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">           152          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 2%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 2%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">           1,386.00          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 2%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">           4/15/2021          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; padding-left: 0.1in">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           253          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,137.60          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1/3/2022          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; padding-left: 0.1in">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           203          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           594.00          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           3/16/2025          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; padding-left: 0.1in">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           506          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           918.00          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           12/14/2025          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; padding-left: 0.1in">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           440          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           918.00          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           02/02/2026          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; padding-left: 0.1in">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           390          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           702.00          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           02/13/2027          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; padding-left: 0.1in">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           946          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           174.60          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           03/07/2028          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; padding-left: 0.1in">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           2,779          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           52.50          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           4/2/2029          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Sunil Bhonsle          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           203          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,386.00          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           4/15/2021          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-indent: -12.25pt; padding-left: 12.25pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           304          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,137.60          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1/3/2022          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-indent: -12.25pt; padding-left: 12.25pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           243          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           594.00          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           3/16/2025          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           506          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           918.00          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           12/14/2025          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           496          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           918.00          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           2/2/2026          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; padding-left: 0.1in">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           445          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           702.00          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           02/13/2027          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; padding-left: 0.1in">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           945          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           174.60          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           03/7/2028          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; padding-left: 0.1in">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           2,778          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           52.50          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           4/2/2029          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Katherine Beebe DeVarney, Ph.D.          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           102          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           46.58          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           5/11/2021          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-indent: -12.25pt; padding-left: 12.25pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           152          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           46.58          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1/3/2022          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-indent: -12.25pt; padding-left: 12.25pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           142          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           594.00          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           3/16/2025          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           223          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           46.58          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           12/14/2025          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           223          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           46.58          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           2/13/2027          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; padding-left: 0.1in">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           945          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           174.60          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           3/7/2028          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Dane Hallberg          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,389          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           37.80          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           04/24/2021          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-indent: -12.25pt; padding-left: 12.25pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           2,667          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           45.00          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           04/24/2021          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        There were no options granted to or exercisedby our named executive officers during 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Pension Benefits        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        We do not sponsor any qualified or non-qualifieddefined benefit plans.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Nonqualified Deferred Compensation        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        We do not maintain any non-qualified definedcontribution or deferred compensation plans. The Compensation Committee, which is comprised solely of “outside directors”as defined for purposes of Section 162(m) of the Code, may elect to provide our officers and other employees with non-qualifieddefined contribution or deferred compensation benefits if the Compensation Committee determines that doing so is in our best interests.We sponsor a tax qualified defined contribution 401(k) plan in which Dr. Rubin and Mr. Bhonsle participated.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Employment Agreements        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        In February 2021 Dr. Rubin’sand Dr. Beebe DeVarney’s employment agreements were amended providing annual salaries of $395,000 and $385,000, respectively,and the term of Dr. Rubin’s agreement was extended to September 30, 2021. All other agreement terms remain substantiallythe same.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In October 2020, Mr. Bhonsle retired.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In April 2019, we entered into employmentagreements with Dr. Rubin and Mr. Bhonsle providing for base annual salaries of $325,000 and $425,000, respectively. The employmentagreements contain the following terms:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">         <tbody>          <tr style="vertical-align: top">           <td style="width: 0px">           </td>           <td style="width: 24px; font-size: 10pt">            <font style="font-size: 10pt">             ·            </font>           </td>           <td style="font-size: 10pt">            <font style="font-size: 10pt">             Bonuses. The executive may, at the sole discretion of the board of directors    or the compensation committee, be considered for an annual bonus of up to 50% of their then base salary, payable in cash or awards    under our equity incentive plan.            </font>           </td>          </tr>         </tbody>        </table>       </p>       <p style="margin-top: 0; margin-bottom: 0">        <font style="font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">         <tbody>          <tr style="vertical-align: top">           <td style="width: 0px">           </td>           <td style="width: 24px">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             ·            </font>           </td>           <td>            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Term; Termination. The Employment Agreements have a    24 month term expiring on April 1, 2021 but may be terminated by us for any reason at any time. In the event of termination    by us without cause or by the executive for good reason not in connection with a change of control, as those terms are defined in    such agreements, the executive is entitled to (i) severance for the greater of 12 months or the balance of the term, (ii) a    pro rata portion of any annual bonus, (iii) 12 months of COBRA payments, and (iv) the immediate accelerated vesting of    any unvested restricted shares and stock options. In the event such a termination is within 30 days prior to or six months following    a change of control, the executive is entitled to an additional six months of COBRA payments.            </font>           </td>          </tr>         </tbody>        </table>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0px">          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Restrictive Covenants. The Employment Agreements contain    one-year post-termination noncompetition and non-solicitation provisions.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 34; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         34         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0px">          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Clawback. The Employment Agreements contain a two-year    post-termination clawback of benefits provision in the event of a restatement of financial results upon which such benefits were    based.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In November 2018, we entered into an employmentagreement with Dr. Beebe DeVarney providing for a base annual salary of $365,000. The employment agreement contains the followingterms:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0px">          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Bonuses. The executive may, at the sole discretion    of the board of directors or the compensation committee, be considered for an annual bonus of up to 50% of her then base salary,    payable in cash or awards under our equity incentive plan.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0px">          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Term; Termination. The Employment Agreement may be    terminated by us for any reason at any time. In the event of termination by us without cause or by the executive for good reason    or in connection with a change of control, as those terms are defined in such agreements, the executive is entitled to (i) severance    for 12 months following the termination date, (ii) a pro rata portion of any annual bonus, (iii) 12 months of COBRA payments,    and (iv) the immediate accelerated vesting of any unvested restricted shares and stock options.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0px">          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Restrictive Covenants. The Employment Agreement contains    six-month post-termination noncompetition and non-solicitation provisions.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In September 2018, we entered into an employmentagreement with Mr. Hallberg providing for a base annual salary of $350,000. Mr. Hallberg’s employment terminated in April 2020.The employment agreement contained the following terms:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0px">          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Bonuses. The executive may, at the sole discretion    of the board of directors or the compensation committee, be considered for an annual bonus of up to 50% of her then base salary,    payable in cash or awards under our equity incentive plan.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">         <tbody>          <tr style="vertical-align: top">           <td style="width: 0px">           </td>           <td style="width: 24px; font-size: 10pt">            <font style="font-size: 10pt">             ·            </font>           </td>           <td style="font-size: 10pt">            <font style="font-size: 10pt">             Term; Termination. The Employment Agreement may be terminated by us for    any reason at any time. In the event of termination by us without cause or by the executive for good reason not in connection with    a change of control, as those terms are defined in such agreements, the executive is entitled to (i) severance for six months following    the termination date, (ii) a pro rata portion of any annual bonus, (iii) six months of COBRA payments, and (iv) the immediate accelerated    vesting of any unvested restricted shares and stock options. In the event such a termination is within 30 days prior to or six months    following a change of control, the executive is entitled to an additional three months of severance and COBRA payments.            </font>           </td>          </tr>         </tbody>        </table>       </p>       <p style="margin-top: 0; margin-bottom: 0">        <font style="font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">         <tbody>          <tr style="vertical-align: top">           <td style="width: 0px">           </td>           <td style="width: 24px">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             ·            </font>           </td>           <td>            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Restrictive Covenants. The Employment Agreement contains    six-month post-termination noncompetition and non-solicitation provisions.            </font>           </td>          </tr>         </tbody>        </table>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         DIRECTOR COMPENSATION        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Summary of Director Compensation        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The following table summarizes compensation that our non-employeedirectors earned during 2020 for services as members of our Board.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">           Name          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Fees           <br/>           Earned or           <br/>           Paid in           <br/>           Cash ($)          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Stock           <br/>           Awards ($)          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Options           <br/>           Awards ($)(1)          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Non-Equity           <br/>           Incentive Plan           <br/>           Compensation           <br/>           ($)          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Nonqualified           <br/>           Deferred           <br/>           Compensation           <br/>           Earnings ($)          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           All Other           <br/>           Compensation           <br/>           ($)          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Total ($)          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 23%; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.7pt; padding-left: 8.7pt">           Joseph    A. Akers (2)          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">           56,875          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">           56,875          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -7.65pt; padding-left: 7.65pt">           M. David MacFarlane,    Ph.D. (3)          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           56,875          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           56,875          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.7pt; padding-left: 8.7pt">           James R. McNab, Jr.    (4)          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           44,375          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           44,375          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.7pt; padding-left: 8.7pt">           Scott A. Smith (5)          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           51,875          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           51,875          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; padding-right: 0.8pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (1)           </font>          </td>          <td style="padding-right: 0.8pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Amounts shown represent    the grant date fair value computed in accordance with FASB ASC 718. The assumptions used by us with respect to the valuation of option    grants and stock awards are set forth in Note 9 to the financial statements.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-right: 0.8pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (2)           </font>          </td>          <td style="padding-right: 0.8pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The aggregate number of    option awards held at December 31, 2020 was 207.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-right: 0.8pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (3)           </font>          </td>          <td style="padding-right: 0.8pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The aggregate number of    option awards held at December 31, 2020 was 303.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-right: 0.8pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (4)           </font>          </td>          <td style="padding-right: 0.8pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The aggregate number of    option awards held at December 31, 2020 was 207.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-right: 0.8pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (5)           </font>          </td>          <td style="padding-right: 0.8pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The aggregate number of    option awards held at December 31, 2020 was 84.  Scott A. Smith did not stand for re-election to the Board at our    January 2021 Annual Stockholder Meeting.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 35; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         35         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0%">          </td>          <td style="width: 8%">           <a name="sp04-04">           </a>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Item 12.            </b>           </font>          </td>          <td style="text-align: justify; width: 92%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Security    Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The following table sets forth as of March 26,2021, the number of shares of our common stock beneficially owned by (i) each person who is known by us to be the beneficial owner ofmore than five percent of our common stock; (ii) each director and director nominee; (iii) each of the named executive officers in theSummary Compensation Table; and (iv) all directors and executive officers as a group. As of March 26, 2021, we had 9,864,068 shares ofcommon stock issued and outstanding.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Beneficial ownership is determined in accordancewith the rules of the Securities and Exchange Commission (the “SEC”) and generally includes voting or investment powerwith respect to securities. Unless otherwise indicated, the stockholders listed in the table have sole voting and investment power withrespect to the shares indicated.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table align="CENTER" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 93%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Name and Address of Beneficial Owner             <sup>              (1)             </sup>            </b>           </font>          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Shares             <br/>             Beneficially             <br/>             Owned             <sup>              (2)             </sup>            </b>           </font>          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">           <sup>           </sup>          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Percent of Shares           <br/>           Beneficially           <br/>           Owned          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 72%; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Joseph    A. Akers          </td>          <td style="width: 2%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           2,504          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           <sup>            (3)           </sup>          </td>          <td style="width: 2%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            *           </font>          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Katherine DeVarney,    Ph.D.          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,765          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           <sup>            (4)           </sup>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            *           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           M. David MacFarlane,    Ph.D.          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,268          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           <sup>            (5)           </sup>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            *           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           James R. McNab, Jr.          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           2,988          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           <sup>            (6)           </sup>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            *           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           Marc Rubin, M.D.          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           10,843          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           <sup>            (7)           </sup>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            *           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">           All executive officers    and directors as a group (5) persons          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           19,368          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           <sup>           </sup>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            *           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0in">          </td>          <td style="width: 0.25in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            *           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Less                                            than one percent.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0in">          </td>          <td style="width: 0.25in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (1)           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Unless                                            otherwise indicated, the address of such individual is c/o Titan Pharmaceuticals, Inc.,                                            400 Oyster Point Boulevard, Suite 505, South San Francisco, California 94080.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0in">          </td>          <td style="width: 0.25in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (2)           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            In                                            computing the number of shares beneficially owned by a person and the percentage ownership                                            of a person, shares of our common stock subject to options held by that person that are currently                                            exercisable or exercisable within 60 days of March 26, 2021 are deemed outstanding.                                            Such shares, however, are not deemed outstanding for purposes of computing the percentage                                            ownership of each other person. Except as indicated in the footnotes to this table and pursuant                                            to applicable community property laws, the persons named in the table have sole voting and                                            investment power with respect to all shares of common stock.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">         <tbody>          <tr style="vertical-align: top">           <td style="width: 0px">           </td>           <td style="width: 24px; font-size: 10pt">            <font style="font-size: 10pt">             (3)            </font>           </td>           <td style="font-size: 10pt">            <font style="font-size: 10pt">             Includes (i) 207 shares issuable upon exercise of outstanding options and    (ii) 1,112 shares issuable upon exercise of outstanding warrants.            </font>           </td>          </tr>         </tbody>        </table>       </p>       <p style="margin-top: 0; margin-bottom: 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0in">          </td>          <td style="width: 0.25in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (4)           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Includes                                            1,685 shares issuable upon exercise of outstanding options.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0in">          </td>          <td style="width: 0.25in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (5)           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Includes                                            (i) 251 shares issuable upon exercise of outstanding options and (ii) 445 shares                                            issuable upon exercise of outstanding warrants.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0in">          </td>          <td style="width: 0.25in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (6)           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Includes                                            (i) 207 shares issuable upon exercise of outstanding options and (ii) 1,112 shares                                            issuable upon exercise of outstanding warrants.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0in">          </td>          <td style="width: 0.25in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (7)           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Includes                                            (i) 5,517 shares issuable upon exercise of outstanding options and (ii) 2,223 shares                                            issuable upon exercise of outstanding warrants.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 8%">           <a name="sp04-05">           </a>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Item 13.            </b>           </font>          </td>          <td style="text-align: justify; width: 92%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Certain    Relationships and Related Transactions, and Director Independence            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Certain Relationships and Related Transactions.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        None.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Independence of Directors        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The following members of our Board meet the independencerequirements and standards currently established by the Nasdaq: Joseph A. Akers, M. David MacFarlane and James R. McNab, Jr.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Board Committees        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Our Board has established the following threestanding committees: audit committee; compensation committee; and nominating and governance committee, or governance committee.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 36; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         36         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The audit committee was formed in compliancewith Section 3(a)(58)(A) of the Exchange Act and consists of Joseph A. Akers, M. David MacFarlane and James R. McNab, Jr.,each of whom meets the independence requirements and standards currently established by Nasdaq and the SEC. In addition, the Board hasdetermined that Messr. Akers is an “audit committee financial expert” and “independent” as defined under therelevant rules of the SEC and Nasdaq. The audit committee assists the Board by overseeing the performance of the independent auditorsand the quality and integrity of Titan’s internal accounting, auditing and financial reporting practices. The audit committee isresponsible for retaining (subject to stockholder ratification) and, as necessary, terminating, the independent auditors, annually reviewsthe qualifications, performance and independence of the independent auditors and the audit plan, fees and audit results, and pre-approvesaudit and non-audit services to be performed by the auditors and related fees.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The compensation committee makes recommendationsto the Board concerning salaries and incentive compensation for our officers, including our Principal Executive Officer, and employeesand administers our stock option plans. The compensation committee consists of Joseph A. Akers, M. David MacFarlane and James R. McNab, Jr.,each of whom meets the independence requirements and standards currently established by Nasdaq.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The purpose of the governance committee is toassist the Board in identifying qualified individuals to become Board members, in determining the composition of the Board and in monitoringthe process to assess Board effectiveness. The governance committee consists of M. David MacFarlane and Joseph A. Akers, each of whommeets the independence requirements and standards currently established by Nasdaq.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The charters for the audit, compensation andgovernance committees, which have been adopted by our Board, contain detailed descriptions of the committees’ duties and responsibilitiesand are available in the Investor Relations section of our website at        <i>         www.titanpharm.com.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Role of the Board in Risk Oversight        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Our audit committee is primarily responsiblefor overseeing our risk management processes on behalf of the full Board. The audit committee receives reports from management at leastquarterly regarding our assessment of risks. In addition, the audit committee reports regularly to the full Board, which also considersour risk profile. The audit committee and the full Board focus on the most significant risks we face and our general risk managementstrategies. While the Board oversees our risk management, management is responsible for day-to-day risk management processes. Our Boardexpects management to consider risk and risk management in each business decision, to proactively develop and monitor risk managementstrategies and processes for day-to-day activities and to effectively implement risk management strategies adopted by the audit committeeand the Board. We believe this division of responsibilities is the most effective approach for addressing the risks we face and thatour Board leadership structure, which also emphasizes the independence of the Board in its oversight of its business and affairs, supportsthis approach.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Board Meetings        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Our business and affairs are managed under thedirection of our Board, which is currently composed of five members. The primary responsibilities of the Board are to provide oversight,strategic guidance, counseling and direction to our management. During the fiscal year ended December 31, 2020, the Board met seventeentimes and took action by written consent one time. No director attended fewer than 75% of the meetings of the Board and Board committeesof which the director was a member.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 8%">           <a name="sp04-06">           </a>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Item 14.            </b>           </font>          </td>          <td style="text-align: justify; width: 92%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Principal    Accounting Fees and Services.            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Aggregate fees billed by OUM &amp; Co. LLP,an independent registered public accounting firm, during the fiscal years ended December 31, 2020 and 2019 were as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           2020          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           2019          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 72%; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt">           Audit    Fees          </td>          <td style="width: 2%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           385,546          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 2%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           461,322          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt">           Audit-Related Fees          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -12pt; padding-left: 12pt">           Tax    Fees          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           47,560          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           44,920          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt; padding-left: 9pt">           Total          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           433,106          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           506,242          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          AuditFees         </b>        </font>        —This category includes aggregate fees billed by our independent auditors for the audit of our annual financialstatements, audit of management’s assessment and effectiveness of internal controls over financial reporting, review of financialstatements included in our quarterly reports on Form 10-Q and services that are normally provided by the auditor in connection withstatutory and regulatory filings for those fiscal years, including consents and comfort letters.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 37; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         37         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Split-Segment; Name: a5 -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Audit-RelatedFees         </b>        </font>        —This category consists of services by our independent auditors that, including accounting consultations on transactionrelated matters, are reasonably related to the performance of the audit or review of our financial statements and are not reported aboveunder Audit Fees.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          TaxFees         </b>        </font>        —This category consists of professional services rendered for tax compliance and preparation of our corporate taxreturns and other tax advice.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          AllOther Fees         </b>        </font>        —During the years ended December 31, 2020 and 2019, OUM &amp; Co. LLP did not incur any fees forother professional services.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The audit committee reviewed and approved allaudit and non-audit services provided by OUM &amp; Co. LLP and concluded that these services were compatible with maintaining itsindependence. The audit committee approved the provision of all non-audit services by OUM &amp; Co. LLP.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Pre-Approval Policies and Procedures         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In accordance with the SEC’s auditor independencerules, the audit committee has established the following policies and procedures by which it approves in advance any audit or permissiblenon-audit services to be provided to us by our independent auditor.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Prior to the engagement of the independent auditorsfor any fiscal year’s audit, management submits to the audit committee for approval lists of recurring audits, audit-related, taxand other services expected to be provided by the independent auditors during that fiscal year. The audit committee adopts pre-approvalschedules describing the recurring services that it has pre-approved, and is informed on a timely basis, and in any event by the nextscheduled meeting, of any such services rendered by the independent auditor and the related fees.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The fees for any services listed in a pre-approvalschedule are budgeted, and the audit committee requires the independent auditor and management to report actual fees versus the budgetperiodically throughout the year. The audit committee will require additional pre-approval if circumstances arise where it becomes necessaryto engage the independent auditor for additional services above the amount of fees originally pre-approved. Any audit or non-audit servicenot listed in a pre-approval schedule must be separately pre-approved by the audit committee on a case-by-case basis.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Every request to adopt or amend a pre-approvalschedule or to provide services that are not listed in a pre-approval schedule must include a statement by the independent auditors asto whether, in their view, the request is consistent with the SEC’s rules on auditor independence.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The audit committee will not grant approval for:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            •           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            any services prohibited by applicable law or by any    rule or regulation of the SEC or other regulatory body applicable to us;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            •           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            provision by the independent auditors to us of strategic    consulting services of the type typically provided by management consulting firms; or           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            •           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the retention of the independent auditors in connection    with a transaction initially recommended by the independent auditors, the tax treatment of which may not be clear under the Internal    Revenue Code and related regulations and which it is reasonable to conclude will be subject to audit procedures during an audit of    our financial statements.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Tax services proposed to be provided by the auditorto any director, officer or employee of Titan who is in an accounting role or financial reporting oversight role must be approved bythe audit committee on a case-by-case basis where such services are to be paid for by us, and the audit committee will be informed ofany services to be provided to such individuals that are not to be paid for by us.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In determining whether to grant pre-approvalof any non-audit services in the “all other” category, the audit committee will consider all relevant facts and circumstances,including the following four basic guidelines:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            •           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            whether the service creates a mutual or conflicting    interest between the auditor and us;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            •           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            whether the service places the auditor in the position    of auditing his or her own work;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            •           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            whether the service results in the auditor acting as    management or an employee of our company; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            •           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            whether the service places the auditor in a position    of being an advocate for our company.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 38; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         38         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <a name="sp04-08">        </a>        <b>         PART IV        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 8%">           <a name="sp04-07">           </a>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Item 15.            </b>           </font>          </td>          <td style="text-align: justify; width: 92%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Exhibits    and Financial Statements Schedules.            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in; padding-right: 0.8pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             (a)            </b>           </font>          </td>          <td style="width: 0.25in; padding-right: 0.8pt; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             1.            </b>           </font>          </td>          <td style="padding-right: 0.8pt; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Financial    Statements            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">        An index to Financial Statements appears on page F-1.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in; padding-right: 0.8pt">          </td>          <td style="width: 0.25in; padding-right: 0.8pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             2.            </b>           </font>          </td>          <td style="padding-right: 0.8pt; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Schedules            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        All financial statement schedules are omittedbecause they are not applicable, not required under the instructions or all the information required is set forth in the financial statementsor notes thereto.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 8%">           <a name="sp04-09">           </a>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Item 16.            </b>           </font>          </td>          <td style="text-align: justify; width: 92%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Form 10-K    Summary            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">        None       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 39; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         39         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         TITAN PHARMACEUTICALS, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         INDEX TO FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr>          <td style="vertical-align: top; width: 90%; padding-right: 0.8pt">          </td>          <td style="vertical-align: bottom; width: 10%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Page            </b>           </font>          </td>         </tr>         <tr style="background-color: #CCEEFF">          <td style="vertical-align: top; padding-right: 0.8pt">           <a href="#report">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Report    of Independent Registered Public Accounting Firm            </font>           </a>          </td>          <td style="vertical-align: bottom; padding-right: 0.8pt; text-align: center">           <a href="#report">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             41            </font>           </a>          </td>         </tr>         <tr style="background-color: white">          <td style="vertical-align: top; padding-right: 0.8pt">           <a href="#balancesheet">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Balance    Sheets as of December 31, 2020 and 201            </font>            <u>             9            </u>           </a>          </td>          <td style="vertical-align: bottom; padding-right: 0.8pt; text-align: center">           <a href="#balancesheet">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             42            </font>           </a>          </td>         </tr>         <tr style="background-color: #CCEEFF">          <td style="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">           <a href="#compereheiveloss">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Statements    of Operations and Comprehensive Loss for the years ended December 31, 2020 and 2019            </font>           </a>          </td>          <td style="vertical-align: bottom; padding-right: 0.8pt; text-align: center">           <a href="#compereheiveloss">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             43            </font>           </a>          </td>         </tr>         <tr style="background-color: white">          <td style="vertical-align: top; padding-right: 0.8pt">           <a href="#equlity">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Statements    of Stockholders’ Equity for the years ended December 31, 2020 and 201            </font>            <u>             9            </u>           </a>          </td>          <td style="vertical-align: bottom; padding-right: 0.8pt; text-align: center">           <a href="#equlity">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             44            </font>           </a>          </td>         </tr>         <tr style="background-color: #CCEEFF">          <td style="vertical-align: top; padding-right: 0.8pt">           <a href="#cashflow">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Statements    of Cash Flows for the years ended December 31, 2020 and 201            </font>            <u>             9            </u>           </a>          </td>          <td style="vertical-align: bottom; padding-right: 0.8pt; text-align: center">           <a href="#cashflow">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             45            </font>           </a>          </td>         </tr>         <tr style="background-color: white">          <td style="vertical-align: top; padding-right: 0.8pt">           <a href="#a_018">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Notes    to Financial Statements            </font>           </a>          </td>          <td style="vertical-align: bottom; padding-right: 0.8pt; text-align: center">           <a href="#a_018">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             46            </font>           </a>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 40; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         40         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <a name="report">        </a>        <b>         REPORT OF INDEPENDENTREGISTERED PUBLIC ACCOUNTING FIRM        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Stockholders and Board of Directors       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Titan Pharmaceuticals, Inc.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        South San Francisco, California       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Opinion on the Financial Statements        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We have audited the accompanying balance sheets of Titan Pharmaceuticals,Inc. (the “Company”) as of December 31, 2020 and 2019, the related statements of operations and comprehensive loss, stockholders’equity, and cash flows for each of the two years in the period ended December 31, 2020, and the related notes (collectively referredto as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, thefinancial position of the Company at December 31, 2020 and 2019, and the results of their operations and their cash flows for each ofthe two years in the period ended December 31, 2020        <b>         ,        </b>        in conformity with accounting principles generally accepted in the UnitedStates of America.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Going Concern Uncertainty        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The accompanying financial statements have been prepared assumingthat the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has suffered recurringlosses from operations and has an accumulated deficit that raise substantial doubt about its ability to continue as a going concern.Management's plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments thatmight result from the outcome of this uncertainty.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Basis for Opinion        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        These financial statements are the responsibilityof the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on ouraudits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”)and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicablerules and regulations of the Securities and Exchange Commission and the PCAOB.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We conducted our audits in accordance with the standardsof the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statementsare free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform,an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internalcontrol over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internalcontrol over financial reporting. Accordingly, we express no such opinion.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our audits included performing procedures to assessthe risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respondto those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financialstatements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as wellas evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Critical Audit Matters        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">        The critical audit matter communicated below isa matter arising from the current period audit of the financial statements that were communicated or required to be communicated to theaudit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especiallychallenging, subjective, or complex judgments. The communication of a critical audit matter does not alter in any way our opinion onthe financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinionon the critical audit matter or on the accounts or disclosures to which it relates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">        <i>         Discontinued Operations        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.95pt; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">        <u>         Description of the Matter        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.95pt; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        As described in Note 1 to the financial statements, in October 2020,the Company announced a decision to discontinue selling Probuphine implants in the U.S. and wind down the commercialization activitiesand pursue a plan to enable them to focus on ProNeura-based product development programs. Management presents discontinued operationswhen there is a disposal or anticipated disposal of a component group or a group of components that, in management’s judgment,represents a strategic shift that will have a major effect on operations and financial results.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We identified the assessment of the results of discontinued operationsas a critical audit matter. Given the nature of the Company discontinuing its commercialization activities, there is a high degree ofcomplexity in identifying and segregating assets, liabilities, and results of operations for the discontinued operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.65pt 0pt 1.95pt; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <u>         How We Addressed the Matter in Our Audit        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.95pt; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The primary procedures we performed to address this critical auditmatter included the following. We obtained an understanding and evaluated the design of the Company's internal control over accountingof significant unusual transactions. We evaluated management's judgment over the identification of the discontinued operating segmentby obtaining an understanding of management's judgment, reviewing relevant supporting documentation, and inquiring of management regardingspecific assumptions made. We tested the recognition and classifications of the Company’s segregation of assets, liabilities andthe results of operations that are classified as discontinued operations by inspecting the Company’s accounting data and relatedadjustments. We also reviewed the accuracy and completeness of the Company’s disclosures as they relate to discontinued operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="border-bottom: Black 1pt solid; width: 50%; padding-right: 0.8pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            /s/    OUM &amp; CO. LLP           </font>          </td>          <td style="width: 50%; padding-right: 0.8pt">          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-right: 0.8pt">          </td>          <td style="padding-right: 0.8pt">          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-right: 0.8pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            San Francisco, California           </font>          </td>          <td style="padding-right: 0.8pt">          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-right: 0.8pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            March 31, 2021           </font>          </td>          <td style="padding-right: 0.8pt">          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-right: 0.8pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            We have served as the    Company's auditor since 2004.           </font>          </td>          <td style="padding-right: 0.8pt">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: justify">       </p>       <!-- Field: Page; Sequence: 41; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         41         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <a name="balancesheet">        </a>        <b>         TITAN PHARMACEUTICALS, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         BALANCE SHEETS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             December 31,            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             2020            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             2019            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-size: 1pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 1pt">           </font>          </td>          <td colspan="2" style="border-top: Black 1pt solid; text-align: center">           <font style="font-size: 1pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 1pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 1pt">           </font>          </td>          <td colspan="2" style="border-top: Black 1pt solid; text-align: center">           <font style="font-size: 1pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 1pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td colspan="6" style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             (In thousands,    except             <br/>             share and per share data )            </b>           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Assets           </font>          </td>          <td>          </td>          <td colspan="2" style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 12pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Current    assets:           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 74%; padding-left: 27pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Cash    and cash equivalents           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="width: 10%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5,413           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="width: 10%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5,223           </font>          </td>          <td style="width: 1%">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 27pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Receivables           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            884           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            438           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 27pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Inventory           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            328           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            563           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-bottom: 1pt; padding-left: 27pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Prepaid    expenses and other current assets           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            522           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            534           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-bottom: 1pt; padding-left: 27pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Discontinued    operations – current assets           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            181           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1,550           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 45pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Total    current assets           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            7,328           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            8,308           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 12pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Property    and equipment, net           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            618           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            817           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-bottom: 1pt; padding-left: 12pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Operating    lease right-of-use asset           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            141           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            397           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-bottom: 2.5pt; padding-left: 12pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Total    Assets           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            8,087           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            9,522           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Liabilities and Stockholders’    Equity           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 12pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Current    liabilities:           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 27pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Accounts    payable           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1,253           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            815           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 27pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Accrued    clinical trials expenses           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            214           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            169           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 27pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Other    accrued liabilities           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            319           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            264           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 27pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Operating    lease liability, current           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            150           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            272           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-bottom: 1pt; padding-left: 27pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Current    portion of long-term debt           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            327           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-bottom: 1pt; padding-left: 27pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Discontinued    operations – current liabilities           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1,960           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2,080           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 45pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Total    current liabilities           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4,223           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3,600           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 12pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Long-term    debt, net of debt discount of $0 and $346           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            332           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4,019           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 12pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Warrant    liability           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            320           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-bottom: 1pt; padding-left: 12pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Operating    lease liability, non-current           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            150           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-bottom: 1pt; padding-left: 12pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Total    liabilities           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4,555           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            8,089           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 12pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Commitments    and contingencies (Note 5)           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 12pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Stockholders’    equity:           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 27pt; text-indent: -9pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Preferred    stock, $0.001 par value per share; 5,000,000 shares authorized, none issued and outstanding at December 31, 2020 and 2019.           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 27pt; text-indent: -9pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Common    stock, at amounts paid-in, $0.001 par value per share; 225,000,000 shares authorized 7,139,068 and 1,912,627 shares issued and outstanding    at December 31, 2020 and 2019, respectively.           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            7           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 27pt; text-indent: -9pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Additional    paid-in capital           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            370,804           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            350,468           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-bottom: 1pt; padding-left: 27pt; text-indent: -9pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Accumulated    deficit           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (367,279           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (349,037           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-bottom: 1pt; padding-left: 45pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Total    stockholders’ equity           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3,532           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1,433           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-bottom: 2.5pt; padding-left: 12pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Total    liabilities and stockholders’ equity           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            8,087           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            9,522           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        See accompanying notes to financial statements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 42; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         42         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         TITAN PHARMACEUTICALS, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <a name="compereheiveloss">        </a>        <b>         STATEMENTS OFOPERATIONS AND COMPREHENSIVE LOSS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Years    ended December 31,            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             2020            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             2019            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-top: black 1pt solid; text-align: center">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-top: black 1pt solid; text-align: center">          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td colspan="6" style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             (In thousands,    except per share             <br/>             data)            </b>           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Revenue:           </font>          </td>          <td>          </td>          <td colspan="2" style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="width: 74%; padding-left: 27pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            License    revenue           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="width: 10%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            11           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="width: 10%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            315           </font>          </td>          <td style="width: 1%">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 27pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Product    revenue           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            528           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-bottom: 1pt; padding-left: 27pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Grant    revenue           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4,299           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2,290           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 45pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Total    revenue           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4,838           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2,605           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 12pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Operating    expenses:           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 27pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Cost    of goods sold           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            472           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 27pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Research    and development           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5,916           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5,080           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 1pt; padding-left: 27pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            General    and administrative           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5,801           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5,401           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-bottom: 1pt; padding-left: 45pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Total    operating expenses           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            12,189           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10,481           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 45pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Loss    from operations           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (7,351           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (7,876           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 12pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Other    income (expense):           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 27pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Interest    expense, net           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (769           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (967           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 27pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Other    income (expense), net           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (258           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            17           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 27pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Non-cash    gain (loss) on changes in the fair value of warrants           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (923           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1,110           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 27pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Non-cash    gain on changes in the fair value of assets           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1,975           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 1pt; padding-left: 27pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Non-cash    gain (loss) on debt extinguishment           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (81           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            226           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-bottom: 1pt; padding-left: 45pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Other    income (expense), net           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (56           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            386           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 12pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Loss    from continuing operations           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (7,407           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (7,490           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="background-color: white">          <td style="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Loss    on discontinued operations           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; border-bottom: black 1pt solid">          </td>          <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (10,835           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; border-bottom: black 1pt solid">          </td>          <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (8,968           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 2.5pt; padding-left: 12pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Net    loss and comprehensive loss           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (18,242           </font>          </td>          <td style="padding-bottom: 2.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (16,458           </font>          </td>          <td style="padding-bottom: 2.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-bottom: 2.5pt; padding-left: 12pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Basic    and diluted net loss per common share from continuing operations           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (1.96           </font>          </td>          <td style="padding-bottom: 2.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (9.78           </font>          </td>          <td style="padding-bottom: 2.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 2.5pt; padding-left: 12pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Basic    and diluted net loss per common share on discontinued operations           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (2.87           </font>          </td>          <td style="padding-bottom: 2.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (11.71           </font>          </td>          <td style="padding-bottom: 2.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-bottom: 2.5pt; padding-left: 12pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Weighted    average shares used in computing basic and diluted net loss per common share           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3,773           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            766           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        See accompanying notes to financial statements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 43; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         43         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         TITAN PHARMACEUTICALS, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <a name="equlity">        </a>        <b>         STATEMENTS OF STOCKHOLDERS’EQUITY        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         (in thousands)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td style="white-space: nowrap; text-align: center">          </td>          <td style="white-space: nowrap">          </td>          <td colspan="6" style="white-space: nowrap; text-align: center">           <font style="font-size: 10pt">            <b>             Preferred Stock            </b>           </font>          </td>          <td style="white-space: nowrap">          </td>          <td style="white-space: nowrap">          </td>          <td colspan="6" style="white-space: nowrap; text-align: center">           <font style="font-size: 10pt">            <b>             Common Stock            </b>           </font>          </td>          <td style="white-space: nowrap">          </td>          <td style="white-space: nowrap">          </td>          <td colspan="2" style="white-space: nowrap; text-align: center">           <font style="font-size: 10pt">            <b>             Additional             <br/>             Paid-In            </b>           </font>          </td>          <td style="white-space: nowrap">          </td>          <td style="white-space: nowrap">          </td>          <td colspan="2" style="white-space: nowrap; text-align: center">           <font style="font-size: 10pt">            <b>             Accumulated            </b>           </font>          </td>          <td style="white-space: nowrap">          </td>          <td style="white-space: nowrap">          </td>          <td colspan="2" style="white-space: nowrap; text-align: center">           <font style="font-size: 10pt">            <b>             Total             <br/>             Stockholders’            </b>           </font>          </td>          <td style="white-space: nowrap">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="white-space: nowrap; text-align: center">          </td>          <td style="white-space: nowrap; padding-bottom: 1pt">          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Shares            </b>           </font>          </td>          <td style="white-space: nowrap; padding-bottom: 1pt">          </td>          <td style="white-space: nowrap; padding-bottom: 1pt">          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Amount            </b>           </font>          </td>          <td style="white-space: nowrap; padding-bottom: 1pt">          </td>          <td style="white-space: nowrap; padding-bottom: 1pt">          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Shares            </b>           </font>          </td>          <td style="white-space: nowrap; padding-bottom: 1pt">          </td>          <td style="white-space: nowrap; padding-bottom: 1pt">          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Amount            </b>           </font>          </td>          <td style="white-space: nowrap; padding-bottom: 1pt">          </td>          <td style="white-space: nowrap; padding-bottom: 1pt">          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Capital            </b>           </font>          </td>          <td style="white-space: nowrap; padding-bottom: 1pt">          </td>          <td style="white-space: nowrap; padding-bottom: 1pt">          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Deficit            </b>           </font>          </td>          <td style="white-space: nowrap; padding-bottom: 1pt">          </td>          <td style="white-space: nowrap; padding-bottom: 1pt">          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Equity            </b>           </font>          </td>          <td style="white-space: nowrap; padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="width: 23%; padding-left: 9pt; text-indent: -9pt">           <font style="font-size: 10pt">            Balances at December 31, 2018           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 8%; text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="width: 8%; text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 8%; text-align: right">           <font style="font-size: 10pt">            434           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="width: 8%; text-align: right">           <font style="font-size: 10pt">            1           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="width: 8%; text-align: right">           <font style="font-size: 10pt">            339,409           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="width: 8%; text-align: right">           <font style="font-size: 10pt">            (332,579           </font>          </td>          <td style="width: 1%">           <font style="font-size: 10pt">            )           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="width: 8%; text-align: right">           <font style="font-size: 10pt">            6,831           </font>          </td>          <td style="width: 1%">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 9pt; text-indent: -9pt">           <font style="font-size: 10pt">            Net loss           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            (16,458           </font>          </td>          <td>           <font style="font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            (16,458           </font>          </td>          <td>           <font style="font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 9pt; text-indent: -9pt">           <font style="font-size: 10pt">            Issuance of common stock, net           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            1,257           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            1           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            8,236           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            8,237           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 9pt; text-indent: -9pt">           <font style="font-size: 10pt">            Issuance of common stock upon exercise of warrants,    net           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            207           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            1,601           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            1,601           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 9pt; text-indent: -9pt">           <font style="font-size: 10pt">            Stock-based compensation           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            572           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            572           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt">           <font style="font-size: 10pt">            Issuance of common stock upon    conversion of convertible debt           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            15           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            650           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            650           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 9pt; text-indent: -9pt">           <font style="font-size: 10pt">            Balances at December 31, 2019           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            1,913           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            2           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            350,468           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            (349,037           </font>          </td>          <td>           <font style="font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            1,433           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 9pt; text-indent: -9pt">           <font style="font-size: 10pt">            Net loss           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            (18,242           </font>          </td>          <td>           <font style="font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            (18,242           </font>          </td>          <td>           <font style="font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 9pt; text-indent: -9pt">           <font style="font-size: 10pt">            Issuance of common stock, net           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            3,605           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            4           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            10,190           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            10,194           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 9pt; text-indent: -9pt">           <font style="font-size: 10pt">            Issuance of common stock upon exercise of warrants,    net           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            1,563           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            2           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            7,241           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            7,243           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 9pt; text-indent: -9pt">           <font style="font-size: 10pt">            Reverse stock split adjustments           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            58           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            (1           </font>          </td>          <td>           <font style="font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            1           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 9pt; text-indent: -9pt">           <font style="font-size: 10pt">            Reclassification of liability-classified warrants    to equity           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            2,897           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            2,897           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 1pt; padding-left: 9pt; text-indent: -9pt">           <font style="font-size: 10pt">            Stock-based compensation           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            7           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            7           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt">           <font style="font-size: 10pt">            Balances at December 31, 2020           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-size: 10pt">            7,139           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-size: 10pt">            7           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-size: 10pt">            370,804           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-size: 10pt">            (367,279           </font>          </td>          <td style="padding-bottom: 2.5pt">           <font style="font-size: 10pt">            )           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-size: 10pt">            3,532           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        See accompanying notes tofinancial statements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 44; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         44         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         TITAN PHARMACEUTICALS, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <a name="cashflow">        </a>        <b>         STATEMENTS OF CASH FLOWS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: center">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Years    Ended December 31,            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: center">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             2020            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             2019            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: center">          </td>          <td>          </td>          <td colspan="6" style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             (In thousands)            </b>           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 12pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Cash    flows from operating activities:           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="width: 72%; padding-left: 12pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Net    loss           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="width: 11%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (18,242           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="width: 11%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (16,458           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 12pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Adjustments    to reconcile net loss to net cash used in operating activities:           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Non-cash gain on difference    between fair and carrying value of assets transferred in debt settlement           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (1,975           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Depreciation and amortization           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            292           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            244           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Non-cash interest expense           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            498           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            613           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Non-cash loss (gain) on    changes in fair value of warrants           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            923           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (1,110           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Non-cash loss (gain) on    debt extinguishment           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            81           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (226           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Stock-based compensation           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            7           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            572           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Finance costs for issuance    of warrants           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            211           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Other           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (16           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (41           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 12pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Changes    in operating assets and liabilities:           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Receivables           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            186           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            744           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Inventory           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            287           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            264           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Contract assets           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            99           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Prepaid expenses and other    assets           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            391           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (547           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Accounts payable           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1,101           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (125           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Accrued sales allowances           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (747           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            809           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Other accrued liabilities           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (200           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            30           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-bottom: 1pt; padding-left: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Deferred    revenue           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (313           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-bottom: 1pt; padding-left: 12pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Net    cash used in operating activities           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (17,203           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (15,445           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 12pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Cash    flows from investing activities:           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-bottom: 1pt; padding-left: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Purchases    of furniture and equipment           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (540           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (256           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-bottom: 1pt; padding-left: 12pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Net    cash used in investing activities           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (540           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (256           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 12pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Cash    flows from financing activities:           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Proceeds from equity offerings           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            11,636           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            9,665           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Net loan proceeds           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            654           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Proceeds from the exercise    of warrants           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            7,243           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1,603           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-bottom: 1pt; padding-left: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Payments    on long-term debt           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (1,600           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-bottom: 1pt; padding-left: 12pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Net    cash provided by financing activities           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            17,933           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            11,268           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 12pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Net    increase (decrease) in cash           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            190           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (4,433           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-bottom: 1pt; padding-left: 12pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Cash,    cash equivalents and restricted cash at beginning of period           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5,223           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            9,656           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-bottom: 2.5pt; padding-left: 12pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Cash,    cash equivalents and restricted cash at end of period           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5,413           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5,223           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 12pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Supplemental    disclosure of cash flow information           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 12pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Interest    paid           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            295           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            432           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 12pt; text-indent: -12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Purchases    of property and equipment in accounts payable or accrued expenses           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            11           </font>          </td>          <td>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        See accompanying notes to financial statements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 45; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         45         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Split-Segment; Name: a5 -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">        <b>         TITAN PHARMACEUTICALS, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">        <b>         <a name="a_018">         </a>         NOTESTO FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             1.            </b>           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Organization and Summary    of Significant Accounting Policies            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>          The Company         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0.25in">        We are a pharmaceutical companydeveloping therapeutics utilizing our proprietary long-term drug delivery platform, ProNeura™, for the treatment of select chronicdiseases for which steady state delivery of a drug provides an efficacy and/or safety benefit. ProNeura consists of a small, solid implantmade from a mixture of ethylene-vinyl acetate, or EVA, and a drug substance. The resulting product is a solid matrix that is administeredsubdermally, normally in the inner upper arm, in a brief, outpatient procedure and is removed in a similar manner at the end of the treatmentperiod of several months. These procedures may be performed by trained health care providers, or HCPs, including licensed and surgicallyqualified physicians, nurse practitioners, and physician’s assistants in a HCP’s office or other clinical setting.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Our first product based on our ProNeura technologywas our Probuphine        <sup>         ®        </sup>        (buprenorphine) implant, which was approved in the United States, Canada and the European Union, orEU, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine.Following reacquisition of the rights to Probuphine from our former licensee in mid-2018, we endeavored to build our infrastructure andgrow our commercial capabilities with the limited resources at our disposal. While we made important progress in laying the groundworkduring 2019 to transition into a company with full commercial potential, and also among other things manage the challenges of the restrictiveproduct label, the Risk Evaluation and Mitigation Strategy, or REMS, program        <font style="color: #333333">         and the complexity of the distributionchannel        </font>        , the emergence of the Covid-19 pandemic in early 2020 and the resultant restrictions and lockdown of facilities severelyimpacted our ability to continue to expand our commercial operations. With limited financial resources and insufficient sales revenueduring the first three quarters of 2020, we made the decision to discontinue selling Probuphine in the U.S. and wind down our commercializationactivities, and to pursue a plan that will enable us to focus on our current, early-stage ProNeura-based product development programs.Probuphine continues to be commercialized in Canada and the EU by other companies who have either licensed or acquired the rights fromTitan. We operate in only one business segment, the development of pharmaceutical products.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">        In November 2020, pursuant to prior stockholderauthorization, our board of directors, or the Board, effected a reverse split of the outstanding shares of our common stock at a ratioof one share for every thirty shares then outstanding, or the Reverse Split. Pursuant to their respective terms, the number of sharesunderlying our outstanding options and warrants was reduced and their respective exercise prices increased by the Reverse Split ratio.The number of shares of common stock authorized and the par value of $0.001 per share did not change as a result of the Reverse Split.All share and per share amounts contained in this Annual Report on Form 10-K give retroactive effect to the Reverse Split.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in">        The accompanying financialstatements have been prepared assuming we will continue as a going concern.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        At December 31, 2020, we had cash and cash equivalentsof approximately $5.4 million, which we believe, together with the net cash proceeds of approximately $8.9 million received from theregistered direct offering of our common stock in January 2021, is sufficient to fund our planned operations into the first quarter of2022. We will require additional funds to finance our operations. We are exploring several financing alternatives; however, there canbe no assurance that our efforts to obtain the funding required to continue our operations will be successful. There is substantial doubtabout our ability to continue as a going concern.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>          Discontinued Operations         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In October 2020, we announced our decision todiscontinue selling Probuphine in the U.S. and wind down our commercialization activities, and to pursue a plan that will enable us tofocus on our current, early-stage ProNeura-based product development programs.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The accompanying financial statements have beenrecast for all periods presented to reflect the assets, liabilities, revenue and expenses related to our U.S. commercialization activitiesas discontinued operations (see Note 11). The accompanying financial statements are generally presented in conformity with our historicalformat. We believe this format provides comparability with the previously filed financial statements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>          Use of Estimates         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The preparation of financial statements in conformitywith accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the amountsreported in the financial statements and accompanying notes. Actual results could differ from those estimates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: 0.5in">        <b>         <i>         </i>        </b>       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>          Going concern assessment         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        We assess going concern uncertaintyin our financial statements to determine if we have sufficient cash on hand and working capital, including available borrowings on loans,to operate for a period of at least one year from the date the financial statements are issued or available to be issued, which is referredto as the “look-forward period” as defined by Accounting Standard Update ASU No. 2014-15. As part of this assessment,based on conditions that are known and reasonably knowable to us, we will consider various scenarios, forecasts, projections, estimatesand will make certain key assumptions, including the timing and nature of projected cash expenditures or programs, and its ability todelay or curtail expenditures or programs, if necessary, among other factors. Based on this assessment, as necessary or applicable, wemake certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extentwe deem probable those implementations can be achieved and we have the proper authority to execute them within the look-forward periodin accordance with ASU No. 2014-15.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Based upon the above assessment,we concluded that, at the date of filing the financial statements in this Annual Report on Form 10-K for the year ended December 31,2020, we did not have sufficient cash to fund our operations for the next 12 months without additional funds and, therefore, there wassubstantial doubt about our ability to continue as a going concern within 12 months after the date the financial statements were issued.Additionally, we have suffered recurring losses from operations and have an accumulated deficit that raises substantial doubt aboutour ability to continue as a going concern.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 46; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         46         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>          Inventories         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in">        Inventories are recorded atthe lower of cost or net realizable value. Cost is based on the first in, first out method. We regularly review inventory quantitieson hand and write down to its net realizable value any inventory that we believe to be impaired. The determination of net realizablevalue requires judgment including consideration of many factors, such as estimates of future product demand, product net selling prices,current and future market conditions and potential product obsolescence, among others. The components of inventories are as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt; text-align: center">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           As of December 31,          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt; text-align: center">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           2020          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           2019          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; width: 74%; text-align: left">           Raw materials and supplies          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           170          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           563          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Finished goods          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           158          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           328          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           563          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The approximately $158,000of finished goods inventory at December 31, 2020 included materials held for sale to Molteni and Knight. We had approximately $435,000of finished goods inventory at December 31, 2019 which has been reclassified to discontinued operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>          Stock-Based Compensation         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        We recognize compensation expenseusing a fair-value based method, for all stock-based payments including stock options and restricted stock awards and stock issued underan employee stock purchase plan. These standards require companies to estimate the fair value of stock-based payment awards on the dateof grant using an option pricing model. See Note 9 “Stock Plans,” for a discussion of our stock-based compensation plans.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>          Warrants Issued in Connection with EquityFinancing         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        We generally account for warrantsissued in connection with equity financings as a component of equity, unless there is a deemed possibility that we may have to settlethe warrants in cash. For warrants issued with deemed possibility of cash settlement, we record the fair value of the issued warrantsas a liability at each reporting period and record changes in the estimated fair value as a non-cash gain or loss in the Statements ofOperations and Comprehensive Loss.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>          Cash and Cash Equivalents         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Our investment policy emphasizesliquidity and preservation of principal over other portfolio considerations. We select investments that maximize interest income to theextent possible given these two constraints. We satisfy liquidity requirements by investing excess cash in securities with differentmaturities to match projected cash needs and limit concentration of credit risk by diversifying our investments among a variety of highcredit-quality issuers and limit the amount of credit exposure to any one issuer. The estimated fair values have been determined usingavailable market information. We do not use derivative financial instruments in our investment portfolio.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        All investments with originalmaturities of three months or less are considered to be cash equivalents. We had money market funds of approximately $5.1 million and$4.9 million as of December 31, 2020 and 2019, respectively, included in our cash and cash equivalents.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>          Property and Equipment         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Property and equipment arerecorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets ranging from three to fiveyears. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the assets.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>          Revenue Recognition         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">        We generate revenue principallyfrom collaborative research and development arrangements, technology licenses and sales, government grants, sales of Probuphine materialsto Molteni and Knight, and prior to the discontinued operations, the sale of Probuphine in the U.S. Consideration received for revenuearrangements with multiple components is allocated among the separate performance obligations based upon their relative estimated standaloneselling price.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In determining the appropriateamount of revenue to be recognized as we fulfill our obligations under our agreements, we perform the following steps for our revenuerecognition: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promisedgoods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurementof the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performanceobligations based on estimated selling prices; and (v) recognition of revenue when (or as) we satisfy each performance obligation.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 47; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         47         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">        <i>         Net Product Revenue        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">        Prior to the discontinuationof our commercialization activities relating to Probuphine in the U.S., we recognized revenue from product sales when control of theproduct transfers, generally upon shipment or delivery, to our customers, which include distributors. As customary in the pharmaceuticalindustry, our gross product revenue was subject to a variety of deductions in the forms of variable consideration, such as rebates, chargebacks,returns and discounts, in arriving at reported net product revenue. This variable consideration was estimated using the most-likely amountmethod, which is the single most-likely outcome under a contract and was typically at stated contractual rates. The actual outcome ofthis variable consideration could materially differ from our estimates. From time to time, we would adjust our estimates of this variableconsideration when trends or significant events indicated that a change in estimate is appropriate to reflect the actual experience.Additionally, we continued to assess the estimates of our variable consideration as we continued to accumulate additional historicaldata.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">        Returns – Consistentwith the provisions of ASC 606, we estimated returns at the inception of each transaction, based on multiple considerations, includinghistorical sales, historical experience of actual customer returns, levels of inventory in our distribution channel, expiration datesof purchased products and significant market changes which could impact future expected returns to the extent that we would not reverseany receivables, revenues, or contract assets already recognized under the agreement.  During the year ended December 31, 2019,we entered into agreements with large national specialty pharmacies with a distribution channel different from that of our existing customersand, therefore, the related reserves had unique considerations. We continued to evaluate the activities with these specialty pharmaciesand updated the related reserves accordingly.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">        Rebates – Ourprovision for rebates was estimated based on our customers’ contracted rebate programs and our historical experience of rebatespaid.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">        Discounts –Theprovision was estimated based upon invoice billings, utilizing historical customer payment experience.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">        The following tableprovides a summary of activity with respect to our product returns and discounts and rebates, which have been reclassified to discontinuedoperations for all periods presented (in thousands):       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">           Accrued Sales Allowances          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; text-align: center">          </td>          <td style="padding-bottom: 1pt; font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt; text-align: center">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Product           <br/>           Return           <br/>           Allowance          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">            <b>             Discounts             <br/>             and             <br/>             Rebates             <br/>             Allowance            </b>           </p>          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>            </b>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>            </b>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">            <b>             Total            </b>           </p>          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Allowance           <br/>           for Doubtful           <br/>           Accounts          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; width: 48%">           Balance at December 31, 2019          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           721          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           88          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           809          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           63          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in">           Provision          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           94          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           40          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           134          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           31          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in">           Payments/credits          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (759          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (123          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (882          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (78          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif">           Balance at December 31, 2020          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           56          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           5          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           61          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           16          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">        <i>         Performance Obligations        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">        Aperformance obligation is a promise in a contract to transfer a distinct good or service to the customer. Our performance obligationsinclude commercialization license rights, development services and services associated with the regulatory approval process.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">        Wehave optional additional items in contracts, which are accounted for as separate contracts when the customer elects such options. Arrangementsthat include a promise for future commercial product supply and optional research and development services at the customer’s discretionare generally considered as options. We assess if these options provide a material right to the customer and, if so, such material rightsare accounted for as separate performance obligations. If we are entitled to additional payments when the customer exercises these options,any additional payments are recorded in revenue when the customer obtains control of the goods or services.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 48; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         48         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">        <i>         Transaction Price        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in; background-color: white">        Wehave both fixed and variable consideration. Non-refundable upfront payments are considered fixed, while milestone payments are identifiedas variable consideration when determining the transaction price. Funding of research and development activities is considered variableuntil such costs are reimbursed at which point they are considered fixed. We allocate the total transaction price to each performanceobligation based on the relative estimated standalone selling prices of the promised goods or services for each performance obligation.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">        Atthe inception of each arrangement that includes milestone payments, we evaluate whether the milestones are considered probable of beingachieved and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable thata significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Milestonepayments that are not within our control, such as approvals from regulators, are not considered probable of being achieved until thoseapprovals are received.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">        Forarrangements that include sales-based royalties or earn-out payments, including milestone payments based on the level of sales, and thelicense or purchase agreement is deemed to be the predominant item to which the royalties or earn-out payments relate, we recognizesrevenue at the later of (a) when the related sales occur, or (b) when the performance obligation to which some or all of theroyalty or earn-out payment has been allocated has been satisfied (or partially satisfied).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">        <i>         Allocation of Consideration        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">        Aspart of the accounting for these arrangements, we must develop assumptions that require judgment to determine the stand-alone sellingprice of each performance obligation identified in the contract. Estimated selling prices for license rights are calculated usingthe residual approach. For all other performance obligations, we use a cost-plus margin approach.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">        <i>         Timing of Recognition        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in; background-color: white">        Significantmanagement judgment is required to determine the level of effort required under an arrangement and the period over which we expect tocomplete our performance obligations under an arrangement. We estimate the performance period or measure of progress at the inceptionof the arrangement and re-evaluate it each reporting period. This re-evaluation may shorten or lengthen the period over which revenueis recognized. Changes to these estimates are recorded on a cumulative catch up basis. If we cannot reasonably estimate when our performanceobligations either are completed or become inconsequential, then revenue recognition is deferred until we can reasonably make such estimates.Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. Revenueis recognized for licenses or sales of functional intellectual property at the point in time the customer can use and benefit from thelicense. For performance obligations that are services, revenue is recognized over time proportionate to the costs that we have incurredto perform the services using the cost-to-cost input method.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>          Research and Development Costs and RelatedAccrual         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">        Research and development expensesinclude internal and external costs. Internal costs include salaries and employment related expenses, facility costs, administrativeexpenses and allocations of corporate costs. External expenses consist of costs associated with outsourced contract research organization(“CRO”) activities, sponsored research studies, product registration, patent application and prosecution, and investigatorsponsored trials. We also record accruals for estimated ongoing clinical trial costs. Clinical trial costs represent costs incurred byCROs and clinical sites. These costs are recorded as a component of research and development expenses. Under our agreements, progresspayments are typically made to investigators, clinical sites and CROs. We analyze the progress of the clinical trials, including levelsof patient enrollment, invoices received and contracted costs when evaluating the adequacy of accrued liabilities. Significant judgmentsand estimates must be made and used in determining the accrued balance in any accounting period. Actual results could differ from thoseestimates under different assumptions. Revisions are charged to expense in the period in which the facts that give rise to the revisionbecome known.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>          Net Loss Per Share         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Basic net loss per share excludesthe effect of dilution and is computed by dividing net loss by the weighted-average number of shares outstanding for the period. Dilutednet loss per share reflects the potential dilution that could occur if securities or other contracts to issue shares were exercised intoshares. In calculating diluted net loss per share, the numerator is adjusted for the change in the fair value of the warrant liability(only if dilutive) and the denominator is increased to include the number of potentially dilutive common shares assumed to be outstandingduring the period using the treasury stock method. Basic and diluted net loss per share was the same for each of the periods presented.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 49; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         49         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The table below presents common shares underlyingstock options and warrants that are excluded from the calculation of the weighted average number of shares of common stock outstandingused for the calculation of diluted net loss per common share. These are excluded from the calculation due to their anti-dilutive effectfor the years ended (in thousands):       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">           December 31,          </td>          <td style="padding-bottom: 1pt; font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           2020          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           2019          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; width: 74%; text-align: left">           Weighted-average anti-dilutive common shares resulting    from stock awards          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           31          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           36          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Weighted-average anti-dilutive common shares resulting from    warrants          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           297          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           256          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Convertible debt          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           49          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           328          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           341          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>          Leases         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In February 2016, theFinancial Accounting Standards Board (the “FASB”) issued Accounting Standard Update, or ASU, No. 2016-02, Leases (Topic842), to enhance the transparency and comparability of financial reporting related to leasing arrangements. We adopted the standard effectiveJanuary 1, 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        We determine whether the arrangementis or contains a lease at inception. Operating lease right-of-use assets and lease liabilities are recognized at the present value ofthe future lease payments at commencement date. The interest rate implicit in lease contracts is typically not readily determinable,and therefore, we utilize our incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similarterm an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be requiredfor items such as initial direct costs paid or incentives received.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Lease expense is recognizedover the expected term on a straight-line basis. Operating leases are recognized on our balance sheet as right-of-use assets, operatinglease liabilities current and operating lease liabilities non-current. We no longer recognize deferred rent on our balance sheet.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The following table presents maturities of ouroperating lease as of December 31, 2020 (in thousands):       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; width: 89%; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">           2021          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 8%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           155          </td>          <td style="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 22.5pt">           Total minimum lease payments (base rent)          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           155          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">           Less:    imputed interest          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (5          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: 22.95pt">           Total operating    lease liabilities          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           150          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>          Subsequent Events         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        We have evaluated events thathave occurred subsequent to December 31, 2020 and through the date that the financial statements are issued.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>          Fair Value Measurements         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        We measure the fair value offinancial assets and liabilities based on authoritative guidance which defines fair value, establishes a framework consisting of threelevels for measuring fair value, and requires disclosures about fair value measurements. Fair value is defined as the exchange pricethat would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market forthe asset or liability in an orderly transaction between market participants on the measurement date. There are three levels of inputsthat may be used to measure fair value:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Level 1 – quoted prices in active marketsfor identical assets or liabilities;       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Level 2 – quoted prices for similar assetsand liabilities in active markets or inputs that are observable;       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Level 3 – inputs that are unobservable(for example cash flow modeling inputs based on assumptions).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 50; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         50         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Financial instruments, includingreceivables, accounts payable and accrued liabilities are carried at cost, which we believe approximates fair value due to the short-termnature of these instruments. The approximately $5.1 million and $4.9 million fair values of money market funds as of December 31,2020 and 2019 included in our cash and cash equivalents are classified as Level 1 and were derived from quoted market prices as activemarkets for these instruments exists. Our warrant and derivative liabilities are classified within level 3 of the fair value hierarchybecause the value is calculated using significant judgment based on our own assumptions in the valuation of these liabilities.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The following table presents a roll forward ofthe fair value of our warrant liability, the fair value of which is determined by Level 3 inputs for the years ended (in thousands):       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           2020          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           2019          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; width: 74%">           Fair value, beginning of period          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           320          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in">           Issuance of warrants          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,654          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,430          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">           Change in fair value           <sup>            (1)           </sup>          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           923          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (1,110          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">           Reclassification of warrants to additional    paid-in capital          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (2,897          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif">           Fair value, end of period          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           320          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in">        (1)  Recognized as non-cashloss on changes in fair value of warrants in the statement of operations and comprehensive loss.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The following table presents a roll forward ofthe fair value of our derivative liability, the fair value of which is determined by Level 3 inputs for the years ended (in thousands):       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">           December 31,          </td>          <td style="padding-bottom: 1pt; font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           2020          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           2019          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; width: 74%">           Fair value, beginning of period          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           25          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in">           Issuance of derivative          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">           Change in fair value          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (25          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif">           Fair value, end of period          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Recent Accounting Pronouncements         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Accounting Standards Adopted        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">        In August 2018, the FASB issuedASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement,which eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of the FASB's disclosure frameworkproject. We adopted ASU 2018-13 effective January 1, 2020 with no material impact to our financial statements and related disclosures.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 51; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         51         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Accounting Standards Not Yet Adopted        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In June 2016, the FASBissued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses, which requires an organization tomeasure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions,and reasonable and supportable forecasts. Financial institutions and other organizations will now use forward-looking information tobetter inform their credit loss estimates. The amendments in this ASU are effective for us in our interim period ending March 31,2023. We are currently assessing the impact of the adoption of Topic 326 on our financial statements and disclosures.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In March 2020, the FASB issued ASU 2020-04, ReferenceRate Reform, which provides companies with optional guidance, including expedients and exceptions for applying generally accepted accountingprinciples to contracts and other transactions affected by reference rate reform, such as the London Interbank Offered Rate (LIBOR).This new standard was effective upon issuance and generally can be applied to applicable contract modifications through December 31,2022. We are evaluating the effects that the adoption of this guidance will have on our financial statements and disclosures.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In August 2020, the FASB issued ASU No. 2020-06,Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, which simplifies the accounting for convertible instruments.ASU 2020-06 eliminates certain models that require separate accounting for embedded conversion features, in certain cases. Additionally,among other changes, the guidance eliminates certain of the conditions for equity classification for contracts in an entity’s ownequity. The guidance also requires entities to use the if converted method for all convertible instruments in the diluted earnings pershare calculation and include the effect of share settlement for instruments that may be settled in cash or shares, except for certainliability-classified share-based payment awards. This guidance is effective beginning after December 15, 2023 and must be applied usingeither a modified or full retrospective approach. Early adoption is permitted. We are currently evaluating the impact this guidance willhave on our financial statements and related disclosures.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             2.            </b>           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Property and Equipment            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Property and equipment consistedof the following (in thousands):       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">           As of December 31,          </td>          <td style="padding-bottom: 1pt; font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           2020          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           2019          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; width: 74%; text-align: left">           Furniture and office equipment          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           388          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           388          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Leasehold improvements          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           408          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           408          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Laboratory equipment          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,108          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           3,413          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Computer equipment          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,262          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,218          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Construction in progress          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           73          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           3,166          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           5,500          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Less accumulated depreciation and amortization          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (2,548          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (4,683          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Property and equipment, net          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           618          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           817          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             3.            </b>           </font>          </td>          <td style="text-align: justify">           <b>            Molteni Purchase Agreement           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In March 2018, we entered into and in August2018 amended an Asset Purchase, Supply and Support Agreement, or the Purchase Agreement, with L. Molteni &amp; C. Dei Frattelli AlittiSocieta Di Esercizio S.P.A., or Molteni, pursuant to which Molteni acquired the European intellectual property related to Probuphineand the exclusive right to commercialize Probuphine (which it renamed Sixmo) in Europe, as well as certain countries of the Commonwealthof Independent States, the Middle East and North Africa, or the Molteni Territory. We received an initial payment of €2.0 million($2,448,000) for the purchased assets and an additional payment of €950,000 ($1,107,000) upon execution of the amendment. Additionally,Titan was entitled to receive earn-out payments for up to 15 years on net sales of Probuphine in the Molteni Territory.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The Purchase Agreement also provided that Titanwould supply Molteni with semi-finished product (i.e., the implant and the applicator) on an exclusive basis at a fixed price throughDecember 31, 2019, with subsequent price increases not to exceed annual cost increases to Titan under its current manufacturing agreementand for the purchase of the active pharmaceutical ingredient.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 52; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         52         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">        We concluded that the performanceobligations identified in the Molteni Purchase Agreement included the transfer of the intellectual property and our efforts towards anapproval by the EMA and other regulatory bodies. The initial payment was allocated between the property transfer and our EMA effortsas set forth below.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        We used the expected cost-plusapproach to estimate the standalone selling price of approximately $1.4 million related to our efforts towards an approval by the EMAand other regulatory bodies (“Titan Services”). This includes employee related expenses as well as other manufacturing, regulatoryand clinical costs, which are incurred as part of our efforts. We recognized revenue associated with Titan Services ratably over theestimated service period. As of March 31, 2019, we fully recognized the revenue associated with the Titan Services under the MolteniPurchase Agreement as we completed the Titan Services.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        We used the residual approachto value the transfer of the intellectual property at approximately $1.0 million as we had not established and had no reliable way toestablish a standalone selling price for the intellectual property.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        As a result of the outcomeof the milestone and earn-out payments being unpredictable due to the involvement of third parties, we believe that using the most likelyamount method is appropriate. Any subsequent revenue related to milestone and earn-out payments will be recognized at the time the milestonesare achieved or when the related net sales have occurred.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in">        The Molteni Purchase Agreementprovides that we supply Molteni with semi-finished product (i.e., the implant, the applicator and related technology) on an exclusivebasis at a fixed price through December 31, 2019, with subsequent price increases not to exceed annual cost increases to us forthe active pharmaceutical ingredient and under our current manufacturing agreement. Revenue is recognized when the semi-finished producthas been transferred to Molteni.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Molteni will be prohibitedfrom marketing a competitor product as defined in the Molteni Purchase Agreement in the Molteni Territory for the five year period followingapproval of the marketing authorization application. Thereafter, Molteni will be required to pay us a low single digit royalty on netsales of any competitor product.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 53; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         53         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The following table presentschanges in contract assets and liabilities during the year ended December 31, 2019 (in thousands):       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Beginning           <br/>           Balance          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Additions          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Deductions          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Ending           <br/>           Balance          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: bold 10pt Times New Roman, Times, Serif">           Year ended December 31, 2019          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; width: 48%; text-align: left">           Contract assets          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           99          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           (99          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Contract liabilities:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">           Deferred revenue          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           313          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (313          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In August 2018, we enteredinto an amendment to the Molteni Purchase Agreement, pursuant to which Molteni made an immediate payment of €950,000 (approximately$1.1 million) and a convertible loan of €550,000 (approximately $0.6 million) (“Molteni Convertible Loan”) (see Note7) to us, both in exchange for the elimination of an aggregate of €2.0 million (approximately $2.3 million) of regulatory milestonesprovided for in the Molteni Purchase Agreement. We concluded that the approximately $1.1 million immediate payment by Molteni reflecteda milestone payment with no additional obligations to us and, therefore, was recognized as revenue during the year ended December 31,2018.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In September 2019, weentered into an additional amendment to the Molteni Purchase Agreement, pursuant to which the percentage earn-out payments on net saleswas reduced from the original range of low-teens to mid-twenties to the current range of low-teens to mid-teens. We also agreed to delaypayment of any earn-outs until the later of (i) January 1, 2021 or (ii) the one year anniversary of completion of complianceby our manufacturer with EU requirements (currently anticipated to occur during the second quarter of this year). The milestone paymentsunder the Molteni Purchase Agreement remain unchanged.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">        In October 2020, we enteredinto a Debt Settlement and Release Agreement (“DSRA Agreement”) with Molteni and Horizon Technology Finance Corporation (“Horizon”),the holders of our outstanding secured debt, to settle such obligations for $1.6 million in cash, the transfer of certain Probuphineassets to Molteni, including all of our manufacturing equipment, and the termination of our rights to future payments under the PurchaseAgreement with Molteni. The DSRA Agreement, provided for the release to us of the remaining collateral. We recorded a loss of approximately$0.1 million related to the DSRA Agreement in the statements of operations and comprehensive loss for the period ended December 31, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             4.            </b>           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             JT Pharmaceuticals Asset    Purchase Agreement            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In October 2020, we entered into an Asset PurchaseAgreement (the “JT Agreement”) with JT Pharmaceuticals, Inc. (“JT Pharma”) to acquire JT Pharma’s kappaopioid agonist peptide, TP-2021, for use in combination with our ProNeura long-term, continuous drug delivery technology, for the treatmentof chronic pruritus and other medical conditions. Under the terms of the JT Agreement, JT Pharma received a $15,000 closing payment andis entitled to receive future milestone payments, payable in cash or in stock, based on the achievement of regulatory milestones, andsingle-digit percentage earn-out payments on net sales of the product if successfully developed and approved for commercialization. Todate, none of these events have occurred and no contingent consideration, milestone or earn-out payments have been recognized.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0px">          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             5.            </b>           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Commitments and Contingencies            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>          Lease Commitments         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        We lease our office facilityunder operating lease that expires in June 2021. Rent expense associated with this lease was approximately $0.3 million each yearfor years ended December 31, 2020 and 2019, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>          Minimum payments         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Our manufacturing agreement, as amended, withDPT, our contract manufacture, provides for a minimum manufacturing fee of $1.0 million. In the event we do not have DPT manufacturesufficient quantities of product to exceed the minimum manufacturing fee, DPT is able to invoice us for the amount of the shortfall.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>          Guarantees and Indemnifications         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        As permitted under Delaware law and in accordancewith our Bylaws, we indemnify our officers and directors for certain events or occurrences while the officer or director is or was servingat our request in such capacity. The term of the indemnification period is for the officer’s or director’s lifetime. Themaximum amount of potential future indemnification is unlimited; however, we have a director and officer insurance policy that limitsour exposure and may enable us to recover a portion of any future amounts paid. We believe the fair value of these indemnification agreementsis minimal. Accordingly, we have not recorded any liabilities for these agreements as of December 31, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In the normal course of business,we have commitments to make certain milestone payments to various clinical research organizations in connection with our clinical trialactivities. Payments are contingent upon the achievement of specific milestones or events as defined in the agreements, and we have madeappropriate accruals in our financial statements for those milestones that were achieved as of December 31, 2020. We also provideindemnifications of varying scope to our CROs and investigators against claims made by third parties arising from the use of our productsand processes in clinical trials. Historically, costs related to these indemnification provisions were immaterial. We also maintain variousliability insurance policies that limit our exposure. We are unable to estimate the maximum potential impact of these indemnificationprovisions on our future results of operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>          Legal Proceedings         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        A legal proceeding has been initiated by a formeremployee alleging wrongful termination, retaliation, infliction of emotional distress, negligent supervision, hiring and retention andslander. An independent investigation into this individual’s allegations, while still an employee, was conducted utilizing an outsideexpert and concluded that such allegations were without merit. We intend to vigorously defend the lawsuit; however, in light of our cashposition, there can be no assurance that the defense and/or settlement of this matter will not have a material adverse impact on ourbusiness.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <!-- Field: Page; Sequence: 54; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         54         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <!-- Field: Split-Segment; Name: a6 -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; font-size: 10pt">           <font style="font-size: 10pt">            <b>             6.            </b>           </font>          </td>          <td style="font-size: 10pt; text-align: justify">           <font style="font-size: 10pt">            <b>             Warrant Liability            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">        <i>         March 2020 Warrant Amendment        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        On March 3, 2020, we amended certain outstandingwarrants to purchase an aggregate of 385,078 shares of common stock, including the January 2020 Warrants and warrants we issued in connectionwith a financing in August 2019 (the “August 2019 Warrants”), to modify certain provisions that had required them to be previouslyclassified as liabilities and to enable them to now be classified as equity under the relevant accounting standards. As a result, wereclassified the fair value of the warrants on the date of the amendment from warrant liabilities to additional paid-in capital in thebalance sheet and recognized a non-cash loss on changes in the fair value of warrants in the statement of operations and comprehensiveloss.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The following table provides a roll forward ofthe fair value of our warrant liabilities, the fair value of which was determined by Level 3 inputs for the year ended December 31, 2020(in thousands):       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top; background-color: #CCEEFF">          <td style="width: 87%">           <font style="font-size: 10pt">            Fair value, December 31, 2019           </font>          </td>          <td style="width: 13%; padding-right: 5.3pt; text-align: right">           <font style="font-size: 10pt">            $	320           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-size: 10pt">            Issuance of the January 2020 Warrants           </font>          </td>          <td style="padding-right: 5.3pt; text-align: right">           <font style="font-size: 10pt">            1,654           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: #CCEEFF">          <td style="padding-top: 1.05pt">           <font style="font-size: 10pt">            Change in fair value            <sup>             (1)            </sup>           </font>          </td>          <td style="padding-top: 1.05pt; padding-right: 5.3pt; text-align: right">           <font style="font-size: 10pt">            923           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-size: 10pt">            Reclassification of warrants to additional paid-in capital           </font>          </td>          <td style="padding-right: 2.55pt; text-align: right">           <font style="font-size: 10pt">            <u>             (2,897            </u>            )           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: #CCEEFF">          <td>           <font style="font-size: 10pt">            Fair value, December 31, 2020           </font>          </td>          <td style="border-bottom: black 1pt double; padding-top: 0.7pt; padding-right: 5.3pt; text-align: right">           <font style="font-size: 10pt">            $	—           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin: 0; font-size: 10pt">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 87%">           (1) Recognized as non-cash loss on changes    in fair value of warrants in the statement of operations and comprehensive loss.          </td>          <td style="font-size: 10pt; width: 1%">          </td>          <td style="font-size: 10pt; text-align: left; width: 1%">          </td>          <td style="font-size: 10pt; text-align: right; width: 10%">          </td>          <td style="font-size: 10pt; text-align: left; width: 1%">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The warrant liability associatedwith the January 2020 Warrants was classified within Level 3 of the fair value hierarchy. The following table presents the weighted-averagekey assumptions used to calculate the fair value of the January 2020 Warrants:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">           As of          </td>          <td style="padding-bottom: 1pt; font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           March 3,    2020          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           January 7,    2020          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: left">           Expected volatility          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">           124          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">           121          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Risk-free interest rate          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           0.8          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1.6          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Dividend yield          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Expected term (in years)          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           4.9          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           5.0          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif">           Weighted-average fair value per share warrant          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           7.80          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           5.70          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.7pt 0pt 0; text-indent: 15.3pt">        The warrant liability associated withthe August 2019 Warrants was classified within Level 3 of the fair value hierarchy. The following table presents the weighted-averagekey assumptions used to calculate the fair value of the August 2019 Warrants:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">           As of          </td>          <td style="padding-bottom: 1pt; font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           March 3,    2020          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           December 31,    2019          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: left">           Expected volatility          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">           124          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">           125          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Risk-free interest rate          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           0.8          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1.7          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Dividend yield          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Expected term (in years)          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           4.5          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           4.6          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif">           Weighted-average fair value per share warrant          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           6.30          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           3.30          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         August 2019 Warrant Liability        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.5pt 0pt 0; text-align: justify; text-indent: 0.25in">        In August 2019,we completed a registered direct offering (the “August 2019 Offering”) and issued warrants to purchase 95,078 shares of ourcommon stock with an exercise price of $32.10 per share (the “Placement Warrants”) in a concurrent private placement (seeNote 6). The Placement Warrants agreement contained a provision where the warrant holder had the option to receive cash, equal to theBlack Scholes fair value of the remaining unexercised portion of the warrant, as cash settlement in the event that there is a fundamentaltransaction (contractually defined to include various merger, acquisition or stock transfer activities). As a result of this provision,in accordance with ASC 480, “Distinguishing Liabilities from Equity,” the Placement Warrants were required to be classifiedas liabilities at the time of issuance. The fair value of the Placement Warrants was determined using the Black-Scholes Option Pricingmodel to calculate the call option and a Binomial Option Pricing model to calculate the put option with changes in the fair value recordedin our statements of operations and comprehensive loss. As of December 31, 2019, total fair value of the Placement Warrants was approximately$0.3 million, which is included within warrant liabilities in our balance sheet.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 55; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         55         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">        The warrant liability associatedwith the Placement Warrants is classified within level 3 of the fair value hierarchy. The below table represents the weighted-averagekey assumptions used to calculate the fair value of the Placement Warrants:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="margin: 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">           As of          </td>          <td style="padding-bottom: 1pt; font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           August 7,    2019          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           December 31,    2019          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: left">           Expected volatility          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">           87          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">           125          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Risk-free interest rate          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1.5          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1.7          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Dividend yield          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Expected term (in years)          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           4.9          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           4.6          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif">           Weighted-average fair value per share warrant          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           15.00          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           3.30          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; font-size: 10pt">           <font style="font-size: 10pt">            <b>             7.            </b>           </font>          </td>          <td style="font-size: 10pt; text-align: justify">           <font style="font-size: 10pt">            <b>             Debt Agreements            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Horizon and Molteni Loan        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In July 2017, we enteredinto a venture loan and security agreement (the “Horizon Loan Agreement”) with Horizon Technology Finance Corporation (“Horizon”),which provided up to $10.0 million in loans, including an initial loan in the amount of $7.0 million funded upon signing of the HorizonLoan Agreement.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In connection with the HorizonLoan Agreement, we issued Horizon seven-year warrants to purchase common stock (the “Horizon Warrants”). The Horizon Warrantswere classified as equity and the fair value of the Horizon Warrants at the time of issuance was determined using a Lattice valuationmodel.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Our obligations under the LoanAgreement are secured by a first priority security interest in all of our assets, with the exception of our intellectual property. Weagreed not to pledge or otherwise encumber our intellectual property assets, subject to certain exceptions.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In February 2018, we enteredinto an amendment to the Original Loan Agreement (the “Amended Loan Agreement”) pursuant to which we prepaid $3.0 millionof the outstanding $7.0 million principal amount and provided Horizon with a lien on our intellectual property.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In March 2018, we enteredinto an Amended and Restated Venture Loan and Security Agreement (the “Restated Loan Agreement”) with Horizon and Moltenipursuant to which Horizon assigned approximately $2.4 million of the $4.0 million outstanding principal balance of the loan to Molteniand Molteni was appointed as the collateral agent and assumed majority and administrative control of the loan. Under the Restated LoanAgreement, Molteni had the right to convert its portion of the debt into shares of our common stock at a conversion price of $216.00per share and was required to effect this conversion of debt to equity if we complete an equity financing resulting in gross proceedsof at least $10.0 million at a price per share of common stock in excess of $216.00 and repay the $1.6 million balance of Horizon’sloan amount. In connection with the Restated Loan Agreement, we issued additional warrants to purchase an aggregate of 223 shares ofour common stock with an exercise price per share of $216.00 to Horizon (collectively, the “Horizon Warrants”). These warrantswere classified as equity and the key assumptions used to value these warrants as of the date of the issuance were as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; width: 87%">           Expected price volatility          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           86          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Expected term (in years)          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           7.0          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Risk-free interest rate          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           2.8          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Dividend yield          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           0.0          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif">           Weighted-average fair value per share warrant          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           145.80          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In consideration of Molteni’s entry intothe Horizon Loan Agreement and the Molteni Purchase Agreement (see Note 3), in March 2018, we entered into a rights agreement (the “RightsAgreement”) with Molteni pursuant to which we agreed to (i) issue Molteni seven-year warrants to purchase 3,000 shares of our commonstock at an exercise price of $216.00 per share (the “Molteni Warrants”), (ii) provide Molteni customary demand and piggy-backregistration rights with respect to the shares of common stock issuable upon conversion of its loan and exercise of the Molteni Warrants,(iii) designate one member of our board of directors following conversion of the loan in full and (iv) provide board observer rightsto Molteni if it has not designated a board nominee as well as certain information rights. The board designation, observer and informationrights will terminate at such time as Molteni ceases to beneficially own at least one percent of our outstanding capital stock (inclusiveof the shares issuable upon conversion of debt under the Restated Loan Agreement and exercise of the Molteni Warrants). The Molteni Warrantshave been classified as equity and their fair value at the time of issuance was determined using a Black Scholes valuation model. Theamount was allocated equally between the Restated Loan Agreement and the Purchase Agreement and was recorded in the Balance Sheets asa discount to the Molteni loan and a contract asset, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 56; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         56         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">        The key assumptions used to value the Molteni Warrantswere as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; width: 87%">           Expected price volatility          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           86          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Expected term (in years)          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           7.0          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Risk-free interest rate          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           2.8          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Dividend yield          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           0.0          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif">           Weighted-average fair value of warrants          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           145.80          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Repayment of the loans wason an interest-only basis, followed by monthly payments of principal and accrued interest for the balance of the 46-month term. The loansbear interest at a floating coupon rate of one-month LIBOR (floor of 1.10%) plus 8.40%. A final payment equal to 5.0% of each loan tranchewill be due on the scheduled maturity date for such loan. In addition, if we repay all or a portion of the loan prior to the applicablematurity date, we will pay Horizon and Molteni prepayment penalty fees.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.55pt 0pt 0; text-indent: 0.25in">        In connection with our equity offeringin September 2018, the Horizon Warrants to purchase 12,223 shares of our common stock at $45.00 per share became exercisable. In accordancewith the guidance in ASU 2017-11, we recognized the effect of triggering the down round feature as a dividend in our balance sheets atDecember 31, 2018 and as an addition to net loss attributable to common stockholders and in our calculation of basic and fully dilutedearnings per share in our statements of operations and comprehensive loss for the year ended December 31, 2018. We calculated the dividendof approximately $0.3 million resulting from the trigger of the down round provision in September 2018 using the Black Scholes OptionPricing Model and the assumptions indicated in the table below:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Pre-reset          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Post-reset          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; width: 74%">           Exercise price per share          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           352.80          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           45.00          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif">           Expected price volatility          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           71          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           71          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Expected term (in years)          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           5.8          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           5.8          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Risk-free interest rate          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           3.0          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           3.0          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Dividend yield          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           0.0          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           0.0          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif">           Weighted-average fair value of warrants          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           9.00          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           25.20          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In September 2019, weentered into an amendment to the Restated Loan Agreement pursuant to which the interest-only payment and forbearance periods were extendedby one year to December 31, 2020 and the maturity date was extended by one year to June 1, 2022. In connection with the amendmentto the Restated Loan Agreement (as clarified by a second amendment in March 2020), the final payments to the lenders were increasedby an aggregate of approximately $0.3 million (exclusive of a restructuring fee payable to Horizon) and the conversion provisions relatedto Molteni’s portion of the loan amount were revised to eliminate the mandatory conversion feature, to reduce the conversion priceto $6.75 and to cap the number of shares issuable upon conversion to 114,093.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In accordance with ASC 470, Debt, the amendmentto the loan from Molteni is accounted for under debt extinguishment accounting, which required us to extinguish the carrying amount ofthe loan prior to the amendment and reacquire the loan after the amendment. As a result, during the year ended December 31, 2019, werecorded approximately $0.3 million gain on debt extinguishment related to the write-off of the balance of the accreted final paymentof the loan. The modification to the loan from Horizon did not constitute debt extinguishment and, therefore, did not have any impactto our financial statements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In October 2020, we enteredinto the DSRA Agreement with Molteni and Horizon to settle our obligations for $1.6 million in cash, the transfer of certain Probuphineassets to Molteni, including all of our manufacturing equipment, and the termination of our rights to future payments under the PurchaseAgreement with Molteni. The DSRA Agreement, provided for the release to us of the remaining collateral. As a result, during the yearended December 31, 2020, we recorded an approximately $0.1 million loss on debt extinguishment.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Molteni Convertible Loan        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Due to the conversion provision of the MolteniConvertible Loan, ASC 815, Derivatives and Hedging required us to classify the conversion provision as an embedded derivative with changesin the fair value recorded in the statements of operations and comprehensive loss.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 57; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         57         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The key assumptions used tovalue the Convertible Loan embedded derivative were as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">           As of          </td>          <td style="padding-bottom: 1pt; font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           September 18,    2018          </td>          <td style="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           December 31,    2018          </td>          <td style="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 70%; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in">           Expected    volatility          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">           87          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">           135          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in">           Expected term (in    years)          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           0.75          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           0.50          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in">           Risk-free interest    rate          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           2.32          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           2.51          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in">           Dividend yield          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in">           Fair value of conversion    provision (in thousands)          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           159          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           25          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In connection with the amendment to theMolteni Purchase Agreement (see Note 3), in June 2019, the Molteni Convertible Loan, together with unpaid accrued interest, was convertedin full into 14,943 shares of our common stock at $45.00 per share upon the receipt of EMA approval of Sixmo. As a result, we recordedapproximately $0.1 million loss on debt extinguishment.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Paycheck Protection Program Loan        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        On April 20, 2020, we received an approximately$654,000 loan (“PPP Loan”) pursuant to the Paycheck Protection Program of the CARES Act. The PPP Loan matures in April 2022with an annual interest rate of 1.0%. The PPP Loan originally had a six month deferral of payments period which was extended to sixteenmonths during the third quarter of 2020 and may be prepaid at any time without penalty. All other terms remained the same. Forgivenessof the loan, when requested, is not automatic and is only available for principal that is used for the limited purposes that expresslyqualify for forgiveness under SBA requirements. The proceeds of the PPP Loan are to be used to retain workers and maintain payroll andmake mortgage interest, lease and utility payments. A loan forgiveness application was submitted in December 2020. Approximately $0.3million of the PPP loan is included in current portion of long-term debt and approximately $0.3 million is included in long- term debton our balance sheet at December 31, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; font-size: 10pt">           <font style="font-size: 10pt">            <b>             8.            </b>           </font>          </td>          <td style="font-size: 10pt; text-align: justify">           <font style="font-size: 10pt">            <b>             Stockholders’ Equity            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <b>         <i>          Common Stock         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         October 2020 Public Offering        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In October 2020, we completedthe 2020 Public Offering pursuant to which we sold 2,666,667 units at a price of $3.00 per unit, with each unit consisting of (i) oneshare of common stock and (ii) one warrant (the “October 2020 Warrants”) to purchase one share of common stock,resulting in gross proceeds of approximately $8.0 million. The net proceeds of the 2020 Public Offering, after deduction of underwritingdiscounts and commissions and other offering expenses and the $1.6 million payment pursuant to the DSRA Agreement, were approximately$5.7 million. The October 2020 Warrants have an exercise price of $3.00, were exercisable on December 1, 2020 following thereverse split of our common stock, and will expire on the fifth anniversary of the initial exercise date.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         September 2020 Offering        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in">        In September 2020, wecompleted a registered direct offering with several institutional investors pursuant to which we issued 648,000 shares of our commonstock at a price of $4.20 per share. We received net cash proceeds of approximately $2.4 million, after deduction of underwriting feesand other offering expenses.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         January 2020 Offering        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.95pt 0pt 0; text-indent: 15.3pt">        In January 2020, we completed a financingwith several institutional investors pursuant to which we issued 290,000 shares of our common stock in a registered direct offering andwarrants to purchase 290,000 shares of our common stock with an exercise price of $7.50 per share in a concurrent private placement (the “January 2020 Warrants”) pursuant to which we received net cash proceeds of approximately $1.9 million, after deduction ofunderwriting fees and other offering expenses. The January 2020 Warrants became exercisable in September 2020 following receipt of stockholderapproval of an increase in our authorized shares of common stock and they expire in July 2025. Financing costs of approximately $0.2million allocated to the January 2020 warrant liability were expensed and included in other income (expense) in the statements of operationsand comprehensive loss.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         October 2019 Public Offering        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In October 2019, we completedan underwritten public offering pursuant to which we issued 1,342,534 units at an offering price of $6.75 per unit, consisting of 1,196,200shares of our common stock and pre-funded warrants to purchase 146,334 shares of our common stock with an exercise price of $0.30 pershare, and class B warrants to purchase 1,342,534 shares of our common stock at $6.75 per share (the “Class B Warrants”).The pre-funded warrants, which were exercised for common stock in October 2019, were issued in lieu of common stock in order toensure the investor did not exceed certain beneficial ownership limitations. The Class B Warrants are immediately exercisable andwill expire in October 2024. The Class B Warrant agreement contains a provision where the warrant holder has the option toreceive cash equal to the Black Scholes fair value of the remaining unexercised portion of the Class B Warrant only in the eventthat there is a fundamental transaction approved by the Board (contractually defined to include various merger, acquisition or stocktransfer activities). The Class B Warrants issued in connection with the October 2019 public offering were classified as equity.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 58; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         58         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         August 2019 Offering        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In August 2019, we completed an offering witha single accredited institutional investor pursuant to which we issued 49,334 shares of our common stock and pre-funded warrants to purchase45,744 shares of our common stock with an exercise price of $0.30 per share in a registered direct offering and the Placement Warrantsto purchase 95,078 shares of our common stock with an exercise price of $32.10 per share in a concurrent private placement. The pre-fundedwarrants, which were exercised for common stock in September 2019, were issued in lieu of common stock in order to ensure the investordid not exceed certain beneficial ownership limitations. The Placement Warrants became exercisable in February 2020 and will expire inFebruary 2025. At the time of issuance, the Placement Warrants contained a provision where the warrant holder has the option to receivecash, equal to the Black Scholes fair value of the remaining unexercised portion of the warrant, as cash settlement in the event thatthere is a fundamental transaction (contractually defined to include various merger, acquisition or stock transfer activities). The PlacementWarrants were classified as a liability in the balance sheet at December 31, 2019. In March 2020, we amended the warrants to modify theprovisions that had required them to be previously classified as liabilities and enabled them to be classified as equity under the relevantaccounting standards (see Note 6).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         At-the-Market Offering (the “ATM”)        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In April 2019, we implementedthe ATM for the sale of up to $8.6 million of our common stock. During the year ended December 31, 2019, we issued a total of 10,989shares of our common stock at a weighted-average price of $48.00 per share for total net proceeds of approximately $0.5 million underthe ATM. In August 2019 and January 2020, we reduced the dollar amount that can be sold under ATM to $4.0 million and $0.8million, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         Common Stock Warrants        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        During the year ended December 31,2020, we received an aggregate of approximately $7.2 million in cash proceeds from the exercises of warrants to purchase 1,112,313 sharesof our common stock.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        During the year ended December 31,2020, we issued 450,761 shares of our common stock upon the cashless exercise of 1,022,408 warrants.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        As of December 31, 2020,the following warrants to purchase shares of our common stock were outstanding (in thousands, except per share price):       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Date Issued          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Expiration Date          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Exercise Price          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Outstanding          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; width: 24%; text-align: center">           07/27/2017          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 23%; text-align: center">           07/27/2024          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 23%; font: 10pt Times New Roman, Times, Serif; text-align: right">           45.00          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 23%; font: 10pt Times New Roman, Times, Serif; text-align: right">           12          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">           03/21/2018          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">           03/21/2025          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           216.00          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">           03/21/2018          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">           03/21/2025          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           216.00          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           3          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">           09/25/2018          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">           09/25/2023          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           18.00          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           154          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">           09/25/2018          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">           09/25/2023          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           50.40          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           8          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">           08/09/2019          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">           02/09/2025          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           32.10          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           95          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">           10/18/2019          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">           10/18/2024          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           3.00          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           230          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">           01/09/2020          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">           07/09/2025          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           7.50          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           290          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">           10/30/2020          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">           12/01/2025          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           3.00          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           1,644          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: center; font-size: 10pt">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="text-align: center; font-size: 10pt">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           2,437          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <i>         Shares Reserved for FutureIssuance        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        As of December 31, 2020,shares of common stock reserved by us for future issuance consisted of the following (in thousands):       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; width: 87%; text-align: left">           Stock options outstanding          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           28          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif">           Shares issuable upon the exercise of warrants          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           2,437          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           2,465          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 59; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         59         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; font-size: 10pt">           <font style="font-size: 10pt">            <b>             9.            </b>           </font>          </td>          <td style="font-size: 10pt; text-align: justify">           <font style="font-size: 10pt">            <b>             Stock Plans            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font-size: 10pt; margin-top: 0; margin-bottom: 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         InAugust 2015, our stockholders approved the 2015 Omnibus Equity Incentive Plan (the “2015 Plan”). The 2015 Plan, as subsequentlyamended, authorized a total of 55,556 shares of our common stock for issuance to employees, directors, officers, consultants and advisors.As of December 31, 2020, options to purchase 30,786 shares of our common stock were available for grant and 24,770 shares of ourcommon stock outstanding under the 2015 Plan. I        </font>        n January 2021, our stockholders approved an amendment to the 2015 Plan toincrease the number of authorized shares to 1,000,000 shares.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In February 2014, ourBoard adopted the 2014 Incentive Plan (the “2014 Plan”), pursuant to which 2,526 shares of our common stock were authorizedfor issuance to employees, directors, officers, consultants and advisors. The 2014 Plan was terminated upon the approval of the 2015Plan. As of December 31, 2020, options to purchase 1,285 shares of our common stock were outstanding under the 2014 Plan.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In July 2002, we adoptedthe 2002 Stock Incentive Plan (the “2002 Plan”). The 2002 Plan, as amended in 2005, authorized a total of approximately 7,234shares of our common stock for issuance to employees, officers, directors, consultants, and advisers. The exercise prices of optionsgranted under the 2002 Plan were 100% of the fair market value of our common stock on the date of grant. The 2002 Plan expired by itsterms in July 2012. As of December 31, 2020, options to purchase an aggregate of 1,426 shares of our common stock were outstandingunder the 2002 Plan.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In August 2001, we adoptedthe 2001 Employee Non-Qualified Stock Option Plan (the “2001 NQ Plan”) pursuant to which 1,768 shares of common stock wereauthorized for issuance for option grants to employees and consultants who are not officers or directors of Titan. The exercise pricesof options granted under the 2001 NQ Plan were 100% of the fair market value of our common stock on the date of grant. The 2001 StockOption Plan expired by its terms in August 2011. As of December 31, 2020, options to purchase an aggregate of 412 shares ofour common stock were outstanding under the 2001 NQ Plan.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In January 2019, our stockholders approved arepricing of 4,071 fully-vested stock options with exercise prices in excess of $630.00 held by employees and consultants other thanthe named executive officers or members of the Board. The effected options were repriced at $46.50. As a result of the repricing of thesestock options, we incurred a total of approximately $81,000 of additional stock-based compensation expense during the year ended December31, 2019, of which approximately $54,000 was recorded within research and development and approximately $27,000 within selling, generaland administrative in our statement of operations and comprehensive loss.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The following table summarizesoption activity for the year ended December 31, 2020:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center">            <b>             Shares            </b>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center">            <b>             (in thousands)            </b>           </p>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Weighted             <br/>             Average             <br/>             Exercise             <br/>             Price per Share            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Weighted             <br/>             Average             <br/>             Remaining             <br/>             Contractual             <br/>             Term (years)            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center">            <b>             Aggregate             <br/>             Intrinsic             <br/>             Value            </b>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center">            <b>             (in thousands)            </b>           </p>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="width: 48%; padding-left: 12pt; text-indent: -12pt">           <font style="font-size: 10pt">            Outstanding at January 1, 2020           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 10%; text-align: right">           <font style="font-size: 10pt">            40           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="width: 10%; text-align: right">           <font style="font-size: 10pt">            187.09           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 10%; text-align: right">           <font style="font-size: 10pt">            7.85           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="width: 10%; text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td style="width: 1%">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 12pt; text-indent: -0.55pt">           <font style="font-size: 10pt">            Granted           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            2           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            7.95           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 1pt; padding-left: 12pt; text-indent: -0.55pt">           <font style="font-size: 10pt">            Cancelled/expired           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            (14           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 10pt">            )           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            49.76           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-bottom: 2.5pt; padding-left: 12pt; text-indent: -12pt">           <font style="font-size: 10pt">            Outstanding at December 31,    2020           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-size: 10pt">            28           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-size: 10pt">            242.70           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-size: 10pt">            6.35           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 2.5pt; padding-left: 12pt; text-indent: -12pt">           <font style="font-size: 10pt">            Exercisable at December 31,    2020           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-size: 10pt">            27           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-size: 10pt">            247.27           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-size: 10pt">            6.29           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in">        We use the Black-Scholes-Mertonoption-pricing model with the following assumptions to estimate the stock-based compensation expense:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">           Years Ended December 31,          </td>          <td style="padding-bottom: 1pt; font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           2020          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           2019          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; width: 74%; text-align: left">           Weighted-average risk-free interest rate          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           0.4          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           2.21          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Expected dividend payments          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif">           Expected holding period (years)(1)          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           5.79          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           5.41          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Weighted-average volatility factor(2)          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1.04          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           0.94          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Estimated forfeiture rates for options granted          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           27          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           21          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (1)           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Expected holding period is    based on historical experience of similar awards, giving consideration to the contractual terms of the stock-based awards, vesting    schedules and the expectations of future employee behavior.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (2)           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Weighted average volatility    is based on the historical volatility of our common stock.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 60; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         60         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (3)           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Estimated forfeiture rates    are based on historical data.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Based upon the above methodology, the weighted-averagefair value of options and awards granted during the years ended December 31, 2020 and 2019 was $6.30 and $49.20, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The following table summarizesthe stock-based compensation expense (in thousands):       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">           Years Ended December 31,          </td>          <td style="padding-bottom: 1pt; font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           2020          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           2019          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; width: 74%; text-align: left">           Research and development          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           91          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           General and administrative          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           7          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           481          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Total stock-based compensation expenses          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           7          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           572          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        As of December 31, 2020,there was approximately $5,500 of total unrecognized compensation expense related to non-vested stock options. This expense is expectedto be recognized over a weighted-average period of 1.4 years.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; font-size: 10pt">           <font style="font-size: 10pt">            <b>             10.            </b>           </font>          </td>          <td style="font-size: 10pt; text-align: justify">           <font style="font-size: 10pt">            <b>             Income Taxes            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        As of December 31, 2020, we had federal net operatingloss carryforwards of approximately $227.0 million that expire at various dates through 2037 and approximately $41.8 million which donot expire but are subject to 80% taxable income limitations. As of December 31, 2020, we had federal research and development tax creditsof approximately $8.0 million that expire at various dates through 2040. We also had net operating loss carryforwards for Californiaincome tax purposes of approximately $109.7 million that expire at various dates through 2040 and state research and development taxcredits of approximately $9.2 million which do not expire.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Current federal and Californiatax laws include substantial restrictions on the utilization of net operating losses and tax credits in the event of an ownership changeof a corporation under Internal Revenue Code Section 382 and 383.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Deferred income taxes reflectthe net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposesand the amounts used for income tax purposes and operating loss and credit carryforwards. Significant components of our deferred taxassets are as follows (in thousands):       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             As of December 31,            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             2020            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             2019            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 12pt; text-indent: -12pt">           <font style="font-size: 10pt">            Deferred tax assets:           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="width: 74%; padding-left: 0.25in">           <font style="font-size: 10pt">            Net operating loss carryforwards           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="width: 10%; text-align: right">           <font style="font-size: 10pt">            64,120           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="width: 10%; text-align: right">           <font style="font-size: 10pt">            63,910           </font>          </td>          <td style="width: 1%">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 0.25in">           <font style="font-size: 10pt">            Research credit carryforwards           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            15,228           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            15,683           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-bottom: 1pt; padding-left: 0.25in">           <font style="font-size: 10pt">            Other, net           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            1,005           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            1,303           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 12pt; text-indent: -12pt">           <font style="font-size: 10pt">            Total deferred tax assets           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            80,353           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            80,896           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 12pt; text-indent: -12pt">           <font style="font-size: 10pt">            Deferred tax liabilities:           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 1pt; padding-left: 0.25in">           <font style="font-size: 10pt">            Other, net           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            (31           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 10pt">            )           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            (84           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 12pt; text-indent: -12pt">           <font style="font-size: 10pt">            Total deferred tax liabilities           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            (31           </font>          </td>          <td>           <font style="font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            (84           </font>          </td>          <td>           <font style="font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 1pt; padding-left: 12pt; text-indent: -12pt">           <font style="font-size: 10pt">            Valuation allowance           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            (80,322           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 10pt">            )           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            (80,812           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-bottom: 2.5pt; padding-left: 12pt; text-indent: -12pt">           <font style="font-size: 10pt">            Net deferred tax assets           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        ASC 740 requires that the taxbenefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that managementassesses that realization is "more likely than not." Realization of the future tax benefits is dependent on our ability togenerate sufficient taxable income within the carryforward period. Because of our recent history of operating losses, our managementbelieves that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely tobe realized and, accordingly, has provided a valuation allowance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Realization of deferred tax assets is dependentupon future earnings, if any, the timing and amount of which are uncertain. Accordingly, the net deferred tax assets have been fullyoffset by a valuation allowance. The valuation allowance decreased by approximately $0.5 million during 2020 and increased by approximately$0.7 million during 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 61; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         61         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">        The provision for income taxes consists of state minimumtaxes due. The effective tax rate of our provision (benefit) for income taxes differs from the federal statutory rate as follows (inthousands):       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: center">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Years Ended December    31,            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: center">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             2020            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             2019            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="width: 72%">           <font style="font-size: 10pt">            Computed at 21%           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="width: 11%; text-align: right">           <font style="font-size: 10pt">            (3,830           </font>          </td>          <td style="width: 1%">           <font style="font-size: 10pt">            )           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="width: 11%; text-align: right">           <font style="font-size: 10pt">            (3,451           </font>          </td>          <td style="width: 1%">           <font style="font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-size: 10pt">            State taxes           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            (220           </font>          </td>          <td>           <font style="font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            (146           </font>          </td>          <td>           <font style="font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-size: 10pt">            Change in valuation allowance           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            (491           </font>          </td>          <td>           <font style="font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            768           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-size: 10pt">            Other           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            26           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            56           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-size: 10pt">            Revaluation of warrant liability           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            194           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            (238           </font>          </td>          <td>           <font style="font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-size: 10pt">            Research and development credits           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            (65           </font>          </td>          <td>           <font style="font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            (54           </font>          </td>          <td>           <font style="font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-size: 10pt">            Tax attributes expirations           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            4,352           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            2,698           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-bottom: 1pt">           <font style="font-size: 10pt">            Impact of IRC 162m           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            34           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            367           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 2.5pt">           <font style="font-size: 10pt">            Total           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in">        We had no unrecognized taxbenefits or any amounts accrued for interest and penalties for the three years ended December 31, 2020. Our policy is to recognizeinterest and penalties related to income taxes as a component of income tax expense. We do not expect the amount of unrecognized taxbenefits will materially change in the next twelve months.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        We file tax returns in theU.S. federal jurisdiction and various state jurisdictions. We are subject to the U.S. federal and state income tax examination by taxauthorities for such years 2001 through 2020, due to net operating losses that are being carried forward for tax purposes.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; font-size: 10pt">           <font style="font-size: 10pt">            <b>             11.            </b>           </font>          </td>          <td style="font-size: 10pt; text-align: justify">           <font style="font-size: 10pt">            <b>             Discontinued Operations            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The components of loss from discontinued operationsas reported in our statements of operations were as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Years ended December 31,            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             2020            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             2019            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center">          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td colspan="6" style="text-align: center">           <font style="font-size: 10pt">            <b>             (In thousands, except per share data)            </b>           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-size: 10pt">            Revenue:           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="width: 72%; padding-left: 27pt; text-indent: -12pt">           <font style="font-size: 10pt">            Product revenue           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="width: 11%; text-align: right">           <font style="font-size: 10pt">            376           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="width: 11%; text-align: right">           <font style="font-size: 10pt">            1,006           </font>          </td>          <td style="width: 1%">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 45pt; text-indent: -12pt">          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 12pt; text-indent: -12pt">           <font style="font-size: 10pt">            Costs and expenses:           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 27pt; text-indent: -12pt">           <font style="font-size: 10pt">            Cost of goods sold           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            1,332           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            1,288           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 27pt; text-indent: -12pt">           <font style="font-size: 10pt">            Research and development           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            1,917           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            2,162           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 1pt; padding-left: 27pt; text-indent: -12pt">           <font style="font-size: 10pt">            Selling, general and administrative           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            7,224           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            6,524           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-bottom: 1pt; padding-left: 45pt; text-indent: -12pt">           <font style="font-size: 10pt">            Total costs and expenses           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            10,473           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            9,974           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 12pt; text-indent: -12pt">           <font style="font-size: 10pt">            Loss from discontinued operations           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            (10,097           </font>          </td>          <td>           <font style="font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            (8,968           </font>          </td>          <td>           <font style="font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-bottom: 1pt; padding-left: 12pt; text-indent: -12pt">           <font style="font-size: 10pt">            Other expense, net           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            738           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            —           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 2.5pt; padding-left: 12pt; text-indent: -12pt">           <font style="font-size: 10pt">            Net loss from discontinued    operations           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-size: 10pt">            10,835           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-size: 10pt">            (8,968           </font>          </td>          <td style="padding-bottom: 2.5pt">           <font style="font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-bottom: 2.5pt; padding-left: 12pt; text-indent: -12pt">           <font style="font-size: 10pt">            Basic and diluted net loss    per common share from discontinued operations           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-size: 10pt">            (2.87           </font>          </td>          <td style="padding-bottom: 2.5pt">           <font style="font-size: 10pt">            )           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-size: 10pt">            (11.71           </font>          </td>          <td style="padding-bottom: 2.5pt">           <font style="font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 2.5pt; padding-left: 12pt; text-indent: -12pt">           <font style="font-size: 10pt">            Weighted average shares used    in computing basic and diluted net loss per common share           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-size: 10pt">            3,773           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-size: 10pt">            766           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        The following table presents information relatedto assets and liabilities reported as discontinued operations in our balance sheet:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="6" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           December 31,          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="padding-bottom: 1pt; font-size: 10pt">          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">           2020          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">           2019          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="font-size: 1pt; vertical-align: bottom">          <td style="padding-bottom: 1pt; font-size: 1pt">          </td>          <td style="padding-bottom: 1pt; font-size: 1pt; font-weight: bold">          </td>          <td colspan="2" style="font-size: 1pt; font-weight: bold; text-align: center">          </td>          <td style="padding-bottom: 1pt; font-size: 1pt; font-weight: bold">          </td>          <td style="padding-bottom: 1pt; font-size: 1pt; font-weight: bold">          </td>          <td colspan="2" style="font-size: 1pt; font-weight: bold; text-align: center">          </td>          <td style="padding-bottom: 1pt; font-size: 1pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold">          </td>          <td colspan="6" style="font-size: 10pt; font-weight: bold; text-align: center">           (In thousands)          </td>          <td style="font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 72%; font-size: 10pt; text-indent: -12pt; padding-left: 27pt">           Receivables          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 11%; font-size: 10pt; text-align: right">           —          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 11%; font-size: 10pt; text-align: right">           555          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-indent: -12pt; padding-left: 27pt">           Inventory          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           —          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           435          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -12pt; padding-left: 27pt">           Prepaid expenses and other    current assets          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           181          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           560          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; text-indent: -12pt; padding-left: 45pt">           Discontinued operations    – current assets          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           181          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           1,550          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-indent: -12pt; padding-left: 27pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; text-indent: -12pt; padding-left: 27pt">           Accounts payable          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">           $          </td>          <td style="font-size: 10pt; text-align: right">           1,515          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">           $          </td>          <td style="font-size: 10pt; text-align: right">           585          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; text-indent: -12pt; padding-left: 27pt">           Accrued clinical trials expenses          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           80          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           140          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; text-indent: -12pt; padding-left: 27pt">           Accrued sales allowances          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           61          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           809          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -12pt; padding-left: 27pt">           Other accrued liabilities          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           304          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           546          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; text-indent: -12pt; padding-left: 45pt">           Discontinued operations    – current liabilities          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           1,960          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           2,080          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        During both years ended December 31, 2020 and2019 we recognized non-cash stock-based compensation expenses of approximately $0.1 million which is included in discontinued operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-size: 10pt">            <b>             12.            </b>           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            <b>             Subsequent Events            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Annual Meeting of Stockholders        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        In January 2021, our stockholdersapproved an amendment to the 2015 Omnibus Equity Incentive plan to increase the number of authorized shares to 1,000,000 shares.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         January 2021 Offering        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         InJanuary 2021, we completed an offering with several accredited institutional investors pursuant to which we issued 2,725,000 sharesof our common stock in a registered direct offering and warrants        </font>        to purchase 2,725,000 shares of our common stock with an exerciseprice of $3.55 per share in a concurrent private placement. The warrants were exercisable immediately and will expire in July 2026.The net cash proceeds from this offering were approximately $8.9 million after deduction of underwriting fees and other offering expenses.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 62; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         62         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <!-- Field: Split-Segment; Name: a7 -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         (b)   Exhibits        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="border-bottom: black 1pt solid; text-align: center; width: 8%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             No.            </b>           </font>          </td>          <td style="width: 1%">          </td>          <td style="border-bottom: black 1pt solid; text-align: left; width: 91%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Description            </b>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000110465920120526/tm2034714d1_ex1-1.htm">             1.1            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000110465920120526/tm2034714d1_ex1-1.htm">             Underwriting    Agreement dated October 28, 2020 between Titan Pharmaceuticals, Inc. and Maxim Group LLC             <sup>              (26)             </sup>            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000119312510006562/dex31.htm">             3.1.1            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000119312510006562/dex31.htm">             Amended    and Restated Certificate of Incorporation of the Registrant, as amended             <sup>              (4)             </sup>            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420415056647/v421014_ex3-1.htm">             3.1.2            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420415056647/v421014_ex3-1.htm">             Certificate    of Amendment to the Restated Certificate of Incorporation dated September 24, 2015             <sup>              (6)             </sup>            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420419002680/tv511477_ex3-1.htm">             3.1.3            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420419002680/tv511477_ex3-1.htm">             Certificate    of Amendment to the Restated Certificate of Incorporation dated January 23, 2019             <sup>              (16)             </sup>            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420419002680/tv511477_ex3-1.htm">             3.1.4            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420419002680/tv511477_ex3-1.htm">             Certificate    of Amendment to the Restated Certificate of Incorporation dated September 24, 2020             <sup>              (16)             </sup>            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420417054170/tv477697_ex3-3.htm">             3.2            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420417054170/tv477697_ex3-3.htm">             By-laws    of the Registrant             <sup>              (1)             </sup>            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420417038785/v471646_ex4-4.htm">             4.1            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420417038785/v471646_ex4-4.htm">             Form of    Lender Warrant             <sup>              (8)             </sup>            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420418016884/tv489507_ex10-3.htm">             4.2            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420418016884/tv489507_ex10-3.htm">             Form of    Rights Agreement Warrant             <sup>              (10)             </sup>            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420418050743/tv503422_ex4-1.htm">             4.3            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420418050743/tv503422_ex4-1.htm">             Warrant    Agency Agreement between Titan Pharmaceuticals, Inc. and Continental Stock Transfer &amp; Trust Company and Form of    Offering Warrant             <sup>              (15)             </sup>            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420418050743/tv503422_ex4-2.htm">             4.4            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420418050743/tv503422_ex4-2.htm">             Representative’s    Purchase Warrant             <sup>              (15)             </sup>            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420419038636/tv527052_ex4-2.htm">             4.5            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420419038636/tv527052_ex4-2.htm">             Form of    August 2019 Private Placement Warrant             <sup>              (17)             </sup>            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000110465919054978/tm1920490d1_ex4-1.htm">             4.6            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000110465919054978/tm1920490d1_ex4-1.htm">             Class B    Warrant Agency Agreement dated October 16, 2019 between Titan Pharmaceuticals, Inc. and Maxim Group LLC Form of January 2020    Private Placement Warrant             <sup>              (18)             </sup>            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000110465920002040/tm201430-1_ex41.htm">             4.7            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000110465920002040/tm201430-1_ex41.htm">             Form of    January 2020 Private Placement Warrant             <sup>              (19)             </sup>            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000110465920040354/tm205305-1_ex412.htm">             4.8            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000110465920040354/tm205305-1_ex412.htm">             Form of    March 3, 2020 Warrant Amendment Agreement             <sup>              (23)             </sup>            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000110465920040354/tm205305-1_ex413.htm">             4.9            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000110465920040354/tm205305-1_ex413.htm">             Description    of the Registrant’s Common Stock             <sup>              (22)             </sup>            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000110465920118552/tm2033419d5_ex4-10.htm">             4.10            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000110465920118552/tm2033419d5_ex4-10.htm">             Warrant    Agency Agreement between Titan Pharmaceuticals, Inc. and Continental Stock Transfer &amp; Trust Company and Form of    Warrant             <sup>              (25)             </sup>            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000110465920118552/tm2033419d5_ex4-11.htm">             4.11            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000110465920118552/tm2033419d5_ex4-11.htm">             Form of    Lock-Up and Voting Agreement             <sup>              (25)             </sup>            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000110465921004940/tm213361d1_ex4-1.htm">             4.12            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000110465921004940/tm213361d1_ex4-1.htm">             Form of    January 2021 Private Placement Warrant             <sup>              (28)             </sup>            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000110465921008223/tm214304d1_ex5-1.htm">             5.1            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000110465921008223/tm214304d1_ex5-1.htm">             Opinion    of Loeb &amp; Loeb LLP*            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000091205702012701/a2074337zex-10_35.htm">             10.1            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000091205702012701/a2074337zex-10_35.htm">             2001    Non-Qualified Employee Stock Option Plan             <sup>              (2)             </sup>            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000104746903011223/a2106594zex-10_37.htm">             10.2            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000104746903011223/a2106594zex-10_37.htm">             2002    Stock Option Plan             <sup>              (3)             </sup>            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420414019329/v371702_ex10-30.htm">             10.3            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420414019329/v371702_ex10-30.htm">             Titan    Pharmaceuticals, Inc. 2014 Incentive Plan             <sup>              (5)             </sup>            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420419002680/tv511477_ex10-1.htm">             10.4            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420419002680/tv511477_ex10-1.htm">             Titan    Pharmaceuticals, Inc. Third Amended and Restated 2015 Omnibus Equity Incentive Plan             <sup>              (16)             </sup>            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420419018020/tv517982_ex10-1.htm">             10.5            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420419018020/tv517982_ex10-1.htm">             Employment    Agreement between Titan Pharmaceuticals, Inc. and Sunil Bhonsle             <sup>              (7)             </sup>            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420419018020/tv517982_ex10-2.htm">             10.6            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420419018020/tv517982_ex10-2.htm">             Employment    Agreement between Titan Pharmaceuticals, Inc. and Marc Rubin             <sup>              (7)             </sup>            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420417038785/v471646_ex10-23.htm">             10.7            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420417038785/v471646_ex10-23.htm">             Venture    Loan and Security Agreement, dated July 27, 2017, by and between Titan Pharmaceuticals, Inc. and Horizon Technology Finance    Corporation             <sup>              (8)             </sup>            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420418006087/tv484840_ex10-1.htm">             10.8            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420418006087/tv484840_ex10-1.htm">             Amendment    of Venture Loan and Security Agreement, dated February 2, 2018, by and between Titan Pharmaceuticals, Inc. and Horizon    Technology Finance Corporation             <sup>              (9)             </sup>            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420418016884/tv489507_ex10-1.htm">             10.9            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420418016884/tv489507_ex10-1.htm">             Amended    and Restated Venture Loan and Security Agreement, dated March 21, 2018, by and between Titan Pharmaceuticals, Inc., Horizon    Technology Finance Corporation and L. Molteni &amp; C. Dei Frattelli Alitti Società Di Esercizio S.P.A.             <sup>              (10)             </sup>            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420418016884/tv489507_ex10-2.htm">             10.10    ±            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420418016884/tv489507_ex10-2.htm">             Asset    Purchase, Supply and Support Agreement dated March 21, 2018, by and between Titan Pharmaceuticals, Inc. and L. Molteni &amp;    C. Dei Frattelli Alitti Società Di Esercizio S.P.A.             <sup>              (10)             </sup>            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420418016884/tv489507_ex10-3.htm">             10.11            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420418016884/tv489507_ex10-3.htm">             Rights    Agreement dated March 21, 2018, by and between Titan Pharmaceuticals, Inc. and L. Molteni &amp; C. Dei Frattelli Alitti    Società Di Esercizio S.P.A.             <sup>              (10)             </sup>            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420418031721/tv495422_ex10-1.htm">             10.12    ±            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420418031721/tv495422_ex10-1.htm">             Termination    and Transition Services Agreement dated May 25, 2018 by and between Titan Pharmaceuticals, Inc. and Braeburn Pharmaceuticals, Inc.             <sup>              (11)             </sup>            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420418041882/tv500139_ex10-1.htm">             10.13    ±            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420418041882/tv500139_ex10-1.htm">             Amendment    to Asset Purchase, Supply and Support Agreement dated August 3, 2018, by and between Titan Pharmaceuticals, Inc. and L.    Molteni &amp; C. Dei Frattelli Alitti Società Di Esercizio S.P.A             <sup>              (12)             </sup>            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420418044671/tv499850_ex10-22.htm">             10.14    ±            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420418044671/tv499850_ex10-22.htm">             Distribution    and Sublicense Agreement dated February 1, 2016 as amended by agreement dated August 2, 2018 between Titan Pharmaceuticals, Inc.    and Knight Therapeutics Inc.             <sup>              (13)             </sup>            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420418044671/tv499850_ex10-23.htm">             10.15            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420418044671/tv499850_ex10-23.htm">             Amendment    to lease for Registrant’s facility dated March 21, 2016             <sup>              (13)             </sup>            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420418050015/tv503177_ex10-1.htm">             10.16            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420418050015/tv503177_ex10-1.htm">             Unsecured    Convertible Loan Agreement dated September 18, 2018             <sup>              (14)             </sup>            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420419017459/tv516475_ex10-27.htm">             10.17            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420419017459/tv516475_ex10-27.htm">             Employment    Agreement between the Registrant and Katherine Beebe DeVarney             <sup>              (20)             </sup>            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420419017459/tv516475_ex10-28.htm">             10.18            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420419017459/tv516475_ex10-28.htm">             Employment    Agreement between the Registrant and Dane Hallberg             <sup>              (20)             </sup>            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420419038636/tv527052_ex10-1.htm">             10.19            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420419038636/tv527052_ex10-1.htm">             Securities    Purchase Agreement, dated August 7, 2019, by and between Titan Pharmaceuticals, Inc. and the investors named therein             <sup>              (17)             </sup>            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000110465920002040/tm201430-1_ex101.htm">             10.20            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000110465920002040/tm201430-1_ex101.htm">             Securities    Purchase Agreement, dated January 7, 2020, by and between Titan Pharmaceuticals, Inc. and the investors named therein             <sup>              (19)             </sup>            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420419038636/tv527052_ex10-2.htm">             10.21            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420419038636/tv527052_ex10-2.htm">             Placement    Agency Agreement, dated August 7, 2019, by and between Titan Pharmaceuticals, Inc. and Maxim Group LLC             <sup>              (17)             </sup>            </a>           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin: 0">       </p>       <p style="margin: 0">       </p>       <!-- Field: Page; Sequence: 63; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         63         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="margin: 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000110465920002040/tm201430-1_ex102.htm">             10.22            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000110465920002040/tm201430-1_ex102.htm">             Placement    Agency Agreement, dated January 7, 2020, by and between Titan Pharmaceuticals, Inc. and Maxim Group LLC             <sup>              (19)             </sup>            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420419044334/tv529168_ex10-33.htm">             10.23            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420419044334/tv529168_ex10-33.htm">             Amendment    dated September 10, 2019 to Amended and Restated Venture Loan and Security Agreement, dated March 21, 2018, by and between    Titan Pharmaceuticals, Inc., Horizon Technology Finance Corporation and L. Molteni &amp; C. Dei Frattelli Alitti Società    Di Esercizio S.P.A.             <sup>              (21)             </sup>            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420419044334/tv529168_ex10-34.htm">             10.24    ±            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000114420419044334/tv529168_ex10-34.htm">             Amendment    No. 2 dated September 10, 2019 to Asset Purchase, Supply and Support Agreement by and between Titan Pharmaceuticals, Inc.    and L. Molteni &amp; C. Dei Frattelli Alitti Società Di Esercizio S.P.A.(21)            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000110465920040354/tm205305-1_ex1033.htm">             10.25            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000110465920040354/tm205305-1_ex1033.htm">             Amendment    No. 2 dated March 12, 2020 to Amended and Restated Venture Loan and Security Agreement, dated March 21, 2018, by and    between Titan Pharmaceuticals, Inc., Horizon Technology Finance Corporation and L. Molteni &amp; C. Dei Frattelli Alitti    Società Di Esercizio S.P.A.(22)            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000110465920095091/tm2020468d1_ex10-30.htm">             10.26    ±±            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000110465920095091/tm2020468d1_ex10-30.htm">             Agreement    for Co-Promotion Partnership, dated June 23, 2020, by and between Titan Pharmaceuticals, Inc. and Indegene, Inc.(23)            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000110465920117956/tm2033419d3_ex10-1.htm">             10.27            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000110465920117956/tm2033419d3_ex10-1.htm">             Debt    Settlement and Release Agreement by and between Titan Pharmaceuticals, Inc., Horizon Technology Finance Corporation and L. Molteni &amp;    C. Dei Frattelli Alitti Società Di Esercizio S.P.A.(24)            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000110465920125466/tm2029565d1_ex10-28.htm">             10.28±±            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000110465920125466/tm2029565d1_ex10-28.htm">             Asset    Purchase Agreement dated October 27, 2020 between Titan Pharmaceuticals, Inc. and JT Pharmaceuticals, Inc.(27)            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000110465921004940/tm213361d1_ex10-1.htm">             10.29            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000110465921004940/tm213361d1_ex10-1.htm">             Form of    January 15, 2021 Securities Purchase Agreement(28)            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000110465921004940/tm213361d1_ex10-2.htm">             10.30            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000110465921004940/tm213361d1_ex10-2.htm">             Placement    Agency Agreement dated January 15, 2021, by and between Titan Pharmaceuticals, Inc. and Maxim Group LLC(28)            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000119312513111045/d444155dex141.htm">             14.1            </a>           </font>          </td>          <td>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/910267/000119312513111045/d444155dex141.htm">             Code    of Business Conduct and Ethics(5)            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <a href="tm211758d1_ex23-1.htm" style="-sec-extract: exhibit">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             23.1            </font>           </a>          </td>          <td>          </td>          <td style="text-align: left">           <a href="tm211758d1_ex23-1.htm" style="-sec-extract: exhibit">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Consent    of OUM &amp; Co. LLP, Independent Registered Public Accounting Firm            </font>           </a>          </td>         </tr>         <tr>          <td style="text-align: left; vertical-align: top; width: 8%">           <a href="tm211758d1_ex31-1.htm">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             31.1            </font>           </a>          </td>          <td style="width: 1%">          </td>          <td style="text-align: left; vertical-align: top; width: 91%">           <a href="tm211758d1_ex31-1.htm">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Certification    of the Principal Executive and Financial Officer pursuant to Rule 13(a)-14(a) of the Securities Exchange Act of 1934            </font>           </a>          </td>         </tr>         <tr>          <td style="text-align: left; vertical-align: top">           <a href="tm211758d1_ex32-1.htm">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             32.1            </font>           </a>          </td>          <td>          </td>          <td style="text-align: left; vertical-align: top">           <a href="tm211758d1_ex32-1.htm">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Certification    of the Principal Executive and Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley    Act of 2002            </font>           </a>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="text-align: left; width: 8%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            101.INS           </font>          </td>          <td style="text-align: left; width: 1%">          </td>          <td style="text-align: left; width: 91%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            XBRL Instance    Document           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            101.SCH           </font>          </td>          <td style="text-align: left">          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            XBRL Taxonomy Extension Schema    Document           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            101.CAL           </font>          </td>          <td style="text-align: left">          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            XBRL Taxonomy Extension calculation    Linkbase Document           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            101.DEF           </font>          </td>          <td style="text-align: left">          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            XBRL Taxonomy Extension Definition    Linkbase Document           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            101.LAB           </font>          </td>          <td style="text-align: left">          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            XBRL Taxonomy Extension Label    Linkbase Document           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            101.PRE           </font>          </td>          <td style="text-align: left">          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            XBRL Taxonomy Extension Presentation    Linkbase Document           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 34px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ±           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Confidential treatment has been granted as to certain    portions of this exhibit.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ±±           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Certain information has been omitted from this exhibit    in reliance upon Item 601(b)(10) of Regulation S-K.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (1)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Incorporated by reference from the Registrant’s    Registration Statement on Form S-3 (File No. 333-221126).           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (2)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Incorporated by reference from the Registrant’s    Annual Report on Form 10-K for the year ended December 31, 2001.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (3)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Incorporated by reference from the Registrant’s    Annual Report on Form 10-K for the year ended December 31, 2002.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (4)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Incorporated by reference from the Registrant’s    Registration Statement on Form 10 filed on January 14, 2010.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (5)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Incorporated by reference from the Registrant’s    Annual Report on Form 10-K for the year ended December 31, 2013.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (6)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Incorporated by reference from the Registrant’s    Current Report on Form 8-K filed on September 28, 2015.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (7)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Incorporated by reference from the Registrant’s    Current Report on Form 8-K filed on April 3, 2019.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (8)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Incorporated by reference from the Registrant’s    Current Report on Form 8-K filed on July 27, 2017.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (9)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Incorporated by reference from the Registrant’s    Current Report on Form 8-K filed on February 7, 2018.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (10)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Incorporated by reference from the Registrant’s    Current Report on Form 8-K filed on March 26, 2018.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (11)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Incorporated by reference from the Registrant’s    Current Report on Form 8-K filed on May 30, 2018.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (12)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Incorporated by reference from the Registrant’s    Current Report on Form 8-K filed on August 3, 2018.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (13)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Incorporated by reference from the Registrant’s    Quarterly Report on Form 10-Q for the period ended June 30, 2018.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (14)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Incorporated by reference from the Registrant’s    Current Report on Form 8-K dated September 20, 2018.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (15)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Incorporated by reference from the Registrant’s    Current Report on Form 8-K dated September 25, 2018.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (16)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Incorporated by reference from the Registrant’s    Current Report on Form 8-K dated January 25, 2019.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (17)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Incorporated by reference from the Registrant’s    Current Report on Form 8-K dated August 8, 2019.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (18)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Incorporated by reference from the Registrant’s    Current Report on Form 8-K dated October 18, 2019.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (19)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Incorporated by reference from the Registrant’s    Current Report on Form 8-K dated January 7, 2020.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (20)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Incorporated by reference from the Registrant’s    Annual Report on Form 10-K dated April 1, 2019.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (21)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Incorporated by reference from the Registrant’s    Registration Statement on Form S-1 dated September 12, 2019.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (22)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Incorporated by reference from the Registrant’s    Annual Report on Form 10-K dated March 30, 2020.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (23)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Incorporated by reference from the Registrant’s    Quarterly Report on Form 10-Q for the period ended June 30, 2020.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (24)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Incorporated by reference from the Registrant’s    Current Report on Form 8-K dated October 26, 2020.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (25)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Incorporated by reference from the Registrant’s    Registration Statement on Form S-1/A dated October 27, 2020.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (26)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Incorporated by reference from the Registrant’s    Current Report on Form 8-K dated November 2, 2020.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (27)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Incorporated by reference from the Registrant’s    Quarterly Report on Form 10-Q for the period ended September 30, 2020.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (28)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Incorporated by reference from the Registrant’s    Current Report on Form 8-K dated January 19, 2021.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">       </p>       <!-- Field: Page; Sequence: 64; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         64         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">        <b>         <a name="a_017">         </a>         SIGNATURES        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in">        Pursuant to the requirementsof Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on itsbehalf by the undersigned, thereunto duly authorized.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 50%; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Date: March 31,    2021           </font>          </td>          <td style="width: 50%; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            TITAN PHARMACEUTICALS, INC.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 50%; padding-right: 0.8pt">          </td>          <td style="width: 5%; padding-right: 0.8pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            By:           </font>          </td>          <td style="border-bottom: Black 1pt solid; width: 45%; padding-right: 0.8pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            /s/    Marc Rubin           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-right: 0.8pt">          </td>          <td style="padding-right: 0.8pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Name:           </font>          </td>          <td style="padding-right: 0.8pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Marc Rubin           </font>           , M.D.          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-right: 0.8pt">          </td>          <td style="padding-right: 0.8pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Title:           </font>          </td>          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">            Executive Chairman           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">            <i>             (Principal Executive and Principal Financial Officer)            </i>           </p>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        Pursuant to the requirementsof the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and inthe capacities and on the dates indicated.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 30%; text-align: center">           Signature          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; width: 1%">          </td>          <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 38%; text-align: center">           Title          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; width: 1%">          </td>          <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 30%; text-align: center">           Date          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">           /s/ Marc Rubin, M.D.          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Executive Chairman          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           March 31, 2021          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center">           Marc Rubin, M.D.          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <i>             (principal    executive officer and principal financial officer)            </i>           </font>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">           /s/ Katherine Beebe DeVarney,    Ph.D.          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           President, Chief Operating Officer and Director          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           March 31, 2021          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">           Katherine Beebe DeVarney, Ph.D.          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">           /s/ Joseph A. Akers          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           Director          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           March 31, 2021          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">           Joseph A. Akers          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">           /s/ M. David MacFarlane,    Ph.D.          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           Director          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           March 31, 2021          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">           M. David MacFarlane, Ph.D.          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">           /s/ James R. McNab, Jr.          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           Director          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           March 31, 2021          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">           James R. McNab, Jr.          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">           /s/ Brian E. Crowley          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Vice President, Finance          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           March 31, 2021          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">           Brian E. Crowley          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif">          </td>          <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left">           (principal accounting officer)          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 65; Options: Last -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         65         <!-- Field: /Sequence -->        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>      </text>     </description>    </filename>   </sequence>  </type> </document></body>